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Host defence peptides (HDPs) have been proposed as blueprints for the 
development of new antimicrobials to combat drug-resistant infections. To 
enhance their clinical utility, short synthetic analogues have been designed by 
fine-tuning their selectivity to preferentially interact with microbial over 
mammalian cells. However, the strategies employed by the majority of these 
studies are largely empirical and synthetic peptides derived from natural HDPs 
possess high sequence similarity, which may promote cross-resistance when 
applied as therapeutic agents. Adopting a de novo approach enables the 
rational design of short synthetic antimicrobial peptides (AMPs), whilst 
mitigating concerns of resistance development to naturally occurring innate 
immune peptides. Thus, the overall aim of this thesis is to rationally design 
novel short synthetic cationic AMPs using a de novo approach and evaluate 
their efficacy and safety in anti-infective applications. We hypothesised that 
rationally designed synthetic AMPs, comprising of repeated sequences 
corresponding to the hydrophobic periodicity of natural α-helical peptides, can 
be safely and effectively applied in tuberculosis mono- and combination 
therapy, and in the treatment and prevention of drug-resistant biofilms and 
endotoxemia. 
 
To test our hypothesis, we explored four specific aims: 
(1)!Rationally design and evaluate short cationic α-helical AMPs for their 
cytotoxicity, and anti-mycobacterial activity alone and in combination 
with first line anti-tubercular drugs. 
!xvi!
(2)!Investigate the influence of hydrophobicity and helicity of α-helical 
AMPs on the anti-mycobacterial mechanisms of action and synergistic 
interactions in combination therapy. 
(3)!Examine the impact of various unnatural amino acid substitutions on 
the stability and anti-mycobacterial selectivity of synthetic α-helical 
AMPs. 
(4)!Assess the effect of sequence pattern and length on the biological 
activity of multifunctional α-helical peptides with idealised facial 
amphiphilicity. 
 
In Specific Aim 1, we described the rational design of short synthetic 
amphipathic α-helical peptides, and studied the effect of various N- and C-
terminal modifications on cytotoxicity, anti-mycobacterial activity and 
synergism with rifampicin. It was demonstrated that the peptides were 
effective against both drug-susceptible and MDR-TB, displayed minimal 
cytotoxicity, interacted synergistically with rifampicin against M. smegmatis 
and BCG, and that such combination treatment could delay the emergence of 
rifampicin resistance. In Specific Aim 2, six α-helical peptides were designed 
with varied hydrophobicity and helical characters and evaluated for their anti-
mycobacterial mechanisms and synergism with rifampicin. It was found that 
increasing hydrophobicity beyond a certain threshold was detrimental to cell 
selectivity, and that enhancements in hydrophobicity and helicity improved 
synergism and increased the rate and extent of peptide-mediated membrane 
permeabilisation. In Specific Aim 3, several unnatural amino acid-modified 
peptides were assessed for their in vitro and intracellular activity against M. 
!xvii!
tuberculosis, and their ability to resist protease degradation. We demonstrated 
that L to D amino acid substitutions proved most effective in enhancing cell 
selectivity, and that the D-isomer was stable to trypsin degradation and could 
reduce the intracellular bacterial burden of both drug-susceptible and MDR-
TB. In Specific Aim 4, we presented the rational design of α-helical peptides 
with idealised facial amphiphilicity, and evaluated the influence of peptide 
length and sequence on the antimicrobial, anti-biofilm and anti-endotoxin 
activities. The peptide with the optimal composition was found to be a broad-
spectrum and potent inhibitor of both drug-susceptible and MDR bacteria, able 
to suppress biofilm growth after 24 h and disrupt mature biofilms within 2 h of 
treatment, and also suppress the production of LPS-induced pro-inflammatory 
mediators to levels of unstimulated controls at low micromolar concentrations. 
 
In conclusion, the findings of this thesis have supported the hypothesis that 
rationally designed synthetic AMPs, adopting α-helical conformations, are 
safe and effective in TB mono- and combination therapy, and in the treatment 
and prevention of drug-resistant biofilms and endotoxemia. Thus, the de novo 
designed peptides presented herein should be evaluated in vivo using animal 
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treatment with II-D. Peptides displayed minimal haemolytic activity and 
cytotoxicity against mammalian cells at various concentrations tested. Data 
are expressed as mean ± S.D. for two independent experiments. 
 
Figure 6.3. Inhibitory activity of synthetic peptides against BCG at 
concentrations of 4x MIC following 6 h treatment with trypsin at a ratio of 
1:100. Only the unmodified peptide, II, did not inhibit bacterial growth after 7 
days. Data are expressed as mean ± S.D. for two independent experiments. 
 
Figure 6.4. Killing efficiencies of antimicrobial peptide II-D against (a) 
H37Rv, (b) Mtb 411 and (c) CSU87 following treatment for 7 days at various 
concentrations. Data are expressed as mean ± S.D. for two independent 
experiments. 
 
Figure 6.5. Intracellular killing of the drug-susceptible clinical isolate Mtb 411 
by (a) antimicrobial peptide II-D and (b) rifampicin, and the MDR clinical 
isolate CSU87 by (c) antimicrobial peptide II-D and (d) moxifloxacin. Data 
expressed as mean ± S.D. and are representative of two independent 
experiments. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).  
 
Figure 6.6. Time-lapse fluorescence microscopy images of BCG following 
treatment with antimicrobial peptide II-D at (a) 4x MIC and (b) 8x MIC in the 
presence of the membrane-impermeable dye, PI. Peptide-mediated membrane 
disruption promoted uptake of PI into bacterial cells. Scale bar = 10 µm. 
 
Figure 6.7. Flow cytometric analysis of the proportion of bacterial cells 
positively stained by the membrane-impermeable dye PI after 3 h exposure to 
different antimicrobials. Controls consisted of (a) H37Rv and (d) CSU87 
treated with media alone. H37Rv was treated with (b) rifampicin and (c) II-D, 
while CSU87 with (e) moxifloxacin and (f) II-D at 4x MIC concentrations. II-
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D induced a significant shift in the percentage of H37Rv and CSU87 taking up 
PI, suggestive of membrane permeabilising mechanisms of action. The levels 
of PI uptake for negative controls, rifampicin and moxifloxacin, were similar 
to that of media. Data are representative of three independent experiments. 
 
Figure 6.8. The ability of antimicrobial peptide II-D to promote (a) NO and (b) 
TNF-α production in unstimulated RAW 264.7 mouse macrophage cells 
following 24 h treatment. II-D did not induce NO or TNF-α when compared 
to positive controls consisting of cells stimulated with 100 ng mL-1 LPS. Data 
are expressed as mean ± S.D. for two independent experiments. 
 
Figure 6.9. Killing efficiencies of antimicrobial peptides (a) II-D and (b) 
FITC-II-D against BCG following treatment for 7 days at various 
concentrations. II-D had killing efficiencies of > 98% and > 99% at 31.3 and 
62.5 mg L-1, respectively, while FITC-II-D had killing efficiencies of > 99% at 
both 250 and 500 mg L-1. Data are expressed as mean ± S.E.M. for three 
independent experiments. 
 
Figure 6.10. (a) Fluorescence microscopy images of BCG treated with 500 mg 
L-1 FITC-labelled II-D for 2 h using the CellASIC ONIX Microfluidic 
Platform. Scale bar = 10 µm (inset scale bar = 5 µm). Confocal microscopy 
images following incubation of 500 mg L-1 FITC-labelled II-D for 2 h with (b) 
BCG-mCherry and (c) BCG in the presence of 2 µg mL-1 membrane dye FM4-
64. Scale bar = 2 µm. 
 
Figure 6.11. Fluorescence intensity profiles of BCG-mCherry along the cell 
length (dashed lines) showing (a) entry of FITC-II-D into the cytoplasm while 
(b) and (c) represent unaffected cells. Fluorescence intensity profiles of BCG 
along the cell width (dashed lines) showing presence of FITC-II-D in the 
bacterial membrane segments (d) and (e). Images were acquired following 2 h 
treatment with 500 mg L-1 of antimicrobial peptide FITC-II-D. Scale bar = 2 
µm. 
 
Figure 7.1. Helical wheel projection of α-helical peptides with idealised facial 
amphiphilicity, possessing the backbone sequence (X1Y1Y2X2)n, where X1 and 
X2 are hydrophobic amino acids, Y1 and Y2 are cationic amino acids, and n is 
the number repeat units. 
 
Figure 7.2. CD spectra representing α-helical propensity of peptides with the 
backbone sequence (a) (LKKL)n (b) (IKKI)n and (c) (WKKW)n in 25 mM 
SDS micelle solution, where n = 2, 2.5 and 3. Data are expressed as the mean 
of three runs per peptide. 
 
Figure 7.3. Haemolytic activity of synthetic α-helical peptides possessing (a) 2 
repeat units, (b) 2.5 repeat units and (c) 3 repeat units tested against blood 
from two healthy donors. Peptides induced minimal haemolysis at 
concentrations corresponding to the respective MICs. Data are expressed as 




Figure 7.4. Killing efficiency of antimicrobial peptide L12 against (a) E. coli, 
(b) S. aureus, (c) P. aeruginosa and (d) K. pneumoniae following treatment 
for 18 h at concentrations corresponding to 0, 0.5x, 1x, 2x and 4x MIC. Data 
are expressed as mean ± S.D. for two independent experiments. 
 
Figure 7.5. Time-lapse fluorescence microscopy images of E. coli (a, b, c) and 
S. aureus (d, e, f) following treatment with (a and d) media alone, (b and e) 
L12 at 4x MIC and (c and f) L12 at 8x MIC in the presence of the membrane 
impermeable dye, PI. The uptake of PI into bacterial cells within minutes of 
exposure supports the rapid membrane-lytic antimicrobial mechanisms of the 
synthetic peptides. No uptake of PI was observed in negative controls while a 
concentration dependent increase in the proportion of fluorescent bacteria was 
evident with peptide treatment. Scale bar = 10 µm. 
 
Figure 7.6. (a) Inhibition of drug-susceptible and drug-resistant P. aeruginosa 
and S. aureus biofilms formation following overnight exposure to L12. (b) 
IVIS imaging and (c) radiance quantification of biofilm growth inhibition of 
bioluminescent P. aeruginosa treated with L12 overnight. (d) Cell viabilities 
of pre-formed PA-W25 and MRSA 252 biofilms after treatment with L12 for 
2 h. (e) IVIS imaging and (f) radiance quantification of pre-formed biofilm 
disruption of bioluminescent P. aeruginosa exposed to L12 for 2 h. Rows in 
(b) and (e) represent individual replicates. L12 inhibits biofilm formation at 1x 
and 2x MIC, and effectively disrupts pre-established biofilms at supra-MIC 
levels. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). 
 
Figure 7.7. The ability of de novo designed peptides to (a) bind LPS within 30 
min exposure and (b) restrict LPS-stimulated NO production following 24 h 
treatment with peptides at various concentrations. The synthetic peptides L12 
and W12 strongly bound LPS and effectively inhibited NO production at sub-
MIC concentrations of 3.9 µM. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, # p ≤ 
0.0001). (c) The effect of synthetic peptides on viability of RAW 264.7 mouse 
macrophage cells following 24 h treatment with peptides at various 
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CHAPTER 1: Introduction 
1.1. Antimicrobial resistance: An overview 
The widespread emergence of antimicrobial resistance (AMR) over the past 
several decades is rapidly becoming a global health emergency, especially 
given the dwindling number of new antibiotics undergoing clinical 
development [1]. In Europe and the US alone, at least 50,000 deaths are 
attributed to antimicrobial-resistant infections each year [2]. While the 
development of resistance by microorganisms to new drugs is unavoidable due 
to natural evolutionary processes, the indiscriminate use of antibiotics in both 
humans and livestock has inadvertently accelerated the selection of resistant 
pathogens [1, 3]. Inevitably, AMR diminishes drug efficacy which results in 
significant complications, higher costs, poorer treatment outcomes, and 
consequently, higher mortality rates [1]. 
 
Recently, the discovery of bacterial resistance to what was reported as “the 
last line antibiotic”, colistin, has fuelled speculation that the world could be on 
the brink of the post-antibiotic era, an age where common ailments and 
infections could prove deadly [4]. By the middle of the 21st century, AMR is 
expected to pose a greater threat to human health than cancer, resulting in over 
10 million deaths a year [2]. Without any firm action, the economic burden of 
AMR is projected to cost the world up to 100 trillion USD with a reduction in 
global Gross Domestic Product (GDP) of between 2 to 3.5% by 2050 [2]. 
Hence measures to curb the spread of resistance to existing antibiotics, while 
developing therapeutics with novel mechanisms of action, will be instrumental 
in tackling the escalating threat of AMR [1].  
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1.1.1. The burden and management of tuberculosis  
Even though mortality and incidence rates have steadily declined since the 
World Health Organisation (WHO) declared tuberculosis (TB) as a global 
public health emergency over 20 years ago, it now ranks alongside HIV as the 
leading cause of death from an infectious disease worldwide, with 9.6 million 
new cases and 1.5 million deaths in 2014 [5]. Multidrug-resistant TB (MDR-
TB), defined as resistance to at least rifampicin and isoniazid, two of the most 
effective first-line anti-tubercular drugs, accounted for 3.3% of the new cases 
and 20% of the previously treated cases [5]. Approximately 9.7% of MDR-TB 
cases are extensively drug-resistant TB (XDR-TB), an even more severe form 
of the disease, defined as resistance to rifampicin, isoniazid, at least one 
fluoroquinolone, and a second line injectable (amikacin, kanamycin or 
capreomycin) [5]. The WHO recently developed a new framework (The End 
TB Strategy) to succeed the Millennium Development Goals, aimed at 
reducing TB death and incidence rates in 2035 by 95% and 90% respectively, 
in comparison to 2015 [6]. However, given that second-line drugs only cure an 
estimated 60% of MDR-TB, and 40% of XDR-TB, resistant strains of 
Mycobacterium tuberculosis pose a significant challenge to global efforts in 
controlling TB [7].  
 
The standard regimen for drug-susceptible TB comprises a cocktail of four 
drugs administered in two separate phases. The two-month long intensive 
phase consists of isoniazid, rifampicin, ethambutol and pyrazinamide, 
followed by a four-month continuation phase with isoniazid and rifampicin 
[8]. Although highly effective when adhered to strictly, the lengthy and 
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complex nature of this six-month regimen inevitably gives rise to patient 
compliance issues [9]. Moreover, inadequate dosing or inappropriate treatment 
conditions are associated with higher mortality rates and the development of 
MDR-TB [10]. The treatment of MDR-TB requires a combination of second- 
and third-line anti-tubercular agents which are not only more costly and toxic, 
but also less effective and entail prolonged treatment durations of 18 to 24 
months [8]. While two new drugs, bedaquiline and delamanid, have recently 
been approved for MDR-TB treatment, rifampicin was the last first-line drug 
to be developed in 1967. Thus, there is an urgent need for novel anti-
mycobacterial compounds that are more potent, less toxic, and effective 
against both MDR and XDR-TB, with the aim of shortening treatment 
regimens and improving treatment outcomes [6, 10, 11]. 
 
1.1.2. The discovery of new antibiotics  
The serendipitous discovery of penicillin by Alexander Fleming in 1928 
heralded the dawn of the antibiotic era, and has proven vital in saving 
countless number of lives as it enabled the effective control of bacterial 
infections [12]. However, it was the systematic screening approach pioneered 
by Selman Waksman in the 1940s, and subsequently termed as the ‘Waksman 
platform’, which proved widely successful in uncovering major antibiotic 
classes [13]. These discoveries spurred the golden era of antibiotic discovery 
from 1940 to 1960, a period which accounts for a vast majority of the 
antibiotics we use today [12]. Since then however, there has been a dearth in 
the discovery of novel classes of antibiotics [12, 13].  
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In a time when the development of new classes of antibiotics is imperative, 
paradoxically, antibiotic pipelines are shrinking. A combination of high failure 
rates in drug research, uncertainty of future market size for a new antibiotic 
due to ever-changing resistance patterns, and the prospect of achieving 
profitability only decades after initial financial outlay, have served as financial 
disincentives for pharmaceutical companies to invest in the R&D of new 
antibiotics [14]. With approximately two-thirds of the 37 antibiotics under 
development still in phase one or two clinical trials [15], only a handful may 
eventually obtain market approval [16]. With regards to TB, there are 
currently only eight new or repurposed drugs undergoing late phase clinical 
trials [5]. Even then, withdrawals due to efficacy concerns following post-
market surveillance and emergence of resistance for follow-on compounds 
without novel mechanisms of action will increase attrition rates [14]. Hence, 
there is an urgent need to expand the size and quality of the current antibiotic 
pipeline to provide effective therapeutics for drug-resistant and biofilm-related 
infections. 
  
1.2. Natural antimicrobial peptides  
1.2.1. Structure and diversity  
Natural antimicrobial peptides (AMPs) have long been regarded as 
fundamental pillars of human immunity that are indispensable components of 
both the adaptive and innate immune systems. The first in a series of landmark 
studies, which put the spotlight on AMPs was the discovery of cecropins in 
1980 from the haemolymph of the moth Hyalophora cecropia [17]. Further 
revelations of the existence of α-defensins in human neutrophils [18], and 
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magainins in the skin of the frog Xenopus laevis [19], were suggestive of the 
ubiquitous presence of such defence molecules among eukaryotes, possessing 
broad-spectrum antimicrobial activity. Since then, over 2000 AMPs have been 
isolated and characterised to date from various plants and animal species 
including vertebrates such as amphibians, reptiles, birds, mammals, fish, and 
arthropods such as insects and crustaceans. Given the multiplicity of sources, 
it is no surprise that AMPs adopt diverse conformations, belonging to four 
main structural classes: α-helical, β-sheet, extended structures enriched with a 
particular amino acid and loop peptides (Figure 1.1) [20]. Despite the 
exceptional disparities in sequence and configuration, AMPs are innately 
similar with a high proportion of hydrophobic and cationic residues, adopting 
amphipathic structures upon folding, which have been implicated in their 




Figure 1.1. Structure and sequences of naturally occurring antimicrobial 
peptides. Reproduced with permission from [22]. Copyright (2006) Nature 
Publishing Group.   
 
1.2.2. Mechanisms of action  
1.2.2.1. Direct antimicrobial activity  
AMPs are revered for their potential as anti-infective agents due to their 
broad-spectrum of activity encompassing bacteria, fungi, viruses and parasites 
[22]. Although the exact mechanisms of action remain unclear, the cationic 
and amphiphilic regions of AMPs are widely understood to be influential in 
their direct microbicidal activity. These positively charged peptides initially 
accumulate on the bacterial surface, mediated largely by electrostatic 
interactions with anionic polymers, such as lipopolysaccharide (LPS) and 
lipoteichoic acids (LTA) in Gram-negative and Gram-positive bacteria, 
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respectively. Subsequent pore formation has been explained via several 
complex models including the toroidal-pore or barrel-stave mechanisms or 
detergent-like membrane solubilisation as espoused by the “carpet-like” 
mechanism [22, 23]. Penetration of peptides into the lipid bilayer, driven by 
their inherent hydrophobicity, triggers membrane disruption that provokes 
homeostatic imbalances and loss of cellular content, culminating in cell death. 
However, the bacterial membrane may not necessarily be the sole target of 
AMPs as some traverse the lipid bilayer, without inducing membrane 
permeabilisation, and inhibit enzymatic activity or impede cell wall, nucleic 
acid, or protein synthesis [23-25]. Importantly, these bactericidal mechanisms 
are not limited to drug-susceptible bacteria, but also target their drug-resistant 
counterparts including methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus faecalis, MDR Pseudomonas aeruginosa 
and M. tuberculosis [24]. In addition, the rapid membrane-lytic mechanisms of 
AMPs has been suggested to diminish their propensity for resistance 
development, while their ability to synergise with conventional antibiotics 
underlines their potential as adjuvants in combinatorial drug therapies for 
infection control [21, 26]. 
 
1.2.2.2. Immune modulating effects  
AMPs are increasingly understood to play a multifaceted role in the regulation 
of the immune system. Figure 1.2 highlights the diverse biological functions 
of AMPs, comprising a multitude of immunomodulatory properties including 
endotoxin neutralising ability, induction of cytokine and/or chemokine 
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production, modulation of dendritic cell and T cell immune response, and 
promotion of wound healing and angiogenesis [27].  
 
Figure 1.2. Multiple functions of antimicrobial peptides in host defence 
ranging from activation of innate immune cells (monocytes, macrophages, 
neutrophils and epithelial cells), stimulation of cytokine and chemokine 
production, promotion of dendritic and T cells migration, and modulation of 
TLR signalling. Abbreviations: AMP, antimicrobial peptide; DC, dendritic 
cell; LPS, lipopolysaccharide; pDC, plasmacytoid dendritic cell; PMN, 
polymorphonucleocyte; TLR, Toll-like receptor. Reproduced with permission 
from [27]. Copyright (2009) Elsevier B.V. 
 
1.2.3. Biological functions of host defence peptides  
The term host defence peptide (HDP) has been increasingly applied to 
accurately describe peptides exhibiting immune-regulating properties in 
addition to direct antimicrobial activity. Of the countless HDPs prevalent in 
humans and mammals, human defensins and cathelicidins are the two most 
well characterised. The following section explores the direct antibacterial 
activity and immunomodulatory activity of cathelicidins and human defensins. 
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1.2.3.1. HDPs as antimicrobials 
The only member of the cathelicidin family to be isolated from humans is the 
α-helical peptide, hCAP-18. Existing as a pro-peptide, hCAP-18 undergoes 
proteolytic cleavage at the C-terminal region to produce a 37 amino acid 
domain, widely known as LL-37. This cationic peptide has demonstrated 
potent inhibitory activity against a broad range of Gram-positive and Gram-
negative bacteria in vitro [28]. Furthermore, the successful elimination of both 
MDR Acinetobacter baumannii and MRSA in vitro following treatment with 
LL-37, highlights the potential utility of this peptide in eradicating drug-
resistant infections [28, 29]. LL-37 has been found to be inactive against M. 
tuberculosis in vitro up to concentrations of 50 mg L-1 [30]. However, in M. 
tuberculosis infected macrophages, LL-37 exhibited moderate anti-
mycobacterial activity after 24 hours when added exogenously at 
concentrations of 15 to 25 mg L-1 [31]. This observed intracellular activity 
also translated into in vivo efficacy when treatment with 32 µg of LL-37, three 
times per week for four weeks was found to significantly reduce bacterial 
burden in the lungs of mice infected with M. tuberculosis, as compared to 
untreated controls (p < 0.05) [32]. Despite its inherent poor activity in vitro, 
the anti-mycobacterial activity of LL-37 is augmented in vivo, indicative of 
potential underlying immunomodulatory mechanisms.   
 
On the other hand, the two major classes of human defensins are comprised of 
α- and β- defensins, each containing six cysteine (Cys) residues which form 
three pairs of disulfide bonds. The fundamental distinction resides in the 
connectivity of these disulfide bonds, with linkages between Cys residues in 
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positions 1 to 6, 2 to 4 and 3 to 5 in α-defensins, but in positions 1 to 5, 2 to 4 
and 3 to 6 in β-defensins. In a similar fashion to cathelicidins, proteolysis of 
the precursor pro-peptide liberates the active element of defensins. Early work 
on α-defensins, or human neutrophil peptides (HNP), in the mid-1980s 
revealed that HNP 1-3 mixture was not only effective against Gram-positive 
and Gram-negative bacteria, but also displayed antifungal and antiviral 
properties [18]. Follow on studies extended this spectrum of activity to include 
various mycobacterial strains. HNP-1 exhibited bactericidal activity against 
M. tuberculosis while HNP-1, HNP-2 and HNP-3 were found to effectively 
eradicate M. avium complex (MAC) in vitro [33, 34]. Treatment of M. 
tuberculosis infected macrophages with 40 mg L-1 HNP-1 also showed strong 
bactericidal activity with 98% killing after 3 days [35]. In vivo however, a 
much lower dose of 5 µg per mouse once weekly for 4 weeks resulted in 
significant reduction in mycobacterial burden in the lungs (p < 0.001) [36]. 
 
The human β-defensins (hBD) were also effective in eradicating Gram-
positive and Gram-negative bacteria, though hBD-2 demonstrated ~10 fold 
greater activity than hBD-1 [37].  However, their ability to reduce bacterial 
load was severely undermined upon exposure to high salt concentrations of 
NaCl. Interestingly, hBD-3 emerged as a promising candidate for the 
treatment of nosocomial infections, buoyed by evidence of its rapidly 
bactericidal activity against MDR clinical isolates of S. aureus, Enterococcus 
faecium, P. aeruginosa, Stenotrophomonas maltophilia, and A. baumannii 
[38]. Combination treatment with HDPs has been shown to induce synergism 
and improve antimicrobial efficiency as compared to treatment with a lone 
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agent. The addition of hBD-1, hBD-2, hBD-3 and LL-37 in various 
permutations revealed that a combination of two or more HDPs was essential 
in eliciting synergistic interactions against S. aureus and E. coli [39]. A 
separate study evaluating the effect of combining sub-lethal doses of HNP-1 
and LL-37 on their antimicrobial potency found that combination of both 
agents augmented the killing of S. aureus and E. coli [40]. These findings 
suggest that though devoid of activity when present alone at sub-inhibitory 
concentrations, combination of defensins with other HDPs can produce 
synergistic modulation of antibacterial activity in order to exert a bactericidal 
response. 
  
1.2.3.2. HDPs as immune modulators 
Facilitating the chemotaxis of a myriad of immune cells remains one of the 
principal functions of HDPs. This chemotactic activity is induced either 
directly by chemokine production or indirectly via the activation of receptors. 
The ability of LL-37 to promote receptor-mediated chemotaxis of various 
immune cells has been widely established. LL-37 has demonstrated direct 
chemoattractant properties for mast cells, with cell migration mediated via the 
Gi protein-phospholipase C (PLC) signalling pathway [41]. LL-37 was also 
found to be chemotactic for various leucocytes such as monocytes, 
neutrophils, eosinophils and T lymphocytes [42, 43]. The involvement of the 
formyl peptide receptor–like 1 (FPRL1) proved central to the recruitment of 
human leucocytes in mounting an immune response.  
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In pioneering research aimed at elucidating the chemotactic properties of 
human defensins, Yang et al. revealed that hBD-2 was a potent inducer of 
both T cell and immature dendritic cell migration through interactions with 
CC chemokine receptor 6 (CCR6) [42]. In a follow on study, the team 
determined that α-defensins, HNP-1 and HNP-2, were similarly chemotactic 
for both immature human dendritic cells and T lymphocytes, though 
independent of CCR6 activation [44]. Both dendritic and T cells are key 
modulators of adaptive immune responses. Taken together, these findings 
serve to reinforce the critical role of α- and β- defensins in both innate and 
adaptive immunity. HNP-1 and HNP-3 were also found to be chemoattractants 
for mast cells, T lymphocytes and macrophages while HNP-1 and HNP-2 
were implicated as essential mediators of monocyte migration [45, 46]. 
Macrophage recruitment by HNP-1 was initiated following signal transduction 
by Gαi proteins and mitogen-activated protein kinases (MAPK) [46].  
 
Besides their chemotactic activities, HDPs can elicit pro- or anti-inflammatory 
responses, dependent on the extent of cytokine induction or inhibition in 
different cell types. LL-37 effectively inhibited the release of the pro-
inflammatory cytokine, tumour necrosis factor-α (TNF-α), from macrophages 
while inducing anti-inflammatory chemokine monocyte chemoattractant 
protein-1 (MCP-1). In epithelial cells, however, MCP-1 production was 
antagonised, while significant induction of interleukin-8 (IL-8) was observed. 
The immunomodulatory activity of LL-37 was achieved partly through the up-
regulation of chemokine receptors including CCR2, CXC chemokine receptor 
type 4 (CXCR-4) and IL-8RB [47]. HNP-1, HNP-2 and HNP-3 increased 
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TNF-α and IL-1 release from human monocytes while down regulating the 
expression of IL-10, a known inhibitor of cytokine production. Moreover, the 
reduction in vascular cell adhesion molecule 1 (VCAM-1) expression in 
endothelial cells could potentially enhance HNP-mediated chemotaxis of 
leucocytes [48]. The stimulation of keratinocytes by hBD-2 and hBD-3 
induced an array of pro-inflammatory cytokines and chemokines including IL-
6, IL-10, IP-10, MCP-1, macrophage inflammatory protein-3α (MIP-3α) and 
RANTES [49]. The G protein and PLC signalling pathways were found to be 
involved in the potentiation of this stimulatory effect. 
 
1.3. Limitations of HDPs  
The clinical development of HDPs has been largely limited to topical 
applications as anti-infectives in skin diseases, rosacea, oral candidiasis and 
diabetic foot ulcers [50, 51]. There are several pertinent issues related to 
toxicity and stability which need to be resolved before peptides can be 
successfully applied as therapeutics [21, 22]. Firstly, peptides are vulnerable to 
degradation by proteases in the blood, resulting undesirable pharmacokinetic 
properties due to their relatively short in vivo half-lives [50]. To overcome this 
limitation, stability-enhancing modifications including peptide cyclisation, N-
terminal acetylation, unnatural or D-amino acid substitutions, and the 
development of peptidomimetics have been proposed [22, 26]. Secondly, the 
complex interactions of HDPs with the immune system, as a consequence of 
their diverse biological functions (Figure 1.2), could result in undesirable 
systemic toxicities during therapeutic administration [22, 51]. As such, 
investigations into the more subtle cytotoxic effects of HDPs including 
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degranulation of mast cells and induction of apoptosis could facilitate the 
development of safer peptide analogues [22, 51], although this is not in the 
scope of this thesis. Instead, the design of synthetic AMPs which bear minimal 
resemblance to the sequences of HDPs, could be explored as a means of 
reducing undesirable immune activation, and in turn circumventing unwanted 
side effects.  
 
Another major barrier is the high cost of manufacturing, as solid phase 
chemical synthesis of peptides can cost between $100 to $600 per gram [22]. 
Natural peptides tend to have long sequences (> 20 amino acids) and complex 
secondary structures, further complicating synthesis and increasing costs, 
thereby hindering large-scale production [51]. While novel approaches are 
being explored to reduce the manufacturing costs of peptide therapeutics, the 
development of shorter synthetic HDP analogues could also provide an 
effective means of minimising costs [22].  
 
A significant draw of AMPs lies in the diminished propensity of microbes to 
develop resistance against these compounds in comparison to conventional 
antibiotics [52]. Given that AMPs non-specifically target the cytoplasmic 
membrane, it has been suggested that reconfiguration of the bacterial 
membrane, an energetically unfavourable and seemingly unlikely process, 
would be necessary for resistance development [21]. The improbability of 
microbial resistance developing against AMPs was demonstrated in vitro 
when efforts to generate pexiganan resistance against S. aureus and S. 
epidermidis proved unsuccessful [53]. In contrast, a 64-fold increase in the 
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minimum inhibitory concentration (MIC) of mupirocin after seven passages, 
and a >1000-fold increase in the MIC of fusidic acid after 14 passages, was 
observed against S. aureus [53]. Similarly, exposure of P. aeruginosa and 
MRSA to sub-inhibitory concentrations of protegrin-1 (PG-1) failed to induce 
resistance after 11 and 18 passages, respectively [54]. Treatment of P. 
aeruginosa with gentamicin, and MRSA with norfloxacin, under similar 
conditions, produced remarkably different results with 190-fold and 85-fold 
increase in MIC, respectively [54]. However, these studies have only selected 
for resistance over a relatively short period and it has been suggested that 
prolonged exposure to AMPs at high concentrations, when applied 
therapeutically, would almost certainly promote the development of resistance 
[55]. Such a situation, when it arises, would have severe implications for 
human health due to cross-resistance to innate HDPs [22, 55]. 
 
1.4. Clinical application of HDPs  
Although many HDP-based therapeutics have been evaluated clinically over 
the past few decades, none have been approved for use in the clinic to date 
[50]. The development of promising drug candidates including iseganan, 
pexiganan, and omiganan, undergoing late stage phase III trials was hampered 
either due to a lack of efficacy, various regulatory barriers, poor clinical trial 
design or commercial considerations. The development of pexiganan for the 
treatment of diabetic foot ulcers was dealt a major blow back in 1999 when 
the drug was not approved US Food and Drug Administration (FDA) [56]. 
Citing ethical concerns over the trial design and lack of evidence 
demonstrating superiority over conventional therapies, the FDA did not deem 
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the drug approvable. As such, dwindling resources coupled with a shift in 
commercial priorities of its pharmaceutical partner forced Magainin 
Pharmaceuticals to cease operations. However, Dipexium Pharmaceuticals 
recently initiated phase III trials for the pexiganan cream, Locilex, in the 
treatment of diabetic foot ulcers (NCT01590758 and NCT01594762).  
 
Omiganan was also unsuccessful in receiving FDA approval for the treatment 
of catheter-associated infections following phase III trials due to its failure to 
meet its primary clinical endpoint. Despite demonstrating statistically 
significant efficacy in the prevention of both catheter colonisation and 
microbiologically confirmed infections, it did not satisfactorily meet the 
primary clinical endpoint of ‘physician determined infections’ [56]. This 
failure prompted Cutanea Life Sciences to explore other potential indications, 
with the recently initiated phase II and III studies for the treatment of acne 
vulgaris (NCT02571998) and rosacea (NCT02576860), respectively.  
 
The development of iseganan, the first antimicrobial peptide to be evaluated as 
an oral decontaminant, was also discontinued by Intrabiotics following Phase 
3 trials which did not significantly reduce ventilator-associated pneumonia 
(VAP) among surviving patients [57]. The trial was halted early due a higher 
rate of VAP and death in the arm receiving iseganan as compared to placebo, 
although this was not shown to be statistically significant. The investigators 
attributed this failure to the short contact time between iseganan in solution 
and the pathogens [58]. In addition, ethical issues surrounding the design of 
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the trial were also raised as patients in the control arm received placebo rather 
than the best available treatment option [58]. 
 
In other instances, commercial considerations have seen promising lead 
compounds being shelved despite strong preclinical evidence of therapeutic 
efficacy. Plectasin was one such antibiotic which saw its clinical development 
come to a halt following a licensing agreement between Novozymes and 
Sanofi-Aventis in 2008. The relatively small market size of pneumococcal 
infections failed to justify the financial investment required for the clinical 
development of this narrow-spectrum antibiotic [59]. Successful efforts to 
extend the plectasin’s spectrum of activity have led to the development a 
broad-spectrum derivative NZ2114, and despite announcing plans to initiate 
Phase 1 trials in 2010, no progress has been made since [59].  
  
Natural AMPs have been studied for the past 25 years and their importance as 
antimicrobials and immunomodulators is well established. Although none 
have been approved as drugs, there are more than 10 phase II and III clinical 
trials using AMPs or their inducers, currently in progress or recently 
completed [60]. Table 1.1 provides a summary of the AMPs being actively 
pursued in clinical development [61]. Compared to a total of about 37 new 
antibiotics which are mostly analogues of old drug classes in clinical 
development, there is indeed significant emphasis on AMP therapeutics in this 
space as a novel class of antibiotics. Importantly, the industry estimates that 
the proportion of peptides in pharma will grow faster (9.4% annual growth in 
2012–2018) than the global industry (3–6% annual growth in 2012–2016) 
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[62]. This is contrary to longstanding scepticism about this class of molecules 
being unstable and hence ineligible for drug development and inferior to small 
molecules. The difference is that with rapid advancement of peptide science, 
computer-aided analysis and combinatorial chemistry, we now have the means 
to modify and produce clinically relevant artificial variants and alternatives. 
While there are no AMPs currently being evaluated in clinical studies for 
application in TB chemotherapy, our background work has indeed provided 
strong support for this approach in the TB context.
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Table 1.1. Synthetic host defence peptides undergoing active clinical development. Reproduced with permission from [61]. Copyright (2015) 


























a Research programs that were terminated or suspended indefinitely have been excluded 
b Reference or registration numbers are obtained from http://clinicaltrials.gov 
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1.5. Design strategies for development of synthetic AMPs 
In a bid to develop shorter synthetic peptide antibiotics with higher potency, 
greater intrinsic stability and lower toxicity, researchers are turning towards 
naturally occurring peptides for inspiration. One strategy utilises these 
molecules as a reference template for systematic modification by substitution, 
deletion or scrambling of amino acid sequences to produce structurally related 
compounds termed as congeners. When the intention is to strategically 
combine the vital domains of two or more individual compounds, the end 
product is either a conjugate (peptide-ligand) or a hybrid (peptide-peptide). 
Another emerging class of synthetic AMPs is peptidomimetics, designed to 
structurally resemble naturally occurring HDPs whilst addressing their 
inherent drawbacks. The following section closely examines the numerous 
approaches that have been utilised for the purposes of designing synthetic 
peptides endowed with superior killing and immune-regulating properties.  
 
1.5.1. Peptide conjugates 
In essence, this approach entails the coupling of a specific ligand or drug 
molecule to AMPs with the aim of imparting dual antibacterial and 
immunomodulating properties. Though straightforward in principle, the 
application of this design strategy has been limited thus far. Cationic steroid 
antibiotics (CSA), designed as synthetic mimics of the antibiotic polymyxin B, 
consist of steroid polyamine conjugates capable of killing both Gram-positive 
and Gram-negative bacteria [63]. Spermine, a polyamine that has been shown 
to possess broad-spectrum antibacterial activity, is inherently positively 
charged and bears a marked structural resemblance to cationic AMPs [64]. 
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This polycation was covalently linked to dexamethasone, a corticosteroid with 
known anti-inflammatory and immunosuppressant properties, to give a 
disubstituted dexamethasone-spermine (D2S). Not only was this conjugate 
effective against P. aeruginosa and MRSA, D2S was further shown to inhibit 
the release of IL-6 and IL-8 from neutrophils exposed to LPS or LTA [65]. 
The conjugate also retained glucocorticoid activity suggesting that the anti-
inflammatory activity of D2S was likely mediated via the engagement of 
glucocorticoid receptors.  
 
Recently, conjugation of thymopentin (RKDVY), a synthetic pentapeptide 
corresponding to amino acid residues 32-36 from the thymus hormone 
thymopoietin, to the N- and C- terminus of a highly cationic AMP comprising 
of six arginine (Arg) residues to confer the molecule with immunomodulatory 
properties, has been reported [66]. Thymopentin, being an immunostimulant, 
replicates the biological activity of thymopoietin and promotes thymocyte 
differentiation and maturation. The resultant peptides, RR-11 
(RKDVYRRRRRR) and RY-11 (RRRRRRRKDVY), displayed potent 
bactericidal activity against both drug-susceptible and drug-resistant M. 
smegmatis while preserving the pro-inflammatory functions of thymopentin. 
Both RR-11 and RY-11 induced significant TNF-αrelease from macrophages 
which was found to be comparable to levels following stimulation with 
thymopentin alone.  
 
Lipopeptide conjugates are also being explored for their potential as novel 
antibiotics with improved antibacterial and immunomodulatory properties. 
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The conjugation of lipophilic acyl chains of various lengths to 12 amino acid 
residue fragments of human lactoferrin, LF12, was shown to enhance 
antibacterial killing considerably [67]. Lipopeptides comprising of acyl chains 
12 carbon units in length (LF12-C12) were deemed the optimal composition, 
with enhancements in activity of 50-fold and 75-fold against E. coli and S. 
aureus, respectively. Furthermore, LF12-C12 possessed a 12-fold superior 
endotoxin neutralising potency as compared to the parent peptide LF12. These 
results highlight the applicability of lipophilic modification to augment both 
antimicrobial and anti-inflammatory activity of AMPs.  
 
1.5.2. Hybrid peptides  
Hybridisation is a technique combining the functional domains of two or more 
naturally occurring peptides with the intention of enhancing selectivity by 
improving antibacterial activity while minimising cytotoxicity against 
mammalian cells. Liu et al. successfully employed this in the development of 
hybrid β-hairpin peptides by merging various segments derived from porcine 
cathelicidin PG-1, cecropin A (CA) isolated from haemolymph of Hyalophora 
cecropia, and a 25 amino acid peptide from the N-terminus of lactoferrin 
called bovine lactoferricin (LB) [68]. The resulting hybrid peptides, LB-PG 
and CA-PG, exhibited superior antibacterial efficiencies and broader 
antimicrobial spectra as compared to parental peptides. The enhancement in 
potency of the constructed hybrids was attributed in part to their greater net 
positive charge, amphiphilicity and propensity to adopt β-hairpin 
conformation. Moreover, LB-PG and CA-PG inhibited the expression and 
release of pro-inflammatory cytokines, TNF-α and inducible nitric oxide 
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synthase (iNOS), and chemokines, MIP-1α and MCP-1, from macrophages 
stimulated with LPS. This finding underlines their potential as anti-
inflammatory agents to suppress cytokine production and mitigate over-
stimulation of the immune system by bacterial endotoxins.  
 
This design strategy has also been utilised to endow previously inactive 
peptides with enhanced antimicrobial and anti-endotoxic activities. An LPS 
binding motif, termed as β-boomerang motif, GWKRKRFG, was bereft of 
both antimicrobial and anti-endotoxic properties but provided promise due to 
its LPS-anchoring capabilities [69]. This boomerang motif was exploited to 
abolish LPS-induced aggregation, which traps peptides at the outer membrane 
and in turn limits their bactericidal activity. In a bid to salvage inactive 
peptides TA, TB and KL-12, synthetic peptides incorporating the β-
boomerang motif at the C-terminus were constructed and the hybrids 
displayed remarkable improvement in activity against both Gram-positive and 
Gram-negative bacteria [70]. This modification also produced hybrids with 
superior endotoxin-neutralising abilities, with peptides TA and TB having 
previously demonstrated poor activity in neutralising LPS.  
 
Synthetic hybrids may also be designed with the goal of incorporating the 
individual benefits of each fragment into a fusion product capable of 
manifesting desirable traits. Scudiero et al. set out to develop a hybrid peptide 
possessing the high salt tolerance capabilities of hBD-3 while preserving the 
antibacterial activity of hBD-1 [71]. Three analogues, 3N, IC and 3I 
consistently displayed the highest potency against P. aeruginosa, E.coli and E. 
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faecalis, even at high salt concentrations. The chemotactic activity of the 
analogues for neutrophils and monocytes was maintained relative to parent 
peptides hBD-1 and hBD-3.  
 
1.5.3. Peptidomimetics  
In the pursuit of developing novel therapeutics with comparable efficacies to 
AMPs whilst overcoming their shortcomings including poor in vivo stability 
and high manufacturing costs, investigators have focused their attention 
towards designing non-peptidic oligomers and polymers. Drawing inspiration 
from key structural features of natural AMPs, these molecules possess an 
inherent amphiphilic backbone and present net positive charges to mimic the 
biological functions of these peptides.  
 
Magainin, an AMP isolated from the skin of African frog Xenopus laevis, 
provided the template for the development of peptide mimetic, meta-
phenylene ethynylene (mPE), which was explored for its anti-biofilm activity 
against oral pathogens [72]. mPE effectively inhibited the growth of bacterial 
pathogens S. aureus, Porphyromonas gingivalis, and S. mutans, and prevented 
S. mutans biofilm formation. An assessment into the anti-inflammatory 
activity of this peptide mimetic revealed a considerable decline in TNF-α
secretion following LPS stimulation of macrophages, indicative of preserved 
biological function. mPE was further evaluated for its application in 
periodontal disease and displayed inhibitory activity against both A. 
actinomycetemcomitans  and P. gingivalis  biofilms [73]. Low concentrations 
of 2 µg mL-1 adequately suppressed IL-1β and induced IL-8 release in 
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epithelial and myeloid cells, reiterating its potential utility as an anti-
inflammatory agent in the management of other diseases.  
 
CSAs represent another class of peptidomimetics resembling AMPs, with 
positive charges and hydrophobic residues on opposite faces giving rise to 
amphiphilic secondary conformations. Antimicrobial testing of analogues 
CSA-13, CSA-90 and CSA-92 against a wide array of bacterial strains found 
that these mimetics exhibited far superior antimicrobial activities than human 
cathelicidin LL-37 [74]. Furthermore, all three mimetics induced IL-8 release 
from keratinocytes, suggestive of dual antimicrobial and pro-inflammatory 
responses.  
 
In an attempt to overcome challenges associated with poor solubility and 
complicated synthetic pathways, ultra-short histidine (His) derived AMPs 
(HDAMPs) were designed to possess both antimicrobial and anti-
inflammatory activities. Comprising of one His and one or two Arg moieties, 
these peptidomimetics proved effective against both Gram-positive and Gram-
negative bacteria, including MRSA [75]. HDAMPs also demonstrated 
immunosuppressive properties with LPS-neutralising ability and significantly 
inhibited the secretion of NO and TNF-α from macrophages stimulated with 
LPS.   
 
Cyclic peptidomimetics comprising mainly of the cyclic lipo-α-AApeptides 
(N-acylated-N-aminoethyl peptides), on the other hand, displayed enhanced 
antimicrobial activities against both Gram-positive and Gram-negative 
!26!
bacteria as compared to the linear analogue [76]. The ability of these 
peptidomimetics to suppress inflammatory responses was apparent from the 
inhibition of nitric oxide (NO) and TNF-α production, mediated by 
antagonising TLR4-induced nuclear factor kappa-light-chain-enhancer of 
activated B-cells (NF-kB). 
 
1.5.4. Peptide congeners 
A far more direct and common approach, in designing peptides with higher 
antimicrobial efficacy and reduced systemic toxicity, involves systematic 
manipulation of the amino acid sequence of peptides with known activity. 
Many naturally occurring peptides from mammals, amphibians and insects 
have served as AMP templates including cathelicidin LL-37, hBDs, 
lactoferrin, heparin and thrombin. Such template-based studies are carried out 
by either substituting specific amino acids within the parent peptide sequence, 
or truncating the N- and C-terminus of the parent peptide, or a combination of 
both these steps. These systematic modifications not only allow the 
investigation of crucial physiochemical parameters for improved potency and 
efficacy, but also seek to identify the shortest possible active domains of the 
parental peptides. 
 
The effect of length, charge, helicity, hydrophobicity and amphiphilicity on 
antimicrobial and haemolytic activity of AMPs has been extensively evaluated 
and reviewed in-depth [77]. However, the modulating effect of these 
physicochemical parameters on the immunomodulatory functions of AMPs 
has been limited thus far. An investigation into the relationship between 
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hydrophobicity and LPS-neutralising activity of synthetic bovine myeloid 
antimicrobial peptide-18 (BMAP-18) revealed that both factors were linearly 
correlated. Increments in hydrophobicity of BMAP-18 analogues resulted in 
greater inhibition of NO and TNF-α production [78]. These findings were 
echoed in a separate study assessing the amino acid-substituted analogues of 
IG-19, corresponding to the α-helical region of cathelicidin LL-37, which also 
found that enhancements in peptide hydrophobicity showed significant linear 
correlation with improved LPS-binding activity [79].  
  
Apart from overall peptide hydrophobicity, the pinpoint substitution of 
specific hydrophobic amino acids along a peptide sequence can potentiate 
both antimicrobial and anti-inflammatory activities. Swapping out a single 
serine (Ser) residue at position 9 along the hydrophobic face of LL-23 with 
valine (Val), rendered the weakly bactericidal and immunosuppressive peptide 
more active, with a pronounced reduction in the release of pro-inflammatory 
cytokines TNF-α and MCP-1 [80]. This point mutation directed the formation 
of a continuous hydrophobic face, which had previously been segregated by 
the hydrophilic Ser residue. Another study comparing two tryptophan (Trp)-
substituted analogues uncovered that substitution of this hydrophobic amino 
acid at the amphipathic interface, rather than at the centre of the hydrophobic 
face, produced analogues with greater LPS-neutralising activity [79]. Taken 
together, these results highlight the importance of site-specific Trp 
substitutions and a continuous hydrophobic surface in directing the design of 
novel AMPs with improved selectivity and anti-inflammatory activity.  
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The substitution of D-amino acids into the peptide sequence is a practice 
usually aimed at decreasing the inherent cytotoxicity of AMPs, as well as 
improving their stability to proteolytic degradation. Interestingly however, a 
study investigating the effect of swapping the entire amino acid sequence from 
L- to D-isomers found that the D-analogue exhibited the greatest antimicrobial 
potency amongst all the peptides tested [81]. Notably, the D-analogue proved 
to be a stronger inhibitor of NO production and pro-inflammatory cytokines 
TNF-α and MIP-2 at all concentrations. In a separate study, several D-amino 
acid substituted analogues of an amphipathic α-helical peptide, K9L8W, were 
found to possess superior cell selectivity while maintaining potent anti-
inflammatory activity [82]. Given the paucity of research in this regard, the 
benefits of such an approach to develop more potent anti-inflammatory agents 
while concurrently improving their antibacterial activity, warrants further 
investigation. 
 
1.5.5. Genomic mining strategies  
Recently, the first report on mycobacteriophage-derived AMPs found to 
exhibit potent antibacterial and immunoregulative properties has emerged 
[83]. The researchers systematically screened the complete genome of over 70 
mycobacteriophages for peptides capable of inhibiting both the growth of M. 
tuberculosis and activity of trehalose-6,6’-dimycolate (TDM), an 
immunostimulant produced by virulent M. tuberculosis that induces 
inflammatory responses and pulmonary granuloma formation. Out of 200 
shortlisted candidates, a 34 amino acid peptide, PK34, was found to possess 
the strongest anti-mycobacterial activity with an MIC of 50 mg L-1. PK34 also 
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hampered the in vitro release of pro-inflammatory cytokines IFN-γ, TNF-α, 
MCP-1, IL-6, IL-10 and IL-12 in a concentration-dependent manner. In vivo, 
PK34’s mitigating effect on M. tuberculosis granuloma formation and TDM-
induced inflammatory response was likely mediated by blocking MAPK 
activation. Given the diversity of bacteriophages and the abundance of 
information nestled within their genomic sequences, such innovative 
approaches could provide the key to unlocking novel compounds in our quest 
to expand our arsenal of antibiotics. 
 
1.5.6. De novo design strategies 
The de novo design of AMPs is based upon an appreciation of the structural 
commonalities including cationic charge, hydrophobicity, and amphiphilicity, 
and the intricacies surrounding the folding of proteins into different secondary 
conformations. This minimalist approach entails the combination of bulky 
lipophilic and cationic amino acids, often using a generic sequence to generate 
short synthetic peptides, usually consisting of ≤ 20 amino acids [26]. Trp-rich 
peptides such as indolicidin and tritrpticin, and their synthetic analogues, have 
emerged as an important class of peptides due to their broad-spectrum of 
antimicrobial activity, even at very short peptide lengths [84]. Park et al. 
explored short Trp-rich AMPs bearing the sequence XXWXXWXXWXX-
NH2, where X represents leucine (Leu) or lysine (Lys)/Arg, for their potential 
antibacterial and anti-endotoxin activities [85]. Several synthetic analogues 
possessed enhanced activity against E. coli and S. aureus while majority 
displayed superior killing properties against MRSA relative to indolicidin. 
These analogues also proved to be potent anti-inflammatory agents, evident 
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from their ability to strongly inhibit NO production and neutralise LPS. A 
separate study evaluating short peptides ranging from five to 11 amino acids 
revealed that the hexapeptide comprising of three Arg and three Trp residues 
was the most efficient motif for antimicrobial activity [86]. A follow-on study 
aimed at identifying the minimal motif or pharmacophore required to produce 
active antibacterial peptides, comprising solely of Arg and Trp, demonstrated 
that the tripeptide (WRW-NH2) was moderately active against S. aureus [87]. 
In contrast, the tetra- and tripeptides were inactive against the Gram-negative 
E. coli, and a minimum of five residues (three hydrophobic and two cationic) 
were required for antibacterial activity. 
 
A linguistic model – defined by a set of grammatical rules based on the 
sequences of natural AMPs – was proposed in the development of short 
synthetic antibacterial peptides [88]. Recently, α-helical peptides were 
rationally designed based upon principles governing the folding of natural α-
helical AMPs including: 1) stabilisation of the helical coil by repetitive 
hydrogen bonding between the carbonyl oxygen of each amino acid and the 
amide hydrogen four residues ahead [89], 2) maximisation of hydrophobic 
moment with periodic distributions of hydrophobic and cationic amino acids 
having repeat periods corresponding to that of the α-helix of 3.6 residues [90, 
91], and 3) the incorporation of amino acids possessing helix-forming rather 
than helix-breaking tendencies [92]. Natural α-helical AMPs tend to unfold in 
solution and adopt their secondary conformation upon contacting bacterial 
membranes. Thus, same-charge amino acids were placed at (i + 2)th and (i + 
3)th positions so that cationic repulsive forces would ensure peptides remained 
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unfolded in solution. Therefore, the recurring sequence comprising four amino 
acids (XXYY)n – where X is a hydrophobic amino acid, Y is a cationic amino 
acid, and n is the number of repeat units – was devised to preserve the α-
helical periodicity while ensuring a balance between hydrophobic and charged 
residues. The designed peptides were effective against Gram-positive bacteria 
and yeast, with (LLKK)3 exhibiting the highest selectivity for microbial over 
mammalian cells [93]. A follow-on study, aimed at capitalising on the 
presence of free sulfhydryl (thiol) groups in natural AMPs, which has been 
shown to augment antibacterial killing [94], demonstrated that incorporating 
L-Cys residues at the end-terminals of peptides extended the spectrum of 
activity to Gram-negative bacteria [95]. Following this strategy, this thesis 
expounds the applicability of short synthetic AMPs, mimicking the α-helical 
folding of naturally occurring peptides, as a novel class of TB therapeutics. 
 
Another similar strategy for the design of α-helical AMPs was proposed by 
Javadpour et al., based on the repetitive heptad sequence: [(PNN)(PNN)P]n 
and [(PNN)P(PNN)]n (P= polar residue, N = nonpolar residue, and n = 1, 2, 3) 
[96]. An increase in the heptad repeats not only showed an increase in helical 
content, but also antimicrobial activity, with the 7-mers failing to adopt helical 
structures in membrane mimetic environments, thus rendering them inactive. 
While the longer 14- and 21-mers were more potent, a corresponding increase 
in cytotoxic and haemolytic activity was also observed. Recently, β-sheet 
forming peptides were generated using the short recurring sequence 
(X1Y1X2Y2)n-NH2 (X1 and X2= hydrophobic residue, Y1 and Y2 = cationic 
residue, and n = 1, 2, 3) [97]. This design principle was successfully 
!32!
implemented in the development of broad-spectrum synthetic AMPs, capable 
of eradicating biofilms and inhibiting LPS-stimulated NO production. 
Furthermore, the most selective peptides possessed more desirable lethal dose, 
50% values (LD50) of 35.2 mg kg-1 in comparison to gramicidin (1.5 mg kg-1) 
and polymyxin B (5.4 mg kg-1) [97].  
 
Short β-hairpin structured peptides have also been developed using various 
sequence-based approaches [98-100]. Peptides comprising the simplified 
sequence (WRXxRW)n, where Xx represents the turn sequence and n = 1, 2, 3 
or 4, retained antimicrobial activities even in the presence of salts at 
physiological concentrations and demonstrated synergistic interactions with 
ciprofloxacin and chloramphenicol against S. aureus and E. coli respectively 
[100]. Similarly, the generic sequence Ac-C-HBHB(P)HBH-GSG-
HBHB(P)HBH-C-NH2, where Ac is an acetyl moiety, H is a hydrophobic 
residue, P is a polar residue and B is a cationic residue, served as a framework 
to design cyclic β-hairpin peptides with LPS and lipid A binding properties 
[101]. Besides being anti-endotoxic, these synthetic AMPs were highly 
selective for microbes over mammalian cells.  
 
1.5.7. Critical comparison of design strategies 
The various design strategies to develop synthetic AMPs, as discussed in the 
previous sections, each present with their own set of advantages and 
drawbacks. In general, synthetic AMPs are produced with the intention of 
enhancing the clinical utility of natural HDPs, by improving stability, reducing 
toxicity, and enhancing the antimicrobial efficacy of these compounds.  In 
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addition, peptide conjugates and hybrid peptides have the added advantage of 
producing multifunctional peptides endowed with improved biological 
properties. For example, combining an AMPs with an immunomodulating 
peptide or ligand can create conjugates or hybrids with dual functions. In other 
instances, such combinations can produce synthetic conjugates and hybrids 
which are resistant to high salt concentrations found in biological fluids or 
those that possess lower cytotoxicity than the parent peptides. Having said that 
however, these approaches fail to account for the structural folding or 
refolding as a consequence of combining the two separate domains, resulting 
in unpredictable outcomes [102]. In line with this, one study investigating the 
activity of SMAP28 with a targeting domain for P. gingivalis did not find any 
significant increase in activity or specificity against the bacteria [103]. 
Similarly, peptide congeners produced by modifications to template sequences 
derived from natural HDPs present similar challenges in that the interactions 
between amino acids, which regulate the three-dimensional peptide structure, 
are not accounted for [102]. Furthermore, the influence of specific amino acid 
substitutions is often context-dependent, and varies according to the initial 
template sequences being studied [102]. This in turn limits the generalisability 
of the findings from one study to another.  
 
Despite the abovementioned limitations of hybrid peptides, peptide conjugates 
and congeners, a far greater concern is the implications associated with 
antimicrobial resistance development against these compounds. Should 
bacteria evolve resistance mechanisms against synthetic AMPs, which bear 
close structural similarities to natural HDPs, it would most certainly 
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compromise our innate immune responses during infections [104]. Therefore, 
alternative strategies including the design of synthetic AMPs using de novo 
approaches and the development of peptoids which comprise of non-peptidic 
monomers, could help allay these concerns. A significant draw of peptoids or 
peptidomimetics, over conventional peptides, lies in their ability to resist 
proteolytic degradation due the absence of the α-polyamide backbone [26]. 
This enhances in vivo stability and in turn, prolongs the half-life of these 
compounds. While de novo generated peptides containing L-amino acids are 
typically rendered inactive due to proteases, this limitation can easily be 
overcome by incorporating D-amino acids into the sequence instead [26]. In 
addition, the de novo approach enables the rational design of short synthetic 
peptides while majority of the other approaches are largely empirical and often 
require multiple steps and several substitutions for optimisation of activity. 
Overall, the de novo approach provides a simple and straightforward means of 
producing short synthetic AMPs, allowing for greater flexibility in the design 
process, and the delineation of the effect of various physicochemical 
properties on biological activities.    
 
 
1.6. Summary and concluding remarks 
As discussed in this chapter, the escalating threat of AMR has increased 
pressure to develop novel therapeutic strategies to tackle drug-resistant 
infections. AMPs have gathered considerable interest as a new source of 
antibiotics due to their broad-spectrum and rapid bactericidal activities, in 
addition to their ability to synergise with conventional antibiotics against 
drug-resistant pathogens [105]. Even three decades after their discovery, 
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researchers are still drawing inspiration from naturally occurring peptides, 
including defensins, cathelicidins, magainins, melittins and cecropins, in their 
quest to develop novel peptide therapeutics [24]. However, natural AMPs are 
increasingly recognised as poor therapeutic candidates due to their long 
sequences, which inadvertently induce significant systemic toxicities and 
translate into higher manufacturing costs [22]. To enhance their clinical utility, 
short synthetic analogues have been designed by fine-tuning their selectivity 
to preferentially interact with microbial over mammalian cells. However, the 
strategies employed by the majority of these studies have remained largely 
empirical, often utilising natural AMPs as templates, or helical wheel 
projections to perform modifications by replacing, deleting or scrambling 
amino acid sequences [26]. Rational design strategies based upon an 
appreciation of the structural intricacies surrounding protein secondary 
structures have been successfully implemented in the de novo design of short 
synthetic α-helical [96], β-sheet [97, 106], and β-hairpin peptides [98-100], 
which bear minimal resemblance to natural HDPs. However, such rational 
approaches have yet to be applied to the de novo design of short synthetic anti-
mycobacterial peptides. As such, this thesis first explores the feasibility of 
rationally designed synthetic α-helical AMPs as anti-tubercular agents and 
subsequently, a new sequence-based approach for the design of 
multifunctional α-helical peptides with idealised facial amphiphilicity, is 
proposed. In doing so, we demonstrate that the adoption of such systematic 
design principles, in the optimisation of short synthetic AMPs, could facilitate 
the development of safe and effective novel peptide therapeutics for 
application in infectious and inflammatory human diseases. 
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CHAPTER 2: Hypothesis and aims 
 
The rapid emergence of AMR, coupled with shrinking antibiotic pipelines, has 
increased demands for antimicrobials with novel mechanisms of action. HDPs 
have been proposed as blueprints for the development of new antimicrobials to 
combat drug-resistant infections. Given their nonspecific membrane-lytic 
mechanisms, AMPs possess broad-spectrum activities, are rapidly bactericidal 
and consequently, more resilient to antibiotic resistance development as 
compared to conventional antimicrobials [24]. These inherent advantages have 
firmly placed the limelight on AMPs over the past decade as an alternative 
class of therapeutics. As discussed in Chapter 1, the clinical application of 
HDPs has been limited thus far, due to a combination of high manufacturing 
costs, toxicity issues, poor in vivo stability and reduced efficacy in comparison 
to existing treatment options [56, 107]. The synthetic approach has been 
adopted in the development of HDPs analogues with shorter sequence lengths 
to reduce production costs, while achieving equal, if not greater effectiveness 
and stability under physiological conditions [26, 108]. In addition, various 
structural modifications aimed at improving cell selectivity by minimising 
toxicity to host cells while enhancing antimicrobial potency have been 
proposed [109]. Amongst the different synthetic design strategies, hybrid 
peptides, peptide conjugates, and a template-based approach to generate 
peptide congeners, are most commonly employed. However, these approaches 
are mainly empirical and synthetic peptides derived from natural HDPs 
possess high sequence similarity, which may promote cross-resistance when 
applied as therapeutic agents [55]. Adopting a de novo approach enables the 
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rational design of short synthetic AMPs, whilst mitigating concerns of 
resistance development to naturally occurring innate immune peptides.  
 
Thus, the overall aim of this thesis is to rationally design novel short synthetic 
cationic AMPs using a de novo approach and evaluate their efficacy and safety 
in anti-infective applications. We hypothesised that rationally designed 
synthetic AMPs, comprising of repeated sequences corresponding to the 
hydrophobic periodicity of natural α-helical peptides, can be safely and 
effectively applied in TB mono- and combination therapy, and in the treatment 
and prevention of drug-resistant biofilms and endotoxemia. 
 
To test our hypothesis, we explored four specific aims: 
(1)!Rationally design and evaluate short cationic α-helical AMPs for their 
cytotoxicity, and anti-mycobacterial activity alone and in combination 
with first line anti-tubercular drugs. 
(2)!Investigate the influence of hydrophobicity and helicity of α-helical 
AMPs on the anti-mycobacterial mechanisms of action and synergistic 
interactions in combination therapy. 
(3)!Examine the impact of various unnatural amino acid substitutions on 
the stability and anti-mycobacterial selectivity of synthetic α-helical 
AMPs. 
(4)!Assess the effect of sequence pattern and length on the biological 




The work undertaken to address each of the specific aims is outlined as 
follows: in Chapter 4, short synthetic amphipathic α-helical peptides, with 
various N- and C-terminal modifications, were evaluated for synergism with 
rifampicin against mycobacteria, and whether such combination therapy was 
effective in delaying the emergence of rifampicin resistance (Specific aim 1). 
In Chapter 5, systematic evaluation of the anti-mycobacterial and cytotoxic 
activities of six α-helical peptides, with varied hydrophobicity and helical 
characters, was performed to determine the optimal composition for enhanced 
mycobacterial selectivity. The modulating effect of hydrophobicity and α-
helicity on the anti-mycobacterial mechanisms of synthetic AMPs, and their 
synergism with rifampicin, was reported for the first time (Specific aim 2). In 
Chapter 6, several unnatural amino acid-modified peptides were assessed for 
their resistance to protease degradation, in addition to their in vitro and 
intracellular activity against M. tuberculosis. Mechanistic studies were also 
undertaken to elucidate the site of action of the most selective peptide 
(Specific aim 3). In Chapter 7, the de novo design of α-helical peptides with 
idealised facial amphiphilicity, based on an understanding of the pertinent 
features of protein secondary structures, is presented. The α-helical 
amphiphiles were evaluated for broad-spectrum antimicrobial activities 
against clinical isolates of drug-susceptible and MDR bacteria, their ability to 
suppress biofilm growth and disrupt mature biofilms, and also their potential 
to neutralise bacterial endotoxins (Specific aim 4). Finally, in Chapter 8, we 
provide conclusions based on the pertinent findings in this thesis and explore 
potential future directions for the development of synthetic peptides as 
therapeutics. 
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The successful completion of this thesis has provided insights into the design 
of synthetic peptide amphiphiles with improved cell selectivity, enhanced 
synergistic interactions and superior anti-biofilm and anti-endotoxin activities. 
Overall, the findings presented in this thesis underscore the applicability of de 
novo strategies employed here for the rational design of synthetic α-helical 
AMPs against drug-susceptible and drug-resistant biofilms and infections, 
including MDR-TB.  
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CHAPTER 3: Materials and methods 
 
3.1. Materials  
Synthetic peptides, including the N-terminal fluorescein isothiocyanate 
(FITC)-labelled II-D, were synthesised by GL Biochem (Shanghai, China) and 
their purity was confirmed to be more than 95% by reversed-phase high-
performance liquid chromatography (RP-HPLC) carried out by the 
manufacturer. Acetonitrile (HPLC grade) and agar-agar technical for 
microbiology were purchased from Merck (Darmstadt, Germany). Dimethyl 
sulfoxide (DMSO, synthesis grade, 99.9%), Dulbecco’s Modified Eagle’s 
medium (DMEM), Dulbecco’s phosphate-buffered saline (PBS) solution, 
Tween 80, glycerol, rifampicin, ethambutol, moxifloxacin, trifluoroacetic acid 
(TFA), propidium iodide (PI), carbenicillin, crystal violet (CV), HPLC grade 
water, Triton X-100, LPS from E. coli 0111:B4 and 150 kDa dextran-FITC 
were acquired from Sigma-Aldrich (St Louis, MO, USA). Hygromycin B was 
from Roche Diagnostics (Indianapolis, IN, USA). Nutrient broth (Acumedia 
No. 7146) and bacteriological agar (Acumedia No. 7176) were purchased 
from Neogen Corporation (Michigan, USA). Difco Middlebrook 7H9 broth, 
Difco Middlebrook 7H11 agar, BBL Middlebrook oleic acid-albumin-
dextrose-catalase (OADC), BBL Middlebrook ADC supplement and Bacto 
Brain Heart Infusion (BHI) were purchased from BD (Sparks, MD, USA). 
Fetal bovine serum (FBS) was obtained from Thermo Scientific Hyclone 
(Logan, UT, USA). 3-(4,5-Dimethylthiazol-yl)-diphenyl tetrazolium bromide 
(MTT) was acquired from Duchefa Biochemie (Haarlem, Netherlands). 3’,3’-
dipropylthiadicarbocyanine (diS-C3-5) dye was purchased from AnaSpec Inc 
(Fremont, CA, USA). Adenosine triphosphate (ATP) bioluminescence kit was 
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obtained from Molecular Probes Inc (OR, USA). Dry powders of the 
phospholipids 1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPG) 
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were obtained 
Avanti Polar Lipids, Inc (Alabaster, AL, USA). The membrane dye FM4-
64FX was from Molecular Probes, Inc (Eugene, OR, USA). N-tosyl-L-
phenylalanyl chloromethyl ketone (TPCK)-treated trypsin was from AB Sciex 
(Framingham, MA, USA). The mouse TNF-α enzyme-linked immune sorbent 
assay (ELISA) Ready-SET-Go kit was from eBioscience (San Diego, CA, 
USA) and Griess Reagent System from Promega (Madison, WI, USA). The 
Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit 
was from Pierce Biotechnology (Rockford, IL, USA). 
 
3.2. Peptide characterisation 
3.2.1 Matrix-assisted laser desorption/ionisation time-of-flight mass 
spectroscopy (MALDI-TOF MS) 
MALDI-TOF MS (Model 4800, Applied Biosystems, USA), using α-cyano-4-
hydroxycinnamic acid (CHCA) as matrix, was performed in Chapters 4 and 5 
to confirm peptide molecular weights and ensure that the peptides were 
synthesised to desired specifications. An equal volume of peptide solution (0.5 
mg mL-1 in deionised water) and CHCA solution (saturated in 
acetonitrile/water mixture at 1:1 volume ratio) was spotted onto the MALDI 
ground-steel target plate for molecular weight determination.  
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3.2.2. Surface-enhanced laser desorption/ionisation-TOF MS (SELDI-TOF 
MS) 
SELDI-TOF MS was performed in Chapters 6 and 7 by Dr Melissa Shea 
Hamilton (Department of Medicine, Imperial College London) to confirm the 
molecular weights of the synthetic peptides. ProteinChip® NP20 arrays (Bio-
Rad Laboratories) were primed with 5 µL of HPLC grade water, and 5 µL of 
each peptide (0.5 mg mL-1) was applied to the array surface and allowed to 
air-dry for 1 h at room temperature. The arrays were washed twice with 5 µL 
of HPLC grade water and allowed to air-dry for a further 15 min at room 
temperature. 20% CHCA was applied twice (2 × 0.7 µL) to each spot on the 
arrays, allowing the matrix to air-dry between each application. Time-of-flight 
spectra were generated using a PCS 4000 SELDI-TOF MS instrument (Bio-
Rad Laboratories). Spectra from the peptide pools were obtained at a laser 
energy of 800 nJ, using a focus mass based on the theoretical molecular 
weight of each individual peptide and with the matrix attenuated to 500 Da. 
Ten shots were obtained per position and a total of 500 shots kept per array. 
Mass accuracy was calibrated externally using All-in-One Peptide (Bio-Rad 
Laboratories).  
 
3.2.3. Circular dichroism (CD) spectroscopy 
The secondary structures of the synthetic peptides were evaluated using CD 
spectroscopy. The peptides were first dissolved in 25 mM sodium dodecyl 
sulphate (SDS) surfactant to a final concentration of 0.5 mg mL-1.  Peptide 
solutions were then transferred to a quartz cell with a path length of 1.0 mm 
and the CD spectra were measured at room temperature with a Jasco J-810 CD 
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spectrometer (Jasco, Tokyo, Japan) at the National University of Singapore, 
and the Chirascan™ CD spectrometer (Applied Photophysics, Surrey, UK) at 
Imperial College London. CD spectra were recorded from a wavelength of 
190 to 240 nm, at a scanning speed of 50 nm min-1 and averaged from two to 
three runs per peptide. The acquired spectra were converted to mean residue 
ellipticity using the following equation:  
θ" = $θ%&'10 ⋅ M,-c ⋅ /  
where θM is the mean residue ellipticity (deg cm2 dmol-1), θobs is the observed 
ellipticity corrected for the blank at a given wavelength (mdeg), MRW is 
residue molecular weight (MW / number of amino acids), c is peptide 
concentration (mg mL-1), and l is the path length (cm).  
 
3.2.4. Peptide hydrophobicity analysis  
The molecular hydrophobicity of the synthetic peptides in Chapter 5 was 
analysed by RP-HPLC on a Shimadzu Prominence UFLC™ system 
(Shimadzu Corporation, Kyoto, Japan) equipped with a CBM-20A 
communications bus module, a SPD-20AV UV/Vis detector, a SIL-20A HT 
autosampler, LC-20AD pumps, a DGU-20A 5 vacuum degasser and a CTO-
20A column oven. Runs were performed using an Agilent Poroshell 120 EC-
C18 Threaded column (4.6 × 50 mm, particle size 2.7 µm) monitored at 220 
nm, with an injection volume of 50 µL and a flow rate of 1 mL min-1. The 
mobile phase consisted of solvent A (0.1% TFA in water) and solvent B (0.1% 
TFA in acetonitrile). The gradient profile applied was a 30 min linear gradient 
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from 5 to 50% of solvent B followed by 1 min linear gradient of 5% solvent B 
and 9 min at 5% solvent B for a total time of 40 min.  
 
3.3. Bacterial and cell cultures 
3.3.1. Mycobacterial strains and growth conditions 
M. smegmatis (ATCC 14468) and M. tuberculosis H37Rv (H37Rv) were 
purchased from ATCC (USA). M. smegmatis was cultured in nutrient broth 
containing 0.05% Tween 80 and colonies were grown on bacteriological agar. 
M. bovis BCG lux (BCG), Montreal strain, transformed with the reporter 
plasmid construct pSMT1 as previously described [110], was a gift from 
Professor Douglas Young (Imperial College London). mCherry-expressing 
BCG (BCG-mCherry) was produced by transforming M. bovis BCG Danish 
strain 1331 (Statens Serum Institut) with pCherry3 (Addgene plasmid #24659 
encoding mCherry and conferring hygromycin resistance) [111], which was a 
kind gift from Dr Tanya Parish (University of Washington), using established 
protocols for mycobacteria [112]. Transformation of BCG-mCherry was 
performed by Dr. Iria Uhia (Department of Medicine, Imperial College 
London). M. tuberculosis CSU87 (CSU87) is a MDR clinical isolate that was 
a gift from Dr Diane Ordway (Colorado State University) and is resistant to 
rifampicin, isoniazid, ethambutol, streptomycin and kanamycin. Three other 
clinical isolates, provided by Dr Guy Thwaites and the Oxford University 
Clinical Research Unit (OUCRU), were M. tuberculosis 173 (Mtb 173) from 
the Euro-American lineage and, M. tuberculosis 212 (Mtb 212) and M. 
tuberculosis 411 (Mtb 411), both from the East Asian/Beijing lineage. Liquid 
cultures of all mycobacterial strains were grown in Middlebrook 7H9 broth 
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supplemented with 0.05% Tween 80, 0.2% glycerol and 10% ADC 
supplement. Mycobacterial colonies were grown on solid media consisting of 
Middlebrook 7H11 agar supplemented with 0.5% glycerol and 10% OADC 
supplement. BCG and BCG-mCherry were grown in 7H9 broth or 7H11 agar 
in the presence of 50 µg mL-1 hygromycin.  Bacterial stocks were frozen at -
80 oC in 15% glycerol and a fresh vial was defrosted, inoculated into media 
and grown at 37 oC in a shaking incubator until mid-log phase.  
 
3.3.2. Gram-positive and Gram-negative bacterial strains and growth 
conditions 
The P. aeruginosa reference strain (PAO1), laboratory strains of E. coli (K-12 
MG1655) and methicillin-sensitive S. aureus (MSSA 8325-4), and the clinical 
isolate of Klebsiella pneumoniae (MIDG1643) were evaluated in this study. 
Drug-resistant strains included the hospital-acquired MRSA (MRSA 252), and 
MDR P. aeruginosa wound isolates (PA-W1, PA-W14 and PA-W25). We 
would like to thank Dr John Tregoning (Imperial College London) for 
providing the MSSA and MRSA strains, Professor Paul Williams (University 
of Nottingham) for the P. aeruginosa wound isolates and Dr Martin Goldberg 
(University of Birmingham) for the E. coli strain. All liquid bacterial strains 
were grown in BHI broth at 37 oC in a shaking incubator until mid-log phase, 




3.3.3. Cell culture 
Mouse macrophage cell line RAW 264.7 was maintained in DMEM 
supplemented with 10% FBS, and cultured in a humidified atmosphere at 37 
oC and 5% CO2.  
 
3.4. Antimicrobial activity  
3.4.1. MIC measurements  
The MIC of the peptides and drugs against the six mycobacterial strains, and 
Gram-positive and Gram-negative bacteria, was determined by the broth 
microdilution method as described previously [93, 113, 114]. Peptide stock 
solutions were prepared in sterile water for all experiments before performing 
a series of two-fold serial dilutions in broth. Solutions were vortexed for 10 to 
15 seconds each time to ensure thorough mixing, prior to removing half for 
dilution. The peptides were serially diluted with the appropriate broth (7H9 for 
mycobacteria and BHI for all other strains), and 100 µL was added to each 
well of the 96-well plate. Bacterial cultures were grown up to mid-log phase 
and diluted to an initial inoculum of 106 CFU mL-1 before seeding an equal 
volume into each well. The plates were incubated at 37 oC and read after 18 h 
for Gram-positive and Gram-negative bacteria, 72 h for M. smegmatis, and 7 
days for BCG, H37Rv, CSU87, Mtb 173, Mtb 212 and Mtb 411. The MIC 
was defined as the concentration at which no microbial growth was observed 
visually or spectrophotometrically by OD600 readings taken by Tecan Infinite 
200 Pro (TECAN, Switzerland). Growth media containing only microbial cells 
was used as the negative control. Each test was carried out in at least three 
replicates and repeated two to three times.  
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3.4.2. In vitro killing efficiency   
The antimicrobial peptides displaying the highest selectivity for bacterial over 
mammalian cells were tested for their ability to kill mycobacteria, and Gram-
positive and Gram-negative bacteria. Peptides were serially diluted with the 
appropriate broth (7H9 for mycobacteria and BHI for all other strains) to give 
solutions with final concentrations ranging from 0.5x to 8x MIC. Bacterial 
cultures were diluted to a cell density of 106 CFU mL-1 and 100 µL was added 
to an equal volume of peptide solution. The plates were incubated at 37 oC for 
18 h for Gram-positive and Gram-negative bacteria, 72 h for M. smegmatis 
and 7 days for all other mycobacterial strains, after which they were serially 
diluted in broth for determination of viable counts. Diluted samples (100 µL) 
were plated in triplicate onto agar plates and total bacterial counts were 
determined after incubation at 37 oC for 24h for Gram-positive and Gram-
negative bacteria, 72 h for M. smegmatis, 14 days for BCG and 14 days in the 
presence of 5% CO2 for all other mycobacterial strains. The results are 
expressed as mean log (CFU mL-1) ± standard deviation (S.D.).  
 
3.4.3. Time-kill curve 
Flasks containing 10 mL of nutrient broth with antimicrobial agents at 
concentrations corresponding to 1x, 4x and 8x MIC were inoculated with M. 
smegmatis at a density of approximately 105 CFU mL-1 and incubated in a 
shaking incubator at 37 oC. A flask without any drug served as a growth 
control. Aliquots were removed at time 0, 8, 24, 48 and 72 h post-inoculation 
and serially diluted in nutrient broth for the determination of viable counts. 
Diluted samples (100 µL) were plated in triplicate onto agar plates and total 
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bacterial counts determined after incubation at 37 oC for 72 h.  The results are 
expressed as mean log (CFU mL-1) ± S.D.  
 
3.4.4. Chequerboard assay  
Antimicrobial interactions between peptides and rifampicin in Chapters 4 and 
5 were evaluated via the chequerboard assay as described elsewhere [115]. 
Briefly, two-fold serial dilutions of rifampicin and each peptide were prepared 
and added in a 1:1 volume ratio to the wells of a 96-well plate. An equal 
volume of bacterial solution (100 µL) at approximately 105 CFU mL-1 was 
then seeded into each well. The plates were incubated in a shaking incubator 
at 37 oC and 200 rpm and read after 72 h for M. smegmatis, and 7 days for 
BCG and H37Rv. Bacterial growth was assessed visually or 
spectrophotometrically via OD600 readings taken by Tecan Infinite 200 Pro 
(TECAN, Switzerland). Each assay was performed in triplicate and repeated 
two to three times. The fractional inhibitory concentration index (FICI) for 
each drug combination was calculated using the following equation: 
0121 = $312$45$67689:7$9;$<4=>9;?894;312$45$67689:7$?/4;7 + $$312$45$A95?=69<9;$9;$<4=>9;?894;312$45$A95?=69<9;$?/4;7  
 
An FICI of ≤ 0.5 was interpreted as synergy, 0.5 < FICI ≤ 1.0 as additive, 1.0 
< FICI ≤ 4.0 as indifferent, and an FICI > 4.0 as antagonism [116, 117]. 
 
3.4.5. Drug resistance stimulation study  
In Chapter 4, drug resistance was induced in M. smegmatis by repeated 
treatment with sub-inhibitory concentrations of antimicrobial agents. The 
MICs of the peptide M(LLKK)2M and rifampicin were tested for up to 10 
passages against M. smegmatis using the same broth microdilution method. 
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For each antimicrobial agent, bacterial cells exposed to sub-MIC (⅛ of MIC at 
that particular passage) were re-grown to the log phase and reused for the 
following passage’s MIC measurement. To explore if the combination of 
rifampicin and peptides could suppress resistance development in M. 
smegmatis, a fixed concentration of M(LLKK)2M (equivalent to ¼ of MIC) 
was added to two-fold increasing concentrations of rifampicin. Bacterial cells 
from the highest drug combination showing growth were re-grown to the log 
phase before measuring the MIC of rifampicin and treating them with the drug 
combination again. Changes in the MIC were depicted by normalising the 
MIC at passage n to that of the first passage.  
 
3.4.6. Intracellular anti-mycobacterial activity  
The intracellular activity of the antimicrobial peptide II-D in Chapter 6 was 
assessed against M. tuberculosis clinical isolates Mtb 411 and CSU87 as 
described previously [118]. Briefly, RAW 264.7 cells were plated at a final 
concentration of 4 x 104 per well in 96-well plates and incubated for 24 h to 
allow adherence. Prior to infection, mid-log phase bacterial cultures were 
washed twice with PBS, resuspended in DMEM, and added at a final 
concentration of 4 x 105 CFU per well to achieve a multiplicity of infection 
(MOI) of 10:1. Plates were incubated at 37 oC and 5% CO2 for 4 h to allow 
uptake of bacteria by macrophages. Subsequently, cells were washed thrice 
with prewarmed DMEM to remove extracellular bacteria before adding 200 
µL of DMEM, with or without drugs, to each well. II-D was tested at 
concentrations corresponding to 0.5x, 1x, 2x and 4x MIC, while rifampicin 
and moxifloxacin were evaluated at 1x, 2x, 4x and 8x MIC. Each 
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concentration was tested in triplicate. For determination of bacterial viability 
at various time points, macrophages were lysed with 200 µL of sterile water 
for 30 min, serially diluted with PBS and 10 µL was plated out in duplicate on 
7H11 agar. Following incubation at 37 oC for 14 days, bacterial colonies were 
enumerated and data are expressed as mean log (CFU mL-1) ± S.D. 
 
3.5. Toxicity and stability  
3.5.1. Haemolytic activity test  
The safety of the peptides against mammalian cells was assessed by evaluating 
their haemolytic activity using freshly drawn RBCs as reported previously [93, 
113, 114]. Rat RBCs used in this study were obtained from the Animal 
Handling Units of the Biomedical Research Centre (AHU, BRC, Singapore) 
while whole blood was obtained from healthy adult donors at Imperial College 
London. Prior to commencement, ethics approval was granted by Imperial 
College London NHS Healthcare Tissue Biobank (sub-collection reference 
number: Pae-SN-15-001) and written informed consent was obtained from all 
participants. Briefly, the RBCs were diluted 25 times with PBS to obtain a 4% 
(v/v) suspension for subsequent testing. Two-fold serial dilutions of the 
peptides were prepared in PBS to give solutions with final concentrations 
ranging from 0 up to 1000 mg L-1 or 2000 µM. Three hundred µL of the blood 
suspension was then mixed with an equal volume of the peptide solution and 
incubated at 37 oC for 2 h. Following incubation, the mixtures were 
centrifuged at 1700 g for 5 min and 100 µL of the supernatant was transferred 
to each well of the 96-well plate. Haemoglobin release was quantified 
spectrophotometrically by absorbance measurements at 576 nm by Tecan 
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Infinite 200 Pro (TECAN, Switzerland). Data are expressed as mean ± S.D. 
for two independent experiments performed in at least four replicates. RBCs 
treated with 1% Triton X-100 served as the positive control while untreated 
RBCs served as the negative control. The extent of haemolysis was calculated 
using the following equation: 
B?7=4/CD9D$ % = (GHIJKLM$NO$PQRSPRT$USVWXRYGHIJKLM$NO$ZR[SP\]R$^NZPQNX)(GHIJKLM$NO$WNU\P\]R$^NZPQNXYGHIJKLM$NO$ZR[SP\]R$^NZPQNX) ×$100%  
 
3.5.2. Cytotoxicity testing 
Peptides were evaluated for their cytotoxicity against the mouse macrophage 
RAW 264.7 cell line using the MTT assay. The cells were seeded into 96-well 
plates at a density of 1 x 104 cells per well and incubated overnight at 37 oC 
and 5% CO2. Peptides, serially diluted in DMEM to give final concentrations 
ranging from 1.95 to 250 mg L-1, were added and the plates further incubated 
for 24 h. Cells without peptides served as controls. Following treatment, the 
media was replaced with 200 µL fresh growth media and 40 µL MTT solution 
(5 mg mL-1) and incubated for an additional 4 h at 37 oC. Next, 150 µL of 
DMSO was added to each well to dissolve the resultant formazan crystals and 
absorbance at 595 nm was measured using Tecan Infinite 200 Pro (TECAN, 
Switzerland) or a VersaMax Tunable microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). Cell viability was expressed as 
aIbILM$%c$defgdfh$'gijkfaIbILM$%c$l%mde%k ×100%. Experiments were performed in triplicate per 
concentration.   
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3.5.3. Protease stability assay 
The proteolytic stability of the synthetic peptides in Chapter 6 was assessed by 
measuring their antimicrobial activity against BCG after pretreatment with the 
serum protease, trypsin, in accordance with methods described previously 
[119]. Briefly, peptide solutions at a fixed concentration of 4x MIC were 
incubated with trypsin at an enzyme to peptide ratio of 1:100. Following 
incubation at 37 oC for 6 h, the solutions were heat-treated at 80 oC for 10 min 
to inactivate the enzyme. One hundred µL of the treated peptide solution was 
then added to an equal volume of bacterial culture (106 CFU mL-1) and 
incubated at 37 oC in a shaking incubator for 7 days. Inhibition of bacterial 
growth was determined by spectrophotometric measurements at OD595. Data 
are expressed as mean ± S.D. for two independent experiments performed in 
triplicate. 
 
3.6. Anti-biofilm activity  
3.6.1. Inhibition of biofilm formation  
The ability of L12 to prevent biofilm formation was studied in Chapter 7 in 
96-well plates using the CV staining assay as described previously [120].  
Briefly, bacterial cultures were grown to mid-log phase before diluting to give 
an inoculum of 106 CFU mL-1. Fifty µL of the bacterial suspension was seeded 
into each well together with an equal volume of peptide solution. The anti-
biofilm activity of the L12 was assessed at concentrations corresponding to 
0.06x 0.125x, 0.25x, 0.5x, 1x and 2x MIC. Following overnight incubation at 
37 oC to facilitate biofilm formation, the culture media was aspirated and wells 
washed with deionised water to remove planktonic cells. Adherent biofilms 
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were stained with 0.1% (w/v) CV solution (125 µL) for 10 min at room 
temperature and subsequently washed with deionised water to remove the 
excess dye. Two hundred µL of 70% ethanol was transferred to each well to 
solubilise the dye and the biomass of biofilms was quantified by absorbance 
measurements at 595 nm taken with the VersaMax Tunable microplate reader 
(Molecular Devices, Sunnyvale, CA, USA). Data are expressed as mean ± 
S.E.M. for three independent experiments performed in triplicate. 
 
3.6.2. Disruption of pre-formed biofilms  
The viability of pre-formed biofilms following peptide treatment was assessed 
in Chapter 7 according to previously established protocols [121]. Mid-log 
phase cultures of PA-W25 and MRSA 252 were diluted to 106 CFU mL-1 and 
100 µL was added to each well. After incubation for 18 h at 37 oC to allow 
biofilm formation, wells were washed with deionised water and 100 µL of 
peptide solution was added at concentrations equivalent to 2x, 4x, 8x and 16x 
MIC. After 2 h exposure to L12, wells were washed with deionised water 
before determination of biofilm viability using the MTT assay as described in 
Section 3.5.2. Data are expressed as mean ± S.E.M. for three independent 
experiments performed in triplicate. 
 
3.6.3. Bioluminescence imaging of biofilms 
To complement the microbiological biofilm assays, bioluminescence imaging 
studies were performed in Chapter 7 to visualise the extent of peptide-
mediated biofilm eradication and growth suppression. Bioluminescent P. 
aeruginosa (ATCC 9027), transformed using a recombinant plasmid 
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containing the luxCDABE gene cassette of Photorhabdus luminescens excised 
from pAKlux1.1, which was a kind gift from Attilia Karsi (Mississippi State 
University), and cloned into the PUCP19 vector backbone by electroporation, 
was employed in the screening of anti-biofilm activity of the synthetic 
peptides [122]. Transformed P. aeruginosa was maintained in LB broth 
containing carbenicillin (300 µg mL-1). Preparation of bacterial inoculums and 
treatment of biofilms were conducted according to protocols reported in the 
previous sections. Inhibition of biofilm growth was assessed after 18 h 
treatment with L12 up to 4x MIC while pre-formed biofilms were evaluated 
following 2 h exposure to L12 up to 64x MIC. The IVIS imaging system was 
utilised for imaging of bioluminescent biofilms and acquired with Living 
Image software. Bioluminescence signals are expressed as photons per second 
per centimetre squared per steradian (p/s/cm2/sr) and presented as an intensity 
map. Biofilm imaging was performed by Ms. Sybil Obuobi (Department of 
Pharmacy, National University of Singapore).    
 
3.7. Antimicrobial mechanisms  
3.7.1. Membrane permeability studies 
3.7.1.1. Flow cytometry  
Mycobacterial membrane integrity of M. smegmatis, H37Rv and CSU87 
following peptide treatment was evaluated in Chapters 5 and 6 using flow 
cytometry. Briefly, mid-log phase bacterial cultures were washed twice with 
PBS and re-suspended to give ~108 CFU mL-1 in the same buffer. M. 
smegmatis was treated with peptides at different concentrations (62.5, 125 and 
250 mg L-1) for 2 h, while cells treated with rifampicin and ethambutol (1x, 2x 
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and 4x MIC) served as negative controls. H37Rv and CSU87 were treated 
with peptides at 4x MIC for 3 h, while cells treated with rifampicin and 
moxifloxacin at 4x MIC served as negative controls for H37Rv and CSU87, 
respectively. Next, treated cells were incubated with 20 µg mL-1 PI for 30 min, 
followed by washing and re-suspension in PBS to remove any unbound dye. 
Cells were then fixed overnight with 4% formaldehyde solution. The fixed 
samples were washed twice with PBS before performing flow cytometric 
analysis using LSR II and FACSDiva software (Becton Dickinson, San Jose, 
CA) at the St Mary's FACS Facility, Imperial College London or using 
CyAn™ ADP Analyser (Becton Dickinson, San Jose, CA) at the Flow 
Cytometry Laboratory, National University Health System, Singapore.   
 
3.7.1.2. Cytoplasmic membrane depolarisation assay  
The ability of the peptides to disrupt the mycobacterial membrane potential 
was assessed in Chapter 5 using the membrane potential sensitive dye diS-C3-
5. An overnight M. smegmatis culture was first washed with 5 mM HEPES 
buffer containing 20 mM glucose and 0.1 M KCl (pH 7.2) and re-suspended to 
an OD600 of 0.4 in the same buffer. The cells were then incubated with 10 µM 
of diS-C3-5 for 1 h at 37 oC after which 600 µL was transferred to a stirred 
quartz cuvette. Change in fluorescence intensity following the addition of 
peptides at 1x, 4x and 8x MIC was monitored using a Quanta Master 
spectrofluorometer (Photon Technology International, NJ, USA) with an 
excitation and emission wavelength of 622 and 670 nm respectively.  
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3.7.1.3. ATP bioluminescence assay  
Extracellular ATP levels following treatment of M. smegmatis with peptides 
were measured in Chapter 5 as described previously [123]. Briefly, an 
overnight M. smegmatis culture was first washed and re-suspended in 10 mM 
phosphate buffer to an OD600 of 0.4. Peptides serially diluted with the same 
buffer to give final concentrations from 15.6 to 500 mg L-1 were added to an 
equal volume of bacterial suspension (300 µL) and incubated at 37 oC for 2 h. 
Next, samples were centrifuged at 5000 g for 5 min and 50 µL of the 
supernatant was added to 450 µL of boiling TE buffer (50 mM Tris, 2 mM 
EDTA, pH 7.8). The mixture was boiled for an additional 2 min and stored on 
ice until assayed. One hundred µL of cooled mixture was added to 100 µL of 
luciferin-luciferase assay mixture and luminescence was recorded using Tecan 
Infinite 200 Pro (TECAN, Switzerland). Extracellular ATP concentrations 
were determined from ATP standard curves using ATP assay kit according to 
the manufacturer’s instructions. Data are expressed as mean ± S.E.M. for three 
independent experiments performed in duplicate. 
 
3.7.1.4. Calcein leakage assay 
The calcein leakage assay was performed in Chapter 5 by Dr. Ke Xi Yu (IBN, 
Singapore). Large unilamellar vesicles (LUVs) loaded with calcein dye were 
prepared according to methods described previously [124]. Calcein dye was 
dissolved to a final concentration of 40 mM in 10 mM Na2HPO4 in H2O (pH 
7.0). 476 µL PE and 127 µL PG dissolved in 25 mg mL-1 CHCl3 were mixed 
in a round bottom flask. Solvent removal by rotatory evaporator left behind a 
thin lipid film which was then hydrated using 1 mL calcein solution. The 
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mixture was stirred for an additional hour on the rotary evaporator at 
atmospheric pressure before being subjected to ten freeze-thaw cycles (dry 
ice/acetone to freeze and warm water to thaw). Extrusion of the suspension 
was then carried out twenty times through a polycarbonate membrane with 
400 nm pore diameter. Removal of excess dye was performed using a 
Sephadex G-50 column, with a buffer consisting of 10 mM Na2HPO4 and 90 
mM NaCl as the eluent. Dye-filled LUVs were then diluted 2000 times using 
the same buffer to achieve a final lipid concentration of approximately 5.0 
mM. The calcein fluorescence emission intensity It (λem = 515nm, λex = 
490nm) was measured following treatment of LUVs with peptides at various 
concentrations (125, 250 and 500 mg L-1) for 1 h and 2 h. Fluorescence 
emission following addition of 50 µL Triton X-100 (20% in DMSO) (Ix) was 
taken as 100% leakage while the baseline (I0) was measured without peptide 
addition. Treatment with pure DMSO did not produce any leakage. Data are 
expressed as mean ± S.D. for two independent experiments performed in 
triplicate. The percentage of calcein leakage was calculated as follows: 
Leakage (%) = 1P − 1o /(1q − 1o)×100% 
 
3.7.2. Microscopy studies 
3.7.2.1. Membrane integrity study using confocal laser scanning microscopy 
(CLSM) 
The loss of membrane integrity after exposure of M. smegmatis to peptides in 
Chapter 4 was studied using CLSM. M. smegmatis was incubated overnight in 
a Lab-Tek 8-well-chambered coverglass (Nalge Nunc International, 
Rochester, NY, U.S.A.) at 37 oC at 200 rpm to allow for adherence of bacterial 
cells to the chamber surface. After the removal of the bacterial solution from 
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the chamber, the adhered bacterial cells were treated with M(LLKK)2M at its 
MIC for 10, 30 and 60 min, in the presence of FITC-labelled dextran probe. 
Following treatment, the peptide solution was removed and the bacterial cells 
washed thoroughly with PBS thrice to ensure that no free probe remained. 
Imaging was carried out using the Zeiss LSM 510 inverted confocal 
microscope (Carl Zeiss, Inc.) Bacterial cells treated with PBS in the presence 
of FITC-labelled probe served as a control for this study. 
  
3.7.2.2. Peptide localisation study using CLSM  
The site of action of II-D in BCG was studied in Chapter 6 using CLSM. BCG 
and BCG-mCherry cultures were grown to mid-log phase, centrifuged at 2000 
g for 10 min, washed, and resuspended in PBS at a cell density of 108 CFU 
mL-1. Following treatment with 500 mg L-1 FITC-labelled II-D for 2 h, 
bacterial cells were centrifuged at 2000 g for 10 min and washed three times 
with PBS. To stain bacterial membranes, BCG cells were resuspended in PBS 
with 2 µg mL-1 FM4-64 for 10 min at 37 oC with shaking. Cells were then 
pelleted, washed twice with PBS to remove any unbound dye, and fixed 
overnight with 4% formaldehyde solution at 4 oC. Following fixation, cells 
were pelleted, resuspended in PBS and allowed to air dry on microscope slides 
for 20 min. Samples were mounted with Mowiol mounting medium and 
imaged with a 100x oil-immersion objective lens using a Zeiss LSM 510 
inverted confocal microscope (Carl Zeiss, Inc.). FITC was excited with a 488 
nm laser and detected with a 505-530 nm band-pass filter while mCherry and 
FM4-64 were both excited with a 543 nm laser and detected with a 615 nm 
and 650 nm long-pass filters, respectively.  
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3.7.2.3. Field emission scanning electron microscopy (FE-SEM) 
Mycobacterial membrane damage following peptide treatment in Chapter 4 
was visualised using FE-SEM. M. smegmatis suspension at ~108 CFU mL-1 
was treated with an equal volume of peptide at lethal doses of 250 mg L-1 (4x 
MIC) or PBS for 2 h. Five replicates were pooled together, centrifuged at 2700 
g for 10 min and washed twice with PBS. The samples were then fixed with 
4% formaldehyde for 30 min before rinsing with deionised water. A series of 
ethanol solutions (35%, 50%, 75%, 90%, 95%, and 100%) was used to 
perform sample dehydration, after which they were mounted on copper tapes 
and allowed to air-dry for 2 days. Samples were finally sputter coated with 
platinum before imaging under a FE-SEM (JEOL JSM-7400F, Japan) at IBN, 
Singapore.   
 
3.7.2.4. Microfluidic live-cell imaging with time-lapse fluorescence 
microscopy  
Live-cell imaging was performed in Chapters 6 and 7 using the automated 
CellASIC ONIX Microfluidic Platform with the CellASIC ONIX B04A-03 
Microfluidic Bacteria Plates (EMD Millipore Corporation, Hayward, CA, 
USA). Mid-log phase bacterial cultures were first diluted in the appropriate 
broths (7H9 for BCG and BHI for E. coli and S. aureus) to a final density of 
107 CFU mL-1, before adding 100 µL to each of the cell loading wells. To 
evaluate the antimicrobial mechanisms of action, the most selective peptides 
II-D and L12, were serially diluted in broth to give final concentrations 
corresponding to 4x and 8x MIC. Peptide solutions were then added to the 
inlet wells together with the membrane-impermeable dye, PI (10 µg mL-1), in 
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a total volume of 350 µL. Next, the microfluidic plate was vacuum-sealed to 
the F84 manifold and the CellASIC ONIX FG Software initiated. Loading and 
subsequent washing of un-trapped bacterial cells was carried out according to 
the manufacturer’s protocol [125]. Peptide solutions were perfused into 
culture chambers at the recommended pressure of 2 psi for up to 4 h. The 
temperature was maintained at 37 oC and bacterial cells treated with medium 
and PI alone served as negative controls. Phase contrast and fluorescent 
images of bacterial cells were captured with a 63x oil-immersion objective 
lens every 10 min using the Zeiss Axiovert 200M inverted microscope (Carl 
Zeiss, Inc.). Microscopy was performed in the Facility for Imaging by Light 
Microscopy (FILM) at Imperial College London. 
 
3.7.2.5. Image and statistical analysis  
The Huygens Deconvolution software (Scientific Volume Image) was used to 
perform deconvolution of confocal images. Fluorescence intensity profiles 
along the bacterial cell length were obtained with the segmented line and 
multi-channel intensity line profile plot tools in the ImageJ software. 
Processing and compiling of phase and fluorescent images into movies at two 
frames per second, were carried out using the ImageJ software. All statistical 
analysis in this study was performed with GraphPad Prism 6 software 
(GraphPad Software Inc., CA, USA) using either one-way analysis of variance 
(ANOVA), with Bonferroni’s post hoc test for multiple comparisons or a non-
parametric Kruskal Wallis multiple comparisons test with Dunn’s post-test. 
Significant differences between groups were indicated as follows: * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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3.8. Immune-modulating activity   
3.8.1. NO production by peptide-treated macrophages  
The ability of II-D to active macrophages in Chapter 6 was determined by 
measuring NO production following peptide treatment. RAW 264.7 cells were 
seeded in 96-well plates at a density of 4 x 104 per well, followed by 
incubation at 37 oC and 5% CO2 for 24 h. The medium was removed and cells 
were treated with peptide solutions ranging from 7.81 to 250 mg L-1 for an 
additional 24 h. NO production was estimated by measuring nitrite 
concentrations in supernatants using the Griess reagent (0.1% N-1-
napthylethylenediamine dihydrochloride, 1% sulfanilamide and 5% 
phosphoric acid) according to the manufacturer’s protocols. The absorbance 
was measured at 540 nm and nitrite concentrations were determined using 
standard curves generated with NaNO2 solutions. Macrophages stimulated 
with 100 ng mL-1 LPS served as positive controls while unstimulated 
macrophages served as negative controls. Data are expressed as mean ± S.D. 
for two independent experiments performed in triplicate. 
 
3.8.2. TNF-α production by peptide-treated macrophages  
The ability of II-D to active macrophages in Chapter 6 was also determined by 
measuring TNF-α production following peptide treatment. RAW 264.7 cells 
were seeded in 96-well plates at a density of 4 x 104 per well, followed by 
incubation at 37 oC and 5% CO2 for 24 h. The medium was removed and cells 
were treated with peptides solutions ranging from 7.81 to 250 mg L-1 for an 
additional 24 h. TNF-α concentration in supernatants was determined using 
the mouse TNF-α ELISA kit as per the manufacturer’s instructions. 
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Absorbance readings were measured at 450 nm. Unstimulated macrophages 
served as negative controls, and positive controls were stimulated with 100 ng 
mL-1 LPS. Data are expressed as mean ± S.D. for two independent 
experiments performed in triplicate. The degree of TNF-α production was 
calculated as follows: 
rs0 − t$6A4:u<894;$ % GHvIwLM$NO$PQRSPRT$USVWXRYGHvIwLM$NO$ZR[SP\]R$^NZPQNXGHvIwLM$NO$WNU\P\]R$^NZPQNXYGHvIwLM$NO$ZR[SP\]R$^NZPQNX ×100%  
 
3.8.3. NO production by LPS-stimulated macrophages 
The de novo designed peptides were evaluated for their anti-endotoxic activity 
in Chapter 7 by determining the reduction in NO production in macrophages 
stimulated with LPS. RAW 264.7 cells were seeded at a density of 4 x 104 
cells per well in 96-well plates and incubated for 24 hours at 37 oC and 5% 
CO2. Following medium removal, cells were stimulated with LPS (100 ng mL-
1), either in the presence or absence of peptides for an additional 24 hours. NO 
formation was determined by measuring nitrite concentrations in supernatants 
using the Griess reagent (0.1% N-1-napthylethylenediamine dihydrochloride, 
1% sulfanilamide and 5% phosphoric acid) according to the manufacturer’s 
protocols. Absorbance readings were taken at 540 nm by the VersaMax 
Tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA) and 
standard curves generated with NaNO2 solutions were used to quantify nitrite 
levels. Untreated cells and those stimulated with LPS alone served as negative 
and positive controls, respectively. Data are expressed as mean ± S.E.M. for 
three independent experiments performed in triplicate. 
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3.8.4. Neutralisation of endotoxins  
The de novo designed peptides were evaluated for their LPS-binding activity 
in Chapter 7 using the LAL chromogenic assay in accordance with the 
manufacturer’s protocols. Peptides were serially diluted in endotoxin-free 
water and added to an equal volume of LPS (0.5 EU mL-1) in 96-well plates in 
a final volume of 50 µL. The plates were incubated for 30 min at 37 oC to 
facilitate interactions between the peptides and LPS, following which, 50 µL 
of LAL was added to each well. After additional 10 min incubation at 37 oC, 
100 µL of the chromogenic substrate solution (Ac-Ile-Glu-Ala-Arg-p-
nitroalanine) was added to each well. Next, the plates were incubated for a 
further 6 min at 37 oC before adding 50 µL of 25% acetic acid to terminate the 
reaction. The extent of LPS binding was quantified relative to untreated 
controls by absorbance measurements at 405 nm taken with the VersaMax 
Tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA). Data 
are expressed as mean ± S.D. for three independent experiments. 
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CHAPTER 4: Anti-mycobacterial activities of synthetic cationic α-helical 
peptides and their synergism with rifampicin 
4.1. Introduction  
Inspired by nature, many AMPs are currently under clinical development for 
treating various bacterial infections [56]. There is a huge diversity in 
sequences, although their common cationic and amphiphilic nature is apparent 
[22]. With their overall positive charges, AMPs contact bacterial cell surfaces 
by associating with acidic polymers and other negatively charged molecules, 
after which they insert themselves into the membrane and disrupt its physical 
integrity via membrane thinning, transient pore formation and/or disruption of 
the barrier function [126-128]. Some studies have also shown that they kill 
bacteria by translocating across the membrane and acting on internal targets 
[21]. This membrane-targeted mechanism of action is responsible for their 
activity against a wide range of pathogens. While natural AMPs have 
demonstrated potent activity against Gram-positive and Gram-negative 
bacteria, their efficacy tends to be diminished against M. tuberculosis. In the 
context of tuberculosis, even though the composition of the mycobacterial cell 
wall is inherently different with a higher proportion of lipids such as mycolic 
acids, natural AMPs, including the human cathelicidin LL-37, hBDs and 
HNPs, have been documented to kill M. tuberculosis albeit at rather high 
concentrations. LL-37 has been found to be inactive in vitro against H37Rv 
and MDR M. tuberculosis at concentrations of 50 mg L-1 [30]. hBD-2 and 
hBD-3 demonstrated superior in vitro activities in comparison to LL-37, with 
MICs against H37Rv of 12 and 24 mg L-1, respectively [129]. hBD-1, 
however, exhibited poor in vitro killing of H37Rv and MDR M. tuberculosis 
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even up to concentrations of 128 mg L-1 [130]. Amongst the HDPs, HNP-1 
emerged as the most potent inhibitor of H37Rv in vitro with a relatively low 
MIC of 2.5 mg L-1 [35]. 
 
It is, however, widely recognised that natural AMPs do not make good drug 
candidates mainly due to their large sizes that translate to higher production 
cost and significant toxicity [22, 26]. As such, synthetic variants have been 
developed via several design approaches (described in Section 1.5) in attempts 
to enhance the biological activities of natural HDPs against mycobacteria, 
while minimising undesirable toxic side effects. Sonawane et al. prepared a 
truncated LL-37 congener with threefold greater potency than the native 
peptide [31], while a 15-amino acid analogue of LL-37 possessed a fourfold 
lower MIC against M. smegmatis and a 5.6-fold reduction in cytotoxicity 
[131]. The recombinant hBD-2 and hBD-3 hybrid also displayed the best 
activity against MDR M. tuberculosis in comparison to either of the peptides 
alone [129]. Unsurprisingly, the empirical nature of majority of these 
strategies implies that failure, to some extent, is unavoidable. For example, 
congeners based on truncations of granulysin proved unsuccessful in 
producing synthetic analogues with superior killing efficacy against M. 
tuberculosis, with the full-length granulysin exhibiting the most potent 
antimicrobial effect [132]. Additionally, it has been argued that widespread 
clinical use of AMPs bearing close resemblance to host innate immunity 
peptides will inevitably select for drug-resistant bacteria, thereby posing an 
immense threat to human health [104].  
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To mitigate concerns of antimicrobial resistance development to host peptides, 
and to overcome their inherent drawbacks, the rational approach via de novo 
design is thus being adopted to produce counterparts endowed with superior 
properties. To the best of our knowledge, there are no studies assessing 
rationally designed de novo synthetic AMPs for their antimicrobial activity 
against M. tuberculosis. As discussed in Section 1.5.6, the recurring sequence 
comprising four amino acids (XXYY)n – where X is a hydrophobic amino 
acid, Y is a cationic amino acid, and n is the number of repeat units – was 
successfully implemented in the design of α-helical AMPs [93]. C(LLKK)2C 
was shown to be the most selective peptide against Gram-positive and Gram-
negative bacteria, and yeast [95]. The inclusion of arginine instead of lysine as 
the cationic residue was found to produce peptides with greater haemolytic 
activities, while incorporating alanine or phenylalanine instead of leucine as 
the hydrophobic amino acid resulted in peptides with reduced helical 
propensity [95]. Thus, based on this information, (LLKK)2 was used as a 
starting point in this study, to elucidate the influence of various structural 
modifications on anti-mycobacterial activity of the synthetic α-helical AMPs. 
 
The synthetic α-helical AMPs comprising the backbone sequence (XXYY)n 
were systematically evaluated against several mycobacterial strains including 
clinically isolated MDR M. tuberculosis. Additionally, the approach of 
combination therapy of conventional antibiotics and AMPs was evaluated with 
the objective of preventing or delaying the development of antibiotic 
resistance in TB. Such combination has not been reported in the literature and 
if successful, synergism is expected to reduce treatment costs and minimise 
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peptide toxicity for the application of AMPs in TB treatment. Initially, 
characterisation of peptide secondary structures was performed, followed by 
the evaluation of their anti-mycobacterial properties by MIC measurements 
against M. smegmatis, BCG, H37Rv and the MDR strain, CSU87. The 
antimicrobial mechanism of the peptides was evaluated using CLSM, while 
haemolytic toxicity against mammalian cells was assessed using rat RBCs. 
Drug resistance was stimulated in vitro by repeatedly exposing M. smegmatis 
to sub-inhibitory concentrations of rifampicin and the peptides. Lastly, 
synergistic interactions were determined by co-treatment of the mycobacterial 
strains with rifampicin and AMPs via the chequerboard assay. 
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4.2. Results and Discussion 
4.2.1. Peptide design and characterisation 
Peptides were designed on the basis of evaluating if two different structural 
modifications of the primary peptide, (LLKK)2, could potentially modulate its 
anti-mycobacterial activity. The first was to evaluate if the presence of free 
sulfhydryl (thiol) groups in L-Cys residues could enhance the anti-
mycobacterial activity of these synthetic α-helical peptides. The second was to 
assess if positional hydrophobicity was an important determinant of anti-
mycobacterial activity of these synthetic α-helical peptides. To do so, L-Cys 
was substituted to either or both the N- and C-terminals of the peptides to 
obtain the following peptides: C(LLKK)2, (LLKK)2C and C(LLKK)2C. To 
verify the influence of free sulfhydryl groups on antimicrobial activity, control 
peptides were included by substituting methionine (Met) on either or both 
terminals to obtain the following peptides: M(LLKK)2, (LLKK)2M and 
M(LLKK)2M. It should be noted that the peptides (LLKK)2C, C(LLKK)2C 
and M(LLKK)2M have been previously evaluated against yeast and Gram-
positive and Gram negative bacteria, although the influence of positional 
hydrophobicity on antimicrobial activity was not studied [95]. The primary 
peptide without any additional amino acid residues, (LLKK)2, also served as a 
control. C-terminal amidation of peptides was performed to augment anti-
mycobacterial activity via enhancement of net positive charge [133, 134]. 
MALDI-TOF MS analysis showed that there was close agreement between the 
measured and theoretical molecular weights of the peptides (Table 4.1), 
confirming that peptide synthesis had been performed to the desired 
specifications.  
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Table 4.1. α-helical peptide sequences and their molecular weights. The close 
agreement between the theoretical and measured molecular weights (Mw) 
confirmed the fidelity of peptide synthesis.   




(LLKK)2 LLKKLLKK-NH2 982.37 983.02 
C(LLKK)2 CLLKKLLKK-NH2 1085.51 1086.01 




M(LLKK)2 MLLKKLLKK-NH2 1113.57 1113.79 




a Measured by MALDI-TOF MS, apparent Mw = [Mw + H]+. 
 
4.2.2. CD spectroscopic study  
The peptides adopted a random conformation in aqueous solution (data not 
shown) but folded into α-helical structures once a membrane-like environment 
was provided with the addition of SDS surfactant. Figure 4.1 summarises the 
CD spectra of the peptides with Met and Cys terminal residues. The addition 
of Cys and Met residues resulted in greater α-helical folding as characterised 
by the presence of double minima at 208 nm and 222 nm. These additional 
amino acids increased the peptide length and hydrophobicity, which in turn 
enhanced hydrogen bonding between the ith and (i+4)th amino acid in the 
peptide backbone [135]. As a result, there was stabilisation of the α-helix and 
increased peptide helicity. Thus, peptides with amino acid substitutions on 
both faces had the greatest helicity as determined by a more negative mean 
residue ellipticity value (θM). By comparing the θM values of the peptides at 
these wavelengths, it can be ascertained that the peptides C(LLKK)2 and 
(LLKK)2M had a higher propensity for α-helical folding as compared to 
peptides (LLKK)2C and M(LLKK)2, respectively. A plausible explanation is 
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that the substitution of a hydrophobic Met residue onto the non-polar peptide 
face increased peptide amphiphilicity, which in turn stabilised the α-helical 
conformation of (LLKK)2M. Cys, on the other hand, is a polar uncharged 
residue and exerted similar influence only when it was substituted onto the 
polar peptide face in C(LLKK)2 and not the non-polar face as in (LLKK)2C. 
These results are in agreement with previous findings that showed that 
hydrophobicity of the non-polar region is important for conserving the α-
helical configuration of peptides and that addition of polar residues onto the 
non-polar peptide region could potentially destabilise its helical structure 
[136]. 
 
Figure 4.1. CD spectra of α-helical peptides with (a) Met and (b) Cys 
residues. The presence of the double minima at 208 nm and 222 nm confirmed 
the α-helical secondary structures of the synthetic peptides. Data are 
expressed as the mean of two runs per peptide. 
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4.2.3. In vitro anti-mycobacterial activity 
The antimicrobial activities of the peptides were determined by the standard 
broth microdilution method with the corresponding MICs against M. 
smegmatis summarised in Table 4.2. The peptides efficiently inhibited 
bacterial growth at varying MICs, with the primary (LLKK)2 peptide having a 
MIC of 125 mg L-1. Generally, the addition of one or more amino acids either 
increased or preserved the inhibitory activity of the peptides, except for 
C(LLKK)2C which displayed a decline in inhibitory activity as reflected by a 
MIC of 250 mg L-1. The addition of L-Cys to the N-terminus served to 
enhance the potency of the primary peptide with C(LLKK)2 having the lowest 
MIC of 62.5 mg L-1, while its incorporation at the C-terminus did not render 
the parent peptide any more active against M. smegmatis. However for 
C(LLKK)2C, a reduction in efficacy may partly be due to its sparingly soluble 
nature at high concentrations as seen from its high solution turbidity. As for 
the peptides with Met substitutions, (LLKK)2M and M(LLKK)2M recorded 
the lowest MIC of 62.5 mg L-1, while there was no improvement in activity for 
M(LLKK)2 as compared to the primary peptide. It is likely that the increase in 
hydrophobicity/α-helicity enhanced the membrane permeabilisation and 
antimicrobial potency of these peptides. These findings are consistent with 
those reported previously by Chen et al. who found that increasing the 
hydrophobicity of α-helical peptides consequently improved their 
antimicrobial activity against both Gram-positive and Gram-negative bacteria 
[136, 137]. The lack of improvement in activity of M(LLKK)2 and (LLKK)2C 
could be in part due to the influence of positional hydrophobicity, whereby the 
substitution of a hydrophobic Met residue onto the polar peptide face, and a 
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polar Cys residue onto the non-polar peptide face, decreased facial 
amphiphilicity, in turn reducing antimicrobial activity [138]. Notably, the 
antimicrobial potency of the three most effective peptides (MIC of 62.5 mg L-
1) was preserved in rifampicin-resistant M. smegmatis (Table 4.2). This 
confirmed that the synthetic peptides functioned via a different mechanism of 
action as compared to rifampicin, which hinders transcription by inhibiting 
DNA-dependent RNA polymerase. 
 
Table 4.2. MICs of synthetic α-helical peptides against M. smegmatis and 
their 50% haemolysis concentration (HC50). Addition of Cys and Met residues 
enhanced the antimicrobial activity of the primary peptide, (LLKK)2, as 
reflected by lower MIC values. 
Antimicrobial 
agent 
MIC (mg L-1) HC50 (mg L-1) 
Susceptible strain Resistant strain 
Rifampicin 7.8 500 ND 
(LLKK)2 125 NDa >1000 
(LLKK)2M 62.5 62.5 >1000 
M(LLKK)2 125 ND >1000 
M(LLKK)2M 62.5 62.5 >1000 
(LLKK)2C 125 ND >1000 
C(LLKK)2 62.5 62.5 >1000 
C(LLKK)2C 250 ND >1000 
 a ND, not determined 
The antimicrobial activities of the three most effective peptides against M. 
smegmatis were further evaluated in BCG, H37Rv and CSU87 and the results 
are summarised in Table 4.3. Of the three peptides, the most hydrophobic 
analogue M(LLKK)2M proved to be the most effective against all three 
mycobacterial strains. It had the lowest MIC of 15.6 mg L-1 against BCG and 
was the only peptide active against H37Rv with an MIC of 125 mg L-1. 
Against CSU87, the MIC of M(LLKK)2M was reduced to 62.5 mg L-1. It is 
likely that the enhancement of peptide hydrophobicity resulted in an increase 
in anti-mycobacterial activity, in line with observations from previous studies 
[139, 140]. Despite being ineffective against H37Rv, (LLKK)2M had an MIC 
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of 125 mg L-1 against CSU87. Since alterations of the membrane barrier is one 
way in which resistance develops [141], it is plausible that the CSU87 strain 
studied may have undergone cell wall modifications that enhanced the 
permeabilisation of more hydrophobic AMPs. As such, the addition of one or 
two hydrophobic Met residues to the parent (LLKK)2 peptide resulted in an 
increased antimicrobial potency against CSU87 as compared to H37Rv for 
both (LLKK)2M and M(LLKK)2M. Although the inclusion of L-Cys on the N-
terminus of (LLKK)2 corresponded with a twofold reduction in MIC against 
BCG, this modification proved ineffective in augmenting anti-mycobacterial 
activity against both H37Rv and CSU87.   
Table 4.3. MICs of synthetic α-helical peptides against BCG, H37Rv and 




 MIC (mg L-1)  
BCG H37Rv  CSU87 
(LLKK)2 500 >500 >500 
(LLKK)2M 500 >500 125 
M(LLKK)2M 15.6 125 62.5 
C(LLKK)2 250 >500 >500 
Rifampicin 0.001 0.008 >32 
Moxifloxacina ND ND 0.06 
    a Moxifloxacin served as a positive control 
4.2.4. Killing efficiency and time-kill curve 
The antimicrobial potency of the most effective peptide, M(LLKK)2M, was 
further studied by measuring its killing efficiency against M. smegmatis, BCG 
and H37Rv. As shown in Figure 4.2, M(LLKK)2M had a killing efficiency of 
≥ 99.9 % at MIC and 2x MIC levels against both M. smegmatis and BCG. The 
killing efficiency against H37Rv was found to be ≥ 99 % and ≥ 99.9 % at MIC 
and 2x MIC respectively.  
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Figure 4.2. Plot of viable CFUs after treatment of (a) M. smegmatis, (b) BCG 
and (c) H37Rv with M(LLKK)2M at concentrations corresponding to 0, 0.5x, 
1x and 2x MIC. M(LLKK)2M reduced bacterial burden by ≥ 99.9% against M. 
smegmatis and BCG, and ≥ 99 % against H37Rv, at the respective MICs. Data 
expressed as mean ± S.D. and are representative of two independent 
experiments. 
 
The bactericidal properties of M(LLKK)2M were further evaluated by time-
kill assay against M. smegmatis and the results were compared to that of 
rifampicin. As shown in Figure 4.3, the peptide exhibited dose-dependent 
bactericidal effects, defined as a ≥ 3 log decrease in the initial inoculum [142]. 
The peptide was rapidly bactericidal within 8 h of exposure at 8x MIC and 
within 24 h of exposure at MIC and 4x MIC. Furthermore, at 8x MIC, there 
was complete eradication of all bacteria by 24 h. The bactericidal effect of the 
peptide was much stronger than that of the first-line anti-TB drug, rifampicin. 
Rifampicin was only bacteriostatic at MIC and 4x MIC and bactericidal 
activity was achieved only at 8x MIC after 48 h. This rapid killing kinetics is 
commonly observed for AMPs due to their membrane-lytic mechanisms of 
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action, which results in pore formation, and leakage of cellular contents [38, 
143].  
 
Figure 4.3. Killing curves of M. smegmatis following exposure to (a) 
M(LLKK)2M and (b) rifampicin over 72 h at 1x, 4x and 8x MIC. 
M(LLKK)2M was rapidly bactericidal at MIC within 24 h while rifampicin 
remained bacteriostatic at MIC even after 72 h. Data expressed as mean ± S.D. 
for two independent experiments. 
 
4.2.5. Haemolytic activity  
The potential of the synthetic peptides to cause haemolysis was assessed to 
provide an indication of their cytotoxicity. The 50% haemolysis concentration 
of the peptides (HC50) against rat RBCs is summarised in Table 4.2 and Figure 
4.4. Generally, the synthetic peptides, including the most potent peptide 
M(LLKK)2M, exhibited low haemolytic activity even up to concentrations of 
1000 mg L-1. Importantly, the peptides displayed very low haemolytic activity 
at their respective MICs (< 1% haemolysis). The peptides M(LLKK)2M and 
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C(LLKK)2C induced the highest haemolysis of 1.1% and 12.9% respectively 
at 1000 mg L-1. It is likely that both of these peptides possessed higher 
membrane disrupting abilities due to an increase in peptide hydrophobicity, 
thus resulting in greater haemolysis of mammalian RBCs, similar to 
observations in other studies [136, 137]. 
 
Figure 4.4. Haemolytic activity of α-helical AMPs following treatment with 
two-fold increasing peptide concentrations. All peptides possessed desirable 
cytotoxicity profiles with < 1% haemolysis at their respective MIC. Data 
expressed as mean ± S.D. for two independent experiments. 
 
4.2.6. Antimicrobial mechanisms  
M. smegmatis was treated with M(LLKK)2M for 10, 30 and 60 min in the 
presence of FITC-labelled dextran probe so as to elucidate the antimicrobial 
mechanisms of the α-helical peptides. AMPs are membrane active agents 
which compromise the cell membrane integrity and result in pore formation. 
As such, exposure of bacterial cells to the peptides would induce pore 
formation and result in the passive diffusion of the fluorescent dye into the 
cells. It can be seen in Figure 4.5a that treatment with PBS alone did not result 
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in the uptake of FITC-dextran, supported by the absence of any green 
fluorescence signal. Treatment with M(LLKK)2M, however, induced a 
significant increase in the uptake of the fluorescence probe. Furthermore, 
increasing the duration of exposure to this peptide resulted in a greater uptake 
of FITC-dextran, evidenced by the greater proportion of fluorescently stained 
cells at the three different time points (Figures 4.5b to d). This progressive 
increase in the fraction of fluorescent bacterial cells imaged from 10 to 60 min 
implies that longer treatment potentially resulted in greater destruction and 
pore formation in the bacterial membrane. Together, these findings lend 




Figure 4.5. Confocal microscopic images of M. smegmatis after treatment 
with (a) PBS, and M(LLKK)2M at its MIC for (b) 10 min, (c) 30 min and (d) 
60 min in the presence of 150 kDa FITC-dextran. Increasing fluorescence 
intensity from 10 to 60 min after peptide treatment is indicative of progressive 
membrane damage and pore formation, allowing for greater uptake of the 
fluorescent probe. 
 
4.2.7. Development of drug resistance  
The problem of drug resistance mainly stems from inappropriate drug use, 
often associated with poor adherence to regimens or inappropriate dosing. To 
simulate these conditions in vitro, M. smegmatis cells were exposed to sub-
therapeutic doses of rifampicin and M(LLKK)2M over 10 passages. As shown 
in Figure 4.6, there was rapid onset of rifampicin resistance as early as passage 
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two and a 16-fold increase in MIC was observed by passage four. After 10 
passages, the MIC had increased by 32-fold, demonstrating that resistance to 
rifampicin can indeed develop rapidly with sub-therapeutic doses. In contrast, 
resistance did not readily develop with M(LLKK)2M treatment as shown by 
the consistent MIC obtained over 10 passages. Furthermore, the occurrence of 
rifampicin resistance could be delayed with the addition of a fixed 
concentration of M(LLKK)2M (15.6 mg L-1) to rifampicin treatment. This was 
shown by a twofold increase in MIC after five passages and a MIC that was 
four times lower in combination as compared to treatment with rifampicin 
alone after 10 passages. These findings underline the potential benefits that 
using the synthetic α-helical peptide M(LLKK)2M alone or in combination 
with first-line anti-TB drugs can have in preventing the emergence of drug-
resistant bacteria.  
 
Figure 4.6. Changes in MIC of M(LLKK)2M and rifampicin alone, and in 
combination, after exposure of M. smegmatis to sub-lethal doses over 10 
passages. Resistance against rifampicin developed rapidly when administered 
alone but was delayed when a fixed concentration of M(LLKK)2M was added. 
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4.2.8. Synergistic antimicrobial interactions  
The antibacterial interactions between the M(LLKK)2M and rifampicin were 
analysed via the chequerboard assay. As shown in Table 4.4, M(LLKK)2M 
displayed synergism with rifampicin with an FICI value of 0.5 against 
rifampicin-susceptible M. smegmatis. Subsequent testing against rifampicin-
resistant M. smegmatis (MIC = 250 mg L-1) and BCG produced similar results, 
whereas the peptide-drug combination had an additive effect against H37Rv 
with an FICI of 0.56. Notably, a low peptide concentration equivalent to 1/16th 
its MIC, halved the amount of rifampicin required to inhibit H37Rv growth. It 
is likely that peptide-mediated destruction of membrane integrity facilitated 
the entry of rifampicin to cytoplasmic targets and was responsible for the 
synergism observed. Synergistic interactions between rifampicin and natural 
AMPs have been reported previously and this effect has also been attributed to 
the enhanced intracellular access of the drug aided by these membrane-
permeabilising peptides [144-146]. It is thus likely that peptides with stronger 
membrane-permeabilising properties would potentially display stronger 
synergistic interactions. This may be the reason why C(LLKK)2 did not 
exhibit synergism with rifampicin (Table 4.4), in part due to its lower α-
helicity (Figure 4.1) and reduced membrane permeabilisation in comparison to 
M(LLKK)2M and (LLKK)2M, both of which demonstrated synergism with 
rifampicin against rifampicin-susceptible M. smegmatis. 
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Table 4.4. Chequerboard assay of rifampicin and synthetic peptides against 
four different mycobacterial strains. Synergism was observed for the 
Μ(LLKK)2M and rifampicin combination against rifampicin-susceptible and –
resistant M. smegmatis and BCG while additivity was observed against 
H37Rv.  
a Antimicrobial interactions were classified as additive (A) or synergistic (S). 
 
4.3. Conclusions 
In this study, a series of synthetic α-helical peptides modified with L-Cys or 
L-Met residues on either or both the N- and C-terminals have been evaluated 
for their anti-mycobacterial activities and cytotoxicity towards mammalian 
cells. The peptide (LLKK)2 modified with two Met residues (i.e. 
M(LLKK)2M) was effective against both drug-susceptible (H37Rv) and MDR 
(CSU87) M. tuberculosis without causing any cytotoxicity at concentrations 
eightfold greater than its highest MIC. The peptide eradicated mycobacteria 
based on membrane-lytic mechanism, and displayed synergistic interactions 
with rifampicin against both M. smegmatis and BCG, and an additive effect 
against H37Rv. Moreover, resistance against M(LLKK)2M did not develop 
readily, and when used in combination with rifampicin, the peptide was shown 
to delay the emergence of rifampicin resistance. These findings underscore the 
potential applicability of M(LLKK)2M to fight drug-resistant mycobacterial 
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CHAPTER 5: Designing α-helical peptides with enhanced synergism and 
selectivity against Mycobacterium smegmatis − Discerning the role of 
hydrophobicity and helicity 
 
5.1. Introduction 
TB is a preventable and curable infectious disease caused by M. tuberculosis, 
a pathogen which possesses marked biological and genomic differences as 
compared to both Gram-positive and Gram-negative bacterium [147]. One 
major distinction is that the composition of the mycobacterial cell wall, which 
unlike its Gram-positive counterparts, is highly complex and consists of an 
outer membrane with mycolic acids covalently linked to the peptidoglycan-
arabinogalactan polymer (Figure 5.1) [148, 149]. Mycolic acids are high 
molecular weight branched fatty acids containing about 70-90 carbon atoms, 
which accounts for up to 60% of the dry weight of mycobacterial cells [150]. 
This lipid-rich cell envelope forms a formidable barrier to prevent the entry of 
noxious substances and therapeutic agents alike, thereby posing an immense 
challenge to the design of new anti-tubercular drugs which must first penetrate 
this layer to exert their action at the target site [151]. 
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Figure 5.1. Diagram illustrating the basic component of the mycobacterial cell 
wall consisting of MAPc (mycolic acid-arabinogalactan-peptidoglycan 
complex). Reproduced with permission from [149]. Copyright (2008) 
American Society for Microbiology.  
 
The permeation of hydrophilic solutes across the mycobacterial cell wall 
mainly occurs through porin channels while lipophilic solutes are able to 
traverse the lipid-rich outer membrane [152]. As such, it has been suggested 
that in principle, more lipophilic compounds are expected to exhibit improved 
activity against mycobacteria due to enhanced intracellular drug uptake [148]. 
Yajko et al. demonstrated that the more hydrophobic fluoroquinolone, 
sparfloxacin, displayed superior killing effect against the MAC as compared to 
ciprofloxacin [153]. Haemers et al. found that increasing hydrophobicity by 
adding N-alkyl substituents to ciprofloxacin served to enhance M. tuberculosis 
and M. avium inhibition [154]. The enhancement of hydrophobicity of the 
hydrophilic isoniazid by the addition of palmitoyl substituent improved 
activity against the MAC as reported by Rastogi et al. [155]. Hence, structural 
modifications aimed at enhancing the hydrophobicity of compounds could 
!85!
serve as an effective strategy when designing new anti-tubercular drugs with 
enhanced anti-mycobacterial activity. 
 
With respect to AMPs, such a strategy has been used to optimise the activity 
against Gram-positive and Gram-negative bacteria. Lee et al. showed that 
increasing the hydrophobicity of the antimicrobial peptide HP (2-20) by 
specific amino acid substitution brought about a considerable increase in 
antimicrobial activity against both Gram-positive and Gram-negative bacteria 
[139]. Meng and Kumar found that the increased hydrophobicity of peptides 
modified with fluorinated amino acids also yielded greater activity against 
both Gram-positive and Gram-negative bacteria [156]. Radzishevsky et al. 
studied the effect of hydrophobicity by conjugating various acyl moieties to 
AMPs and observed that the potency of the parent peptide against Gram-
positive and Gram-negative bacteria was enhanced [157]. To the best of our 
knowledge, the only study employing this strategy to systematically design 
and evaluate AMPs for their activity against mycobacteria met with limited 
success [158]. In fact, enhancements in peptide hydrophobicity decreased 
antimicrobial efficacy against M. tuberculosis, and this was accompanied by 
dramatic increments in haemolytic activity of up to 120-fold, resulting in 
reduced selectivity indices [158]. These findings highlight the long-standing 
impediment to the clinical application of AMPs: their high systemic toxicity. 
Hence, the challenge thus far has been to develop compounds with improved 
microbial selectivity, especially against the genus Mycobacterium.  
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In Chapter 4, we reported on a series of short amphipathic α-helical peptides, 
comprising the backbone sequence (LLKK)2, with the ability to kill drug-
susceptible and drug-resistant M. tuberculosis. The addition of free sulfhydryl 
(thiol) groups by incorporating Cys residues in the AMPs did not improve 
anti-mycobacterial activity against drug-susceptible and drug-resistant M. 
tuberculosis, while the enhancement of peptide hydrophobicity by 
incorporation of Met residues increased the efficacy of the primary peptide 
against all mycobacterial strains tested, including clinically isolated MDR M. 
tuberculosis. The peptide with the optimal composition M(LLKK)2M was 
bactericidal, and eradicated mycobacteria via a membrane-lytic mechanism. 
Furthermore, a reduction in α-helical character for C(LLKK)2 was found to 
unfavourably impact peptide-drug synergistic interactions. These preliminary 
findings suggest that several key physicochemical parameters, namely 
hydrophobicity and α-helicity, are critical determinants of anti-mycobacterial 
activity, thus warranting further investigation.  
 
In this chapter, we set out to systematically evaluate the importance of both 
hydrophobicity and α-helicity in potentiating the anti-mycobacterial 
mechanism of action of AMPs against the mycobacterial cell wall, as well as 
their synergistic activity in combination with rifampicin. A series of six 
synthetic α-helical peptides, designed from the parent peptide (LLKK)2 over a 
range of hydrophobicities, were evaluated for their activity against M. 
smegmatis and eukaryotic cells, with the primary objective of developing 
synthetic analogues with enhanced selectivity. Herein, we provide the first 
report on the modulating effect of hydrophobicity and α-helicity on the 
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antimicrobial mechanisms of synthetic AMPs and their synergism with first-
line antibiotics against mycobacteria. Peptide hydrophobicity was 
experimentally determined using RP-HPLC and changes in secondary 
conformation were assessed by CD spectroscopy. In vitro antimicrobial 
efficacy was evaluated by MIC and synergy chequerboard assays followed by 
cytotoxicity studies against rat RBCs and the murine macrophage RAW 264.7 
cell line. The anti-mycobacterial mechanisms were investigated by membrane 
depolarisation, flow cytometry and FE-SEM. Membrane destruction triggering 
the leakage of cytoplasmic content was examined by dye leakage and ATP 











5.2. Results and discussion 
5.2.1. Peptide design and characterisation  
The interactions between peptides and bacterial membranes are modulated by 
various physicochemical properties including peptide hydrophobicity, charge, 
secondary structure, and amphiphilicity [102, 159]. In order to elucidate the 
influence of hydrophobicity on their antimicrobial activity, synthetic peptides 
were designed with minimal sequence modification to maintain their charges 
and amphiphilicity fairly unaltered. To achieve this, (LLKK)2 was used as a 
framework to systematically modify peptide hydrophobicity by substituting 
amino acids to both the N- and C- terminals to obtain peptides with the 
backbone sequence X(LLKK)2X, where X is a hydrophobic amino acid. Five 
amino acids, Met, Cys, proline (Pro), isoleucine (Ile) and Trp were selected to 
obtain the following peptides: M(LLKK)2M, C(LLKK)2C, P(LLKK)2P, 
I(LLKK)2I and W(LLKK)2W, which will henceforth be referred to as per their 
abbreviated denotations listed in Table 5.1. The C-terminal of all six 
analogues was amidated to improve antimicrobial activity by conferring 
peptides with an extra net positive charge [133, 134]. The fidelity of peptide 
synthesis was confirmed via MALDI-TOF MS and the results are summarised 
in Table 5.1. The close agreement between the measured and theoretical 
molecular weights of the peptides indicates that the compounds were 
synthesised to the desired specifications. The overall hydrophobicity of the 
peptides was measured by their retention time (tR) using RP-HPLC and ranged 
from 15.68 to 24.40 min (Table 5.1). The parent peptide LK without any 
additional amino acid residues recorded the lowest tR of 15.68 min while WW, 
with two extra Trp residues, displayed the greatest hydrophobicity with a 
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corresponding tR of 24.40 min. The ranking of the peptides in terms of 
increasing overall hydrophobicity is as follows: LK < PP < CC < II < MM < 
WW.      
Table 5.1. Amino acid sequence of synthetic cationic α-helical peptide 
analogues and their physiochemical parameters including charge, hydrophobic 
moment, hydrophobicity and helicity.  
 a Measured by MALDI-TOF MS, apparent Mw = [Mw + H]+. 
b The hydrophobic moment (µH) was determined by the Totaliser module of 
Membrane Protein Explorer (MPEx) which uses the experimentally based interfacial 
Wimley-White hydrophobicity scales and is available online at 
http://blanco.biomol.uci.edu/mpex.  
c Retention time as determined by RP-HPLC. 
d % helicity was calculated from ratio of [θ]222/[θ]max using a modified Baldwin 
equation as described in section 4.3.2. 
e An additional dimer peak was observed at m/z 2374.78 for CC. 
 
 
5.2.2. CD spectroscopic study  
The secondary structure of the synthetic peptides in a membrane-like 
environment was studied using CD spectroscopy and the results are 
summarised in Figure 5.2. The peptides adopted α-helical structures in 25 mM 
SDS solution as confirmed by the presence of the double minima at ~208 and 
222 nm. Generally, the addition of amino acids to both the N- and C- 
terminals resulted in greater α-helical conformation as determined by a more 
negative mean residue ellipticity value at 222 nm (θ222). Although, the value at 
θ222 is commonly used to determine the degree of helicity of peptides, these 
estimates tend to be less accurate for short helices [160]. Hence, the 
percentage α-helicity of synthetic peptides was calculated using an equation 












LLKKLLKK-NH2 LK 982.37 983.02 +4 3.69 15.68 9.3 
PLLKKLLKKP-NH2 PP 1176.60 1177.02 +4 3.69 17.80 9.7 
CLLKKLLKKC-NH2 CC 1188.66 1187.51e +4 3.69 20.76 29.3 
ILLKKLLKKI-NH2 II 1208.69 1209.14 +4 3.69 21.63 38.1 
MLLKKLLKKM-NH2 MM 1244.76 1245.18 +4 3.69 21.69 35.4 
WLLKKLLKKW-NH2 WW 1354.79 1355.15 +4 3.69 24.40 25.1 
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described by Baldwin and subsequently modified by Fairlie, given by the ratio 
of θ222/θmax, and θmax is calculated using the following equation:  θVSq = $ −44000$ + $250T 1 − |m , where T is the temperature in oC, k is 
the finite length correction and n is the number of peptide residues [161, 162]. 
The θmax for 8 and 10 residue helices is -19500 and -23400 respectively when 
k = 4 and T = 20 oC. The percentage helicity of the peptides is summarised in 
Table 5.1. Of the six, LK and PP were found to possess the lowest α-helical 
contents of about 9%, while the α-helicity of the other four peptides was three 
to fourfold greater. These findings suggest that increasing peptide 
hydrophobicity results in an increase in α-helical structure, and is consistent 
with reports by other research groups [137, 163]. Only PP did not conform to 
this trend as its enhanced hydrophobicity as compared to LK did not improve 
its propensity for α-helical folding. This finding implies that factors other than 
hydrophobicity may be modulating the helical propensity of the Pro 
substituted analogue. One possibility could be that steric hindrance induced by 
the bulky pyrrolidine ring present in Pro residues, gives rise to conformational 
distortion in the preceding helical turn, thus hindering the formation of stable 
α-helices [164, 165]. In addition, the inclusion of Pro in the middle of helices 
or near the C-terminal also causes breakage of adjacent hydrogen bonds and 
premature termination of the helix [166, 167]. Both of these factors could have 
in turn mitigated the effects of increasing hydrophobicity on α-helicity, 
resulting in similar α-helical contents as seen for both LK and PP. 
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Figure 5.2. CD spectra of synthetic peptide analogues displaying 
characteristic double minima at ~208 and 222 nm, confirming their α-helical 
secondary conformations. Data are expressed as the mean of two runs per 
peptide. 
 
5.2.3. In vitro anti-mycobacterial activity  
The antimicrobial activities of the synthetic peptides and rifampicin against M. 
smegmatis determined by the broth microdilution method are summarised in 
Table 5.2. The peptide analogues displayed varying efficacy against M. 
smegmatis with MICs ranging from 62.5 to 250 mg L-1. Overall, hydrophobic 
modifications to LK produced three analogues with improved antimicrobial 
activity while the other two inhibited bacterial growth less effectively. The 
addition of Trp, Met and Ile residues to both the N- and C- terminals enhanced 
the potency of LK, reflected by the decrease in MIC from 125 to 62.5 mg L-1 
for WW, MM and II. While enhancing the hydrophobicity of α-helical 
peptides has been shown to improve antimicrobial activity, high peptide 
hydrophobicity is associated with stronger peptide self-association resulting in 
the formation of dimers/oligomers [136, 137]. Peptide self-association in turn 
correlates with weaker antimicrobial activity since peptide dimers/oligomers 
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are prevented from readily passing through the bacterial cell wall in order to 
reach their target plasma membrane. Therefore, a lack of improvement in the 
MIC of the most hydrophobic peptide, WW, against M. smegmatis could 
possibly be attributed to stronger self-association as compared to the less 
hydrophobic analogues, MM and II. Surprisingly, despite its increased 
hydrophobicity and α-helicity, CC demonstrated poorer anti-mycobacterial 
activity as compared to LK. Since CC is less hydrophobic than MM, II and 
WW, any peptide self-association resulting in dimer/oligomer formation 
should not significantly compromise its activity as compared to the three most 
hydrophobic analogues. Yet it was found to be the least potent analogue, 
which implies that another factor unique to this peptide alone might be 
responsible for this observation. Further discussions on the diminished activity 
of CC will be carried out in Section 5.2.6 together with the flow cytometric 
analysis. As for PP, it is likely that the reduced propensity for helical 
formation observed (Figure 5.2) was responsible for the decrease in 
antimicrobial potency as compared to WW, MM and II. A decrease in α-
helicity by introducing Pro residues into helices has been shown to greatly 
reduce the antimicrobial efficacy and activity spectrum of α-helical peptides 
[168]. Hence, peptide helicity is another important parameter which should be 
given due consideration when looking to design more potent peptides. Even 
though our findings highlight that flanking of both the N- and C-terminals 
with Pro can produce detrimental effects on antimicrobial potency, the 
incorporation of Pro residues in peptides should not be dismissed entirely as 
an ineffective strategy in designing more selective analogues. A recent study 
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found that the careful substitution of Pro residues into peptide sequences can 
reduce cytotoxicity and improve antibacterial selectivity [169].  
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a Antimicrobial interactions were classified as additive (A), indifferent (I) or 
synergistic (S). 
b SI is determined as follows: (HC50/MIC). When no detectable haemolysis was 
observed at the highest tested concentration of 500 mg L-1, a value of 1000 mg L-1 
was used for SI calculations. 
 
5.2.4. Haemolytic activity and cell selectivity 
The haemolytic activities of the synthetic peptides were evaluated using 4% 
(v/v) rat blood as a measure of their toxicity against mammalian cells, and the 
results are summarised in Figure 5.3. The HC50 values, defined as the peptide 
concentration producing 50% haemolysis of rat RBCs, are shown in Table 5.2. 
Except for WW, all the other five peptides exhibited very low haemolysis (≤ 
3%) even up to concentrations of 500 mg L-1. Notably, all six peptide 
analogues induced minimal haemolysis (≤ 3%) at their respective MICs. The 
most hydrophobic peptide, WW, displayed the strongest haemolytic activity of 
~19% and 69% at 250 and 500 mg L-1, respectively. This corresponded to a far 
lower HC50 value of 363 mg L-1 for WW as compared to the other peptides (> 
500 mg L-1). While the modulating effect of hydrophobicity on the haemolytic 
activity of the peptides was evident, the contribution of α-helicity was far less 
apparent. The two most helical peptides, MM and II, were minimally 
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haemolytic even at 500 mg L-1, suggesting that hydrophobicity, rather than 
helicity, was more likely the driving force behind the enhanced haemolytic 
activity observed for WW. Previous studies examining the membrane 
permeability of electrically neutral POPC vesicles treated with peptide 
analogues of varying hydrophobicity have also shown that increasing 
hydrophobicity produced a greater degree of haemolysis [140, 170]. This 
phenomenon was attributed to the zwitterionic nature of eukaryotic 
membranes, which facilitates deeper penetration of more hydrophobic 
peptides thus inducing greater pore formation and consequently, stronger 
haemolysis.  
 
Figure 5.3. Haemolytic activity of synthetic α-helical peptides against rat 
RBCs following 2 h treatment. All peptides except WW induced minimal 
haemolysis up to 500 mg L-1. Data expressed as mean ± S.D. for two 
independent experiments. 
 
The selectivity indices (SIs) shown in Table 5.2, defined as the ratio of HC50 
to MIC values, serve as a measure of antibacterial selectivity, with larger SI 
values indicative of greater selectivity towards microbial over mammalian 
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membranes. MM and II proved to be the best analogues (SI = 16), while the 
most hydrophobic analogue, WW, had a lower selectivity index as compared 
to LK. Previous studies have also shown that increasing peptide 
hydrophobicity may decrease antimicrobial selectivity of α-helical peptides 
[158, 171]. However, the findings presented in this study suggest that a 
moderate increase in peptide hydrophobicity can translate into better 
selectivity, as seen for MM and II, but further increments could produce 
deleterious effects on peptide selectivity, as observed for WW.   
 
5.2.5. Cytotoxic effect of peptides on macrophages  
The cytotoxicity of the peptides against mammalian cells was further 
evaluated against RAW 264.7 macrophage cells and the results are shown in 
Figure 5.4. LK, PP and II were found to be the least cytotoxic analogues with 
cell viabilities in excess of 85% even up to concentrations of 250 mg L-1. The 
most hydrophobic analogue, WW, was also the most cytotoxic, recording the 
greatest reduction in cell viability from 92.3 to 13.2% with an increase in 
concentration from 3.95 to 250 mg L-1. At MIC levels (62.5 mg L-1), 
approximately 50% of the cells treated with WW remained viable, whereas for 
MM and II, which also had similar MICs, cell viabilities were higher at 77.9% 
and 98.5%, respectively. Similar to the trends observed with regards to their 
haemolytic activities, hydrophobicity was found to be a more significant 
contributor towards cytotoxicity than the α-helical character of the peptides. 
This observation is in line with previous findings reported by Jacob et al. who 
also found that increasing the hydrophobicity of α-helical peptides induced 
greater cytotoxicity against RAW 264.7 cells [172]. Interestingly, despite its 
superior hydrophobicity and helicity, the Ile substituted analogue II possessed 
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a comparable cytotoxicity profile to LK even up to 250 mg L-1. Though the 
hydrophobic and helical characters of MM and CC were comparable to II, 
both were found to be more toxic towards mammalian cells with 80% cell 
viabilities even at 15.6 mg L-1. Given that macrophages are potentially major 
reservoirs for mycobacteria during pulmonary TB infection, the incorporation 
of Ile as compared to other hydrophobic amino acids such as Met, Cys and 
Trp, may be a more suitable when designing potent peptides with reduced 
cytotoxicity against mammalian cells.  
 
Figure 5.4. Cytotoxicity profiles of the synthetic α-helical peptides against the 
mouse macrophage cell line RAW 264.7 after exposure for 24 h treatment. 
WW was found to be the most toxic analogue of all six peptides tested. Data 
expressed as mean ± S.E.M. for three independent experiments. 
 
5.2.6. Flow cytometry  
To investigate the extent of membrane disruption induced by the peptide 
analogues, M. smegmatis was treated with all six peptides in the presence of 
the DNA intercalating agent PI. Peptide-mediated destruction of the bacterial 
membrane is expected to facilitate the intracellular diffusion of PI and the 
proportion of bacterial cells fluorescently stained by PI following incubation 
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with peptides at various concentrations (62.5, 125 and 250 mg L-1) is 
summarised in Figure 5.5. First-line anti-tubercular agents, rifampicin and 
ethambutol, served as negative controls given that they target DNA-dependent 
RNA polymerases and arabinosyl transferases, respectively, rather than the 
mycobacterial membrane directly. Both drugs resulted in staining of 
approximately 1% of bacterial cells at 1x, 2x and 4x MIC implying that 
mycobacterial membrane integrity remained largely uncompromised (Figure 
5.5b). Notably, > 99% of cells treated with LK and PP did not present any 
fluorescent signal even up to concentrations of 250 mg L-1, indicative of intact 
bacterial cell membranes. This implies that the anti-mycobacterial mechanism 
of action of both these peptides could be different from that of the other 
peptides. In contrast, treatment with the three most hydrophobic peptides, 
WW, MM and II resulted in a significant concentration dependent increase in 
proportion of bacterial cells taking up the fluorescence dye. At concentrations 
equivalent to MIC, 63.8%, 88.3% and 84.0% of cells were stained with PI 
following treatment with WW, MM and II, respectively. The stronger 
membrane-permeabilising capacity of these peptide analogues could be 
attributed to their higher hydrophobic and α-helical character as compared to 
LK and PP. Additionally, we found that helicity was more closely correlated 
to PI uptake as compared to hydrophobicity (Figure 5.5c). This suggests that 
the folding of the synthetic peptides into amphipathic structures was necessary 
for the penetration of peptides into the hydrophobic core and subsequent 
disruption of the lipid bilayer in bacterial cell membranes.  
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Figure 5.5. Flow cytometric analysis of the mycobacterial cell membrane-
permeabilising properties of (a) synthetic α-helical peptides (b) first-line drugs 
ethambutol and rifampicin. WW, MM and II induced significant membrane 
damage as shown by the greater uptake of PI into bacterial cells as compared 
to CC, PP and LK. Negligible PI uptake into bacterial cells after treatment 
with ethambutol and rifampicin confirmed the absence of rapid membrane-
targeted mechanism of action. MIC of ethambutol and rifampicin was 0.5 and 
3.90 mg L-1 respectively. Data expressed as mean ± S.D for three independent 
experiments. (c) Correlation of PI uptake and peptide hydrophobicity (■) or 
helicity (●) with R2 values of 0.6945 and 0.9683 respectively. CC was 
excluded from the analysis due to the formation of dimers.  
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As for CC, only 6% of cells were stained with PI even up to concentrations of 
250 mg L-1. A plausible explanation for this observation could be the 
dimerisation/oligomerisation of CC monomers, driven not by self-association, 
but by the oxidation of reactive sulfhydryl groups present in Cys residues. 
MALDI-TOF MS analysis covering up to 10,000 Da confirmed the formation 
of dimers as a distinct peak was observed at m/z 2374.78 (Figure 5.6), 
however no oligomer formation was observed. It is likely that these CC dimers 
are prevented from readily penetrating the mycobacterial cell wall to reach the 
target cytoplasmic membrane, thus reducing its antimicrobial efficacy. 
 
Figure 5.6. MADLI-TOF mass spectra of CC displaying a distinct peak at m/z 
2374.78, indicating possible dimerisation of CC monomers due to the 
presence of reactive sulfhydryl groups.  
 
5.2.7. Synergistic antimicrobial interactions 
Given that combinatorial drug regimens are the cornerstone of successful anti-
tubercular chemotherapy, the potential for synergistic interactions between the 
peptides and rifampicin was assessed by the chequerboard assay. As shown in 
Table 5.2, none of the six synthetic peptides demonstrated antagonistic 
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activity when treated in combination with rifampicin. The three most effective 
peptides WW, MM and II exhibited synergism with a FICI of 0.5 against M. 
smegmatis while LK and PP both displayed an additive effect with rifampicin 
(FICI of 0.75). The combination of CC and rifampicin was interpreted as 
indifferent with a FICI value greater than 1. The mechanism behind this 
observed synergism could be attributed to the membrane-permeabilising 
activity of peptides that compromises membrane integrity. This in turn allows 
for the increased uptake of rifampicin into the cells and enhances its 
accessibility to intracellular targets [145, 146]. As such, peptides with superior 
membrane-disrupting properties would be expected to better facilitate the 
cytoplasmic entry of rifampicin and consequently demonstrate stronger 
synergistic interactions. The flow cytometric analysis revealed that LK and PP 
possessed poor membrane-permeabilising activity (Figure 5.5a), which lends 
support as to why they were additive with rifampicin while WW, MM and II, 
synergistic. Due to their lower hydrophobic and α-helical propensity, LK and 
PP possessed weaker membrane disrupting properties and hence, a higher 
concentration of these two peptides was required to inhibit bacterial growth as 
compared to WW, MM and II (62.5 and 125 versus 15.6 mg L-1) when co-
administered with the same amount rifampicin (0.98 mg L-1).  
 
5.2.8. Antimicrobial mechanisms  
The ability of the peptides to perturb the phospholipid bilayer was investigated 
by determining the dye leakage from calcein-loaded LUVs composed of 
PE/PG lipids (4:1). As shown in Figure 5.7, II induced calcein release from 
the bacterial membrane-mimicking vesicles in a concentration- and time-
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dependent manner. As compared to LK, ≥ 4 fold increment in dye leakage was 
observed for II at all concentrations tested. The more hydrophobic and helical 
nature of II, in comparison to LK, is likely responsible for its stronger 
membrane-permeabilising properties. This in turn translated into improved 
anti-mycobacterial efficiency, evident from the lower MIC and FICI values 
seen for II (Table 5.2). These results are supported by previous findings that 
compounds inherently more injurious to membranes, as ascertained by dye 
leakage assays, also tend to possess enhanced antimicrobial activities [173].  
 
Figure 5.7. Concentration- and time-dependent dye leakage from PE/PG 
vesicles following antimicrobial peptide treatment. II induced greater leakage 
as compared to LK, representative of its superior membrane-disrupting 
properties. Data are expressed as mean ± S.D. for two independent 
experiments. 
 
Based on the MIC, FICI, and SI values, and cytotoxicity profiles of the 
synthetic peptide analogues, II possessed the greatest potential for practical 
applications and hence, was selected for further evaluation of its antimicrobial 
mechanisms of action against M. smegmatis. The surface morphology of M. 
smegmatis was visualised by scanning electron microscopy following 
incubation with II at 4x MIC for 2 h, and compared to controls treated with 
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PBS. The untreated bacterial cells had regular, smooth surfaces and remained 
visibly intact without any extracellular debris (Figures 5.8a and b). Cells 
treated with II however, had suffered significant structural changes. Compared 
to the control, cells exposed to II possessed extensively rough, corrugated 
surfaces covered with irregular debris (Figures 5.8c and d). The significant 
cell surface damage induced by lethal doses of II provides evidence of the 
membrane-targeted mechanism of action of this peptide. 
 
Figure 5.8. SEM micrographs of M. smegmatis treated with PBS for 2 h, 
imaged at magnifications of (a) 7500× and (b) 18000×. Cells were incubated 
with II at 4x MIC for 2 h and similarly image at magnifications of (c) 7500× 
and (d) 18000×. Untreated cells presented with smooth surfaces while peptide 
treatment induced damage to the cell surface. 
 
This proposed mechanism was further investigated by examining the ability of 
II to depolarise the cytoplasmic membrane of M. smegmatis using the 
membrane potential sensitive dye diS-C3-5. As diS-C3-5 partitions into the 
cytoplasmic membrane, its fluorescence is self-quenched due to the polarised 
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membrane surface. Subsequent exposure to pore-forming or membrane-
disrupting peptides will dissipate the membrane potential, resulting in the 
release of diS-C3-5 into the medium [174]. Fluorescence recovery is then 
measured by spectrofluorometry and is indicative of the extent of membrane 
potential reduction. As seen in Figure 5.9, there was a rapid, concentration-
dependent surge in fluorescence intensity upon the addition of II to M. 
smegmatis. Cells exposed to II at 4x and 8x MIC produced an instantaneous 
increase in fluorescence signals while those treated with II at 1x MIC showed 
gradual dissipation of membrane potential instead.     
 
Figure 5.9.  Dissipation of cytoplasmic membrane potential following 
treatment of M. smegmatis with II at 1x, 4x and 8x MIC. Membrane 
depolarisation, monitored by fluorescence recovery of diS-C3-5, was 
immediate at 4x and 8x MIC.  
 
Membrane destruction leading to loss of barrier function would result in the 
depletion of intracellular stores of critical components. As such, extracellular 
ATP levels following exposure of M. smegmatis to supra and sub-inhibitory 
concentrations of II were assessed and the findings are summarised in Figure 
5.10. The peptide induced concentration-dependent release of ATP from 
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bacterial cells after 2 h, with no detectable ATP at concentrations below 15.6 
mg L-1. At 4x and 8x MIC, the amount of ATP released was 106 and 132 nM 
respectively, an increase of approximately three to fourfold as compared to 
ATP concentrations at MIC (33 nM).  
 
Figure 5.10. Extracellular ATP release in a concentration-dependent manner 
after exposure of M. smegmatis to II for 2 h. Peptide-induced membrane 
damage is accompanied by leakage of intracellular content due to 
compromised membrane integrity. Data expressed as mean ± S.E.M. for three 
independent experiments. 
 
To determine if the bactericidal activity of the peptides is associated with ATP 
release and membrane depolarisation, killing efficiency assays were 
performed for II at the relevant concentrations. As shown in Figure 5.11, 
100% reduction in bacterial load was observed at 2x, 4x and 8x MIC while in 
contrast, II was only bacteriostatic at its MIC, with < 1 log reduction in final 
CFU counts as compared to the initial inoculum. These findings suggest that 
the bactericidal activity of II is possibly mediated through disruption of the 
mycobacterial cytoplasmic membrane, with high levels of ATP release and 




Figure 5.11.  Plot of viable CFU after treatment of M. smegmatis with various 
concentrations of II. 100% reduction in bacterial burden was observed at 2x, 
4x and 8x MIC, suggestive of a bactericidal mechanism of action at these 
concentrations. Data expressed as mean ± S.E.M. for three independent 
experiments.  
 
Taken together, our results highlight that the bacterial membrane is the main 
target site of the synthetic cationic α-helical peptide, II. Flow cytometric 
analysis revealed that the formation of helical structures is crucial for rapid 
pore or channel formation, in agreement with previously published works 
[159]. Though active against mycobacteria, LK and PP did not induce 
significant membrane permeabilisation, suggesting that they may either act via 
non-membrane lytic mechanisms or that the duration of drug exposure was 
insufficient to cause appreciable membrane damage. WW, MM and II, 
however, rapidly permeabilised the mycobacterial membrane, enabling the 
free diffusion of PI into the cytoplasm. Concomitantly, peptides induced 
immediate dissipation of the cytoplasmic membrane potential, accompanied 
by leakage of intracellular components as quantified by the ATP 
bioluminescence assay, eventually leading to cell death. Furthermore, SEM 
analysis revealed that the peptides possessed strong membrane-disrupting 
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properties while calcein leakage from LUVs was reflective of their ability to 
permeabilise the lipid bilayer, resulting in the loss of intracellular contents.  
 
5.3. Conclusions 
In this study, six synthetic peptide analogues with varying hydrophobicity and 
helical propensities were assessed for their potency against M. smegmatis, and 
toxicities towards eukaryotic cells. Hydrophobic modifications produced three 
analogues, WW, MM and II with improved anti-mycobacterial activity. 
Increasing peptide hydrophobicity/helicity induced greater membrane 
perturbation as shown by the significant PI uptake as compared to controls 
during flow cytometry assays. Furthermore, the three most hydrophobic 
peptides were found to interact synergistically with rifampicin, potentially 
mediated by enhanced intracellular access of the drug. Amongst the six, II (the 
Ile substituted peptide) was selected for elucidation of anti-mycobacterial 
mechanisms, given its superior selectivity index and safer toxicity profile 
against macrophage cells. This peptide was shown to primarily target the 
plasma membrane, acting rapidly in a concentration-dependent manner, and 
exhibiting bactericidal activity at ≥ 2x MIC. II induced instantaneous 
membrane depolarisation, damaged structural integrity of the membrane and 
caused the leakage of cellular contents within 2 h. These findings serve to 
deepen our understanding of the modulating effect of hydrophobicity/helicity 
on the anti-mycobacterial mechanisms of action and demonstrate the 
applicability of strategies employed here for the rational design of AMPs with 
the aim of improving cell selectivity and synergistic interactions when co-
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CHAPTER 6: Unnatural amino acid analogues of membrane-active 
helical peptides with enhanced anti-mycobacterial selectivity and 
improved stability 
6.1. Introduction 
Various virulence strategies have been implicated in the persistence and 
survival of microbes during chronic infections, including the secretion of 
proteinases to facilitate tissue invasion, evade host defences and modulate host 
immune responses [175]. Natural HDPs are essential components of the innate 
immune response, and contribute towards the first line of defence against 
invading pathogens [176]. Therefore, unsurprisingly, the inactivation of 
antimicrobial proteins and peptides by microbial proteases could serve as 
crucial means of overcoming host defence mechanisms. This is supported by 
evidence that the human cathelicidin LL-37 was rapidly degraded by 
proteinases of P. aeruginosa, E. faecalis, Proteus mirabilis and Streptococcus 
pyogenes, which resulted in loss of antibacterial activity [177]. LL-37 was also 
found to be inactivated by staphylococcal aureolysin, leading to diminished 
anti-staphylococcal activity [178]. Thus, the production of extracellular 
proteases can contribute towards bacterial resistance against HDPs. 
 
AMPs have gained prominence over the past few decades as a promising class 
of therapeutics due to their potent broad activity spectrum encompassing both 
drug-susceptible and drug-resistant pathogens [24]. However, the transition of 
AMPs from bench to bedside has largely been hindered by their susceptibility 
to enzymes in biological fluids and degradation by bacterial proteases, 
resulting in short half-lives and loss of antimicrobial properties [26]. Several 
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strategies have been employed to enhance AMP stability including the 
incorporation of unnatural amino acids, N- and/or C-terminal modifications, 
cyclisation, inclusion of non-peptidic backbones (peptidomimetics), and 
multimerisation of AMP monomers to form dimers, oligomers and dendrimers 
[26]. Previously, D-enantiomers were studied to determine the influence of 
peptide chirality on function, and the importance of stereospecific interactions 
with enzymes, receptors or lipids in membranes [179, 180]. While both L- and 
D-enantiomers of peptides emerged equally active, suggesting a lack of 
specific peptide-receptor interactions, the latter were more resistant to trypsin 
degradation [181]. This in turn translated into longer half-lives in vivo, 
reinforcing their potential as therapeutic candidates.  
     
Increasing evidence suggests that incorporation of D-amino acids not only 
confers protection against proteolysis by trypsin, but also enhances stability 
against bacterial proteases, thus rendering peptides more active. While the all 
L-amino acid analogue of M33 underwent proteolysis by staphylococcal 
aureolysin within 1 h, the D-amino acid analogue remained unchanged even 
after 24 h of treatment, which in turn translated into superior in vitro and in 
vivo activity for the D-isomer against S. aureus [182]. Similarly, specific D-
amino acid substitutions were also found to enhance stability towards P. 
aeruginosa elastase, staphylococcal V8 protease and aureolysin [183]. 
Recently, the D-enantiomer of a lactoferricin-derived peptide demonstrated 
better inhibitory activity against M. avium in comparison to the L form, likely 
due to higher resistance to proteases [184].  
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M. tuberculosis is also known to secrete enzymes such as proteases, lipases, 
esterases, and dehydrogenases, which contribute towards its pathogenicity and 
persistence in the host [185]. As such, the above mentioned strategy of 
incorporating unnatural amino acids into peptide sequences could potentially 
be exploited to develop more selective anti-mycobacterial peptides. One study 
in particular demonstrated that D-enantiomeric forms of AMPs, including the 
all D-analogue of LL-37, were found to inhibit growth of H37Rv to a greater 
extent than the L-enantiomers [158]. However, there are limited reports 
systematically evaluating the impact of various stability-enhancing 
modifications on the anti-mycobacterial activity of synthetic AMPs.  
 
In Chapter 5, N- and C-terminal capping of short amphipathic α-helical anti-
mycobacterial peptides evaluated in Chapter 4, with hydrophobic residues 
revealed the importance of both hydrophobicity and helicity on the anti-
mycobacterial activity, with I(LLKK)2I emerging as the most selective 
peptide. These synthetic α-helical peptides primarily targeted the 
mycobacterial membrane, inducing rapid membrane permeabilisation and 
depolarisation, resulting in leakage of intracellular contents. In this chapter, 
the effect of various unnatural amino acid substitutions on the anti-
mycobacterial properties and stability of the peptide, I(LLKK)2I, were 
investigated. Peptide secondary structures were assessed by CD spectroscopy, 
while cytotoxicity was evaluated against human RBCs and the murine 
macrophage RAW 264.7 cell line. Antimicrobial activities were studied 
against a panel of six mycobacterial strains using the broth microdilution 
method. The stability of the modified peptides was also evaluated against the 
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serine protease trypsin. Since M. tuberculosis is a major intracellular 
pathogen, the ability of peptides to activate macrophages and eliminate 
intracellular mycobacteria was also examined. Finally, the in vitro anti-




6.2. Results and discussion 
6.2.1. Peptide design and characterisation 
In this study, systematic substitutions with unnatural or D-amino acids were 
performed in an attempt to design synthetic analogues with improved stability 
and selectivity indices. The Ile substituted analogue, I(LLKK)2I or II, which 
emerged as one of the most selective peptides against mycobacteria in Chapter 
5, served as a framework for these structural modifications. To maintain 
sequence identity and structural integrity of the optimised lead peptide, the 
two main modifications involved (a) swapping all L-amino acid with D-amino 
acid residues and (b) substitution of Lys residues with Lys analogues 
possessing shorter side-chains including ornithine (Orn), 2,4-diaminobutyric 
acid (Dab) or 2,3-diaminopropionic acid (Dap). The C-terminal of all 
synthetic analogues was amidated to improve anti-mycobacterial activity by 
increasing net positive charge [133, 134]. The sequences and abbreviated 
names of the five synthetic peptides evaluated in this study are listed in Table 
6.1. In order to verify that the peptides were successfully synthesised 
according to the desired specifications, SELDI-TOF MS was performed for 
molecular weight determination. As shown in Table 6.1, the close agreement 
between the theoretical and measured molecular weights of the peptides 
served as confirmation of the fidelity of peptide synthesis.  
  
!113!
Table 6.1. Design of α-helical peptides modified with unnatural amino acids 
and their molecular weights. 




 [θ]222c Relative 
helicityd  
II I(LLKK)2I-NH2 1208.67 1209 11290 1.00 
II-D i(llkk)2i-NH2 1208.67 1209 10033 0.89 
II-Orn I(LL-Orn-Orn)2I-NH2 1152.56 1153 11432 1.01 
II-Dab I(LL-Dab-Dab)2I-NH2 1096.70 1097 11081 0.98 
II-Dap I(LL-Dap-Dap)2I-NH2 1040.35 1041 11765 1.04 
a D-amino acids are represented by lower case letters. Ornithine, 2,4-diaminobutyric 
acid and 2,3-diaminopropionic acid are abbreviated as Orn, Dab and Dap 
respectively.  
b Mw determined by SELDI-TOF MS. 
c The mean residue ellipticity values at 222 nm (θ222) were measured in 25 mM SDS 
solution by CD spectroscopy. 
d The helical content of modified peptides relative to the mean residue ellipticity 
values at 222 nm of II. 
 
6.2.2. CD spectroscopic study 
The influence of unnatural or D-amino acid substitutions on the secondary 
conformation of the synthetic peptides was investigated in a membrane-like 
environment consisting of 25 mM SDS micelle solution, and studied using CD 
spectroscopy. The CD spectra of the synthetic peptides are summarised in 
Figure 6.1. The presence of the characteristic absorption bands at ~208 and 
222 nm suggests that all five synthetic peptides adopted α-helical structures in 
25 mM SDS. The replacement of Lys residues with Orn, Dab or Dap, did not 
compromise the helical structure of peptides, evident from the comparable 
relative helicities and mean residue ellipticity values at 222 nm (θ222) as 
shown in Table 6.1. As expected, II-D exhibited a CD spectrum of opposite 
sign to that of II, though not an exact mirror image. II-D recorded a lower 
absolute θ222 value than II (10033 versus 11290), indicative of a slight 
reduction in α-helical conformation. Since, D-allo-Ile was utilised during 
peptide synthesis, the observed differences in CD ellipticity at 222 nm could 
be attributed to II and II-D being diastereomers, rather than enantiomers of 
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each other [186]. 
 
Figure 6.1. CD spectra demonstrating α-helical secondary conformations of II 
and its synthetic analogues with unnatural amino acid substitutions in 25 mM 
SDS micelle solution. Data are expressed as the mean of three runs per 
peptide. 
 
6.2.3. In vitro anti-mycobacterial activity 
The antimicrobial activities of the synthetic helical peptides were evaluated by 
the broth microdilution method against a panel of six mycobacterial strains 
and the results are summarised in Table 6.2. Overall, structural modifications 
with unnatural or D-amino acids were effective in producing analogues with 
improved anti-mycobacterial activities. A two to fourfold reduction in the GM 
of the MICs was observed for the modified peptides as compared to II. 
Importantly, three of the synthetic peptides displayed a fourfold reduction in 
MIC in comparison to II against the MDR clinical isolate CSU87. The 
replacement of Lys with Orn proved least effective, with II-Orn demonstrating 
similar activity as II against 50% of the mycobacterial strains tested. This 
analogue was more active against only two of the six strains, while 
replacement of Lys with Dab and Dap resulted in a decrease in MICs against 
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five and four of the six strains, respectively. The all D-amino acid analogue 
exhibited superior efficacy as compared to II against all six mycobacterial 
strains, which translated into a fourfold reduction in the GM of its MICs.  
 
Table 6.2. MICs and SIs of helical peptides against various mycobacterial 















CSU87    
II 125 500 >500 >500 250 250 397 >1000 5 
II-D 31.3 250 125 250 62.5 62.5 99 >1000 20 
II-Orn 62.5 >500 >500 500 250 250 354 >1000 6 
II-Dab 31.3 >500  500 500 62.5 62.5 177 >1000 11 
II-Dap 62.5 >500 > 500 500 62.5 62.5 223 >1000 9 
Rifampicin 0.001 0.015 0.008 0.004 0.002 >32 0.004 - - 
a MIC results are representative of 2 to 3 independent experiments. 
b The geometric mean (GM) of the MICs against the 6 mycobacterial strains. A value 
of 1000 mg L-1 was used for GM calculations when no anti-mycobacterial activity at 
observed at the highest tested concentration of 500 mg L-1. 
c SI is determined as follows: (HC50/GM). When no detectable haemolysis was 
observed at the highest tested concentration of 1000 mg L-1, a value of 2000 mg L-1 
was used for SI calculations. 
 
We had previously reported in Chapter 5 that both hydrophobicity and folding 
of peptides into amphipathic helical structures was crucial for inducing 
mycobacterial membrane permeability and augmenting anti-mycobacterial 
activity. Given that II and II-D are diastereomers of each other, their amino 
acid composition, charge, molecular weight, amphiphilicity and in turn 
hydrophobicity is expected to be similar. However, the lower relative helicity 
of 0.89 for II-D (Table 6.1), as compared to II, would be expected to 
compromise its activity, but the converse was true. The reduced 
hydrophobicities of II-Orn, II-Dab and II-Dap relative to that of II, also did not 
translate into reduced activities. This suggests that factors unrelated to the 
physiochemical properties of the peptides may also be responsible for the 
observed differences in anti-mycobacterial efficacy of the synthetic peptides. 
A plausible explanation is that the structural modifications employed in this 
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study could potentially have enhanced peptide stability to extracellular 
proteolytic enzymes of M. tuberculosis, in turn rendering them more active 
against the pathogen. M. tuberculosis culture filtrates containing proteases 
were found to diminish the anti-tubercular activity of the L- rather than D-
enantiomer of peptides, with the latter demonstrating greater resistance to 
degradation, evident from the significantly higher recovery as compared to the 
L-enantiomer (89% versus 26%) after 7 days exposure [158]. These findings 
suggest that stability-enhancing modifications such as the incorporation of 
unnatural amino acids may be crucial to developing AMPs with superior 
efficacies against slowly-replicating bacilli such as M. tuberculosis. 
 
6.2.4. Haemolytic activity, cytotoxicity and cell selectivity  
The haemolytic activities of the synthetic peptides were evaluated using 4% 
(v/v) human blood from two healthy adult donors and the results are 
summarised in Figure 6.2a. Even at the highest tested concentration of 1000 
mg L-1, all five peptides displayed minimal haemolysis of approximately 2%. 
The HC50 values, defined as the lowest peptide concentration resulting in 50% 
haemolysis of RBCs, of all five peptides was found to be >1000 mg L-1 (Table 
6.2). Similar observations were also made with respect to the cytotoxicity of 
the peptides against the murine macrophage cell line, RAW 264.7. As 
highlighted in Figure 6.2b, cell viabilities remained in excess of 80% even at 
concentrations of 250 mg L-1 following 24 h exposure to synthetic peptides. 
Importantly, none of the modifications produced analogues of II with an 
inferior toxicity profile against mammalian cells. The SIs highlighted in Table 
6.2, defined as the ratio of HC50 to GM MIC values, are often utilised to 
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identify analogues with superior antibacterial selectivity. The D-amino acid 
analogue of II emerged as the most selective for mycobacterial over 
mammalian cells, with a SI value of 20. This was fourfold greater than that of 
II and approximately 1.8 and 2.2 times higher than that of II-Dab and II-Dap, 
respectively. Since larger SI values are deemed as more desirable, the 
strategies presented in this study could therefore prove useful in designing 
more selective AMPs to treat M. tuberculosis infections.  
 
Figure 6.2. Toxicity profiles of synthetic peptides modified with unnatural 
amino acids against (a) human red blood cells and (b) the mouse macrophage 
cell line RAW 264.7. (c) Viability of RAW 264.7 cells after 4 days of 
treatment with II-D. Peptides displayed minimal haemolytic activity and 
cytotoxicity against mammalian cells at various concentrations tested. Data 
are expressed as mean ± S.D. for two independent experiments. 
 
6.2.5. Resistance to protease degradation  
A major barrier limiting the clinical application of AMPs is their susceptibility 
to protease degradation in biological fluids [26]. Trypsin specifically cleaves 
the C-terminal of both Lys and Arg, thus, peptides containing these cationic 
residues are likely to be rendered inactive. We therefore assessed the stability 
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of the Lys-rich II and its unnatural amino acid substituted analogues by pre-
treating the peptides with trypsin before evaluating their antimicrobial 
activities against BCG using the standard broth microdilution method. As 
shown in Figure 6.3, all five peptides inhibited bacterial growth after 7 days 
when no prior treatment with trypsin was performed. However, following pre-
treatment with trypsin, the antimicrobial activity of only II was lost while that 
of the other four modified peptides was preserved. The modifications to II not 
only produced analogues with superior mycobacterial selectivity (Table 6.2), 
but also conferred protection against the serine protease trypsin, enhancing 
their clinical utility.  
 
Figure 6.3. Inhibitory activity of synthetic peptides against BCG at 
concentrations of 4x MIC following 6 h treatment with trypsin at a ratio of 
1:100. Only the unmodified peptide, II, did not inhibit bacterial growth after 7 
days. Data are expressed as mean ± S.D. for two independent experiments. 
6.2.6. In vitro and intracellular killing efficiency  
The D-amino acid analogue of II was not only more resistant to enzymatic 
degradation, but also exhibited the highest SI of all peptides evaluated in this 
study. Hence, II-D was evaluated for its in vitro killing efficiency against 
laboratory strain H37Rv, the drug-susceptible clinical isolate Mtb 411, and the 
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MDR clinical isolate CSU87. II-D displayed killing efficiencies of > 90% at 
the respective MICs for all three strains (Figure 6.4). At 2x the respective MIC 
values, II-D killing efficiency was > 99% against both H37Rv and CSU87 and 
> 97% against Mtb 411.  
 
Figure 6.4. Killing efficiencies of antimicrobial peptide II-D against (a) 
H37Rv, (b) Mtb 411 and (c) CSU87 following treatment for 7 days at various 
concentrations. Data are expressed as mean ± S.D. for two independent 
experiments. 
 
The intracellular activity of II-D was subsequently evaluated against both 
drug-susceptible and MDR clinical isolates of M. tuberculosis during 
macrophage infection, at concentrations corresponding to 0.5x, 1x, 2x and 4x 
MIC. The first-line anti-tubercular drug, rifampicin, and second-line 
fluoroquinolone, moxifloxacin, served as controls for Mtb 411 and CSU87, 
respectively. As shown in Figures 6.5a and b, significant reductions in 
intracellular Mtb 411 counts were observed in comparison to untreated 
controls following 4-day treatment with II-D (p < 0.0001) and rifampicin (p < 
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0.001) at the highest concentrations tested. Both II-D and rifampicin 
demonstrated concentration-dependent killing of Mtb 411, although peptide 
treatment was more effective in rapidly eliminating the intracellular pathogen. 
At their respective MICs, rifampicin and II-D reduced bacillary loads within 3 
days by 36% and 84%, respectively. Furthermore, exposure to II-D at 250 mg 
L-1 (4x MIC) resulted in approximately 1 log reduction of intracellular 
bacterial burden by days 3 and 4 (Figure 6.5a). This effect was less 
pronounced with rifampicin as bacterial counts decreased by 66% and 70% on 
days 3 and 4, respectively, even up to concentrations corresponding to 8x MIC 
(0.016 mg L-1). Similarly, significant reductions in intracellular CSU87 counts 
were observed after 4 days in comparison to untreated controls for both II-D 
(p < 0.001) and moxifloxacin (p < 0.0001) at the highest concentrations tested. 
II-D brought about a 62% decrease in bacterial load within 4 days, even at 
sub-MIC of 31.3 mg L-1 (Figure 6.5c). II-D was also more effective than 
moxifloxacin in clearing intracellular CSU87 at equivalent concentrations of 
1x, 2x and 4x MIC (Figure 6.5d). Given that II-D demonstrated minimal 
toxicity towards RAW 264.7 macrophage cells after 4 days, with a cell 
viability of 75% even up to concentrations of 250 mg L-1 (Figure 6.2c), the 
observed reductions in intracellular mycobacterial load were a direct 
consequence of peptide treatment rather than cytotoxic effects on 
macrophages. Overall, these findings reinforce the applicability of AMPs for 
the treatment of intracellular pathogens such as M. tuberculosis. 
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Figure 6.5. Intracellular killing of the drug-susceptible clinical isolate Mtb 
411 by (a) antimicrobial peptide II-D and (b) rifampicin, and the MDR clinical 
isolate CSU87 by (c) antimicrobial peptide II-D and (d) moxifloxacin. Data 
expressed as mean ± S.D. and are representative of two independent 
experiments. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).  
 
 
6.2.7. In vitro and intracellular antimicrobial mechanisms  
The bactericidal activity of AMPs is largely mediated by non-specific 
membrane-lytic mechanisms, which induce pore formation and/or membrane 
destruction, leading to membrane depolarisation and outflow of cytoplasmic 
contents [22]. In this study, the antimicrobial mechanisms of II-D were 
investigated against BCG using microfluidic live-cell imaging by employing 
the CellASIC™ ONIX Microfluidic Platform. Bacterial cells were treated with 
peptides at 4x and 8x MIC, in the presence of the DNA intercalating dye PI 
for up to 4 h. Exposure of BCG to II-D at 4x and 8x MIC resulted in 
fluorescence staining of bacterial cells within 10 min. The uptake of PI was 
concentration-dependent, with ~50% of bacterial cells exhibiting fluorescence 
after 210 min at 8x MIC of II-D (Figure 6.6b) while a much lower proportion 
of cells were stained over the same time period at 4x MIC of II-D (Figure 
6.6a). Since we do not have facilities for live-cell imaging with Hazard Group 
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3 pathogens such as M. tuberculosis, the ability of II-D to compromise the 
membrane integrity of H37Rv and CSU87 was evaluated using flow 
cytometry of fixed cells. As shown in Figure 6.7, exposure of H37Rv to 
rifampicin, and CSU87 to moxifloxacin, for up to 3 h did not induce any 
appreciable uptake of the fluorescent probe. Treatment with II-D at 4x MIC 
however, resulted in the appearance of a new cell population, with PI-positive 
cells accounting for approximately 21% and 40% of the entire H37Rv and 
CSU87 cell populations, respectively (Figures 6.7c and f). Given the 
membrane-impermeant nature of PI, the dye is generally excluded from viable 
cells with intact bacterial membranes. Hence, the observed fluorescence 
provides evidence of the membrane-permeabilising activity of II-D, resulting 
in the loss of membrane integrity which in turn facilitates intracellular 
diffusion and binding of PI to DNA. These findings also reiterate the rapid 
membrane disruption induced by peptides in comparison to first-line anti-
tubercular drugs. Furthermore, II-D demonstrated bactericidal activity at 4x 
and 8x MIC against BCG with a > 2 log reduction in RLU readings after 7 day 
treatment as compared to controls (Figure 6.9a). Taken together, these 
findings suggest that the bactericidal activity of II-D may partly be mediated 





Figure 6.6. Time-lapse fluorescence microscopy images of BCG following 
treatment with antimicrobial peptide II-D at (a) 4x MIC and (b) 8x MIC in the 
presence of the membrane-impermeable dye, PI. Peptide-mediated membrane 
disruption promoted uptake of PI into bacterial cells. Scale bar = 10 µm. 
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Figure 6.7. Flow cytometric analysis of the proportion of bacterial cells 
positively stained by the membrane-impermeable dye PI after 3 h exposure to 
different antimicrobials. Controls consisted of (a) H37Rv and (d) CSU87 
treated with media alone. H37Rv was treated with (b) rifampicin and (c) II-D, 
while CSU87 with (e) moxifloxacin and (f) II-D at 4x MIC concentrations. II-
D induced a significant shift in the percentage of H37Rv and CSU87 taking up 
PI, suggestive of membrane permeabilising mechanisms of action. The levels 
of PI uptake for negative controls, rifampicin and moxifloxacin, were similar 









Increasingly, the ability of AMPs to modulate the host innate immunity has 
been explored as an alternative strategy for effective infection control [176]. 
To evaluate the capacity of II-D to modulate host immunity by activating 
macrophages, unstimulated RAW 264.7 cells were treated with up to 250 mg 
L-1 of the peptide for 24 h and pro-inflammatory responses were quantified by 
analysing NO and TNF-α production relative to that of LPS-stimulated 
macrophages. As shown in Figure 6.8, II-D neither induced NO nor TNF-α 
production, suggestive of its inability to effect macrophage activation. Thus, 
the observed intracellular anti-mycobacterial activity of II-D is likely due to 
direct bactericidal mechanisms rather than the induction of secondary pro-
inflammatory responses.  
 
Figure 6.8. The ability of antimicrobial peptide II-D to promote (a) NO and 
(b) TNF-α production in unstimulated RAW 264.7 mouse macrophage cells 
following 24 h treatment. II-D did not induce NO or TNF-α when compared 
to positive controls consisting of cells stimulated with 100 ng mL-1 LPS. Data 







6.2.8. Cellular localisation of II-D  
To ascertain the site of action of II-D, BCG was exposed to FITC-labelled II-
D for 2 h using the CellASIC™ ONIX Microfluidic Platform and its 
localisation was visualised by fluorescence microscopy. FITC-II-D was tested 
at 500 mg L-1 as the killing efficacy against BCG was similar to that of II-D at 
2x MIC (Figures 6.9a and b).  
 
Figure 6.9. Killing efficiencies of antimicrobial peptides (a) II-D and (b) 
FITC-II-D against BCG following treatment for 7 days at various 
concentrations. II-D had killing efficiencies of > 98% and > 99% at 31.3 and 
62.5 mg L-1, respectively, while FITC-II-D had killing efficiencies of > 99% at 
both 250 and 500 mg L-1. Data are expressed as mean ± S.E.M. for three 
independent experiments. 
 
As shown in Figure 5.10a, treatment of BCG with 500 mg L-1 of FITC-II-D 
resulted in peptide accumulation within the cytoplasm as evidenced by the 
bright green fluorescence signal. This was confirmed by CLSM studies with 
mCherry-expressing BCG where the co-localisation of FITC-II-D with the 
cytosolic fluorescence protein mCherry was observed (Figure 6.10b). 
Bacterial cells unaffected by FITC-II-D demonstrated strong red fluorescence 
signal across the entire cell length without any detectable green fluorescence 
peptide signal (Figures 6.10b, 6.11b and c), while peptide penetration into 
bacterial cells resulted in a stronger green than red intracellular fluorescence 
intensity profile along the cell length (Figure 6.11a). This observed reduction 
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in red fluorescence mCherry signal in cells which internalised FITC-II-D was 
likely due to peptide-mediated membrane permeabilisation resulting in 
leakage of cytosolic contents.   
 
Figure 6.10. (a) Fluorescence microscopy images of BCG treated with 500 
mg L-1 FITC-labelled II-D for 2 h using the CellASIC ONIX Microfluidic 
Platform. Scale bar = 10 µm (inset scale bar = 5µm). Confocal microscopy 
images following incubation of 500 mg L-1 FITC-labelled II-D for 2 h with (b) 
BCG-mCherry and (c) BCG in the presence of 2 µg mL-1 membrane dye FM4-
64. Scale bar = 2 µm. 
 
Next, co-labelling studies with the membrane-binding dye FM4-64 in BCG 
revealed that the red FM4-64 signal was predominantly located on the 
bacterial cell surface, and showed the same pattern of staining as the green 
fluorescence of FITC-II-D (Figure 6.10c). Moreover, the fluorescence 
intensity profile of FM4-64 across the cell width matched that of FITC-II-D 
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(Figures 6.11d and e). Previous studies have reported that the cell-penetrating 
peptide, buforin II, accumulates in cytoplasm without inducing the influx of PI 
into bacterial cells, suggestive of a non-membrane permeabilising mode of 
action [187]. Following internalisation, buforin II promotes cell death by 
inhibiting cellular functions through binding strongly to DNA and RNA [188]. 
In contrast, the membrane-permeabilising α-helical peptide magainin II, binds 
to the bacterial membrane, inducing pore formation and promoting the influx 
of PI [187]. In this study, fluorescence and CLSM analysis revealed that II-D 
permeates the mycobacterial cell membrane and accumulated in the cytoplasm 
(Figure 6.10). Additionally, membrane integrity studies with PI provided 
evidence of the membrane-lytic mechanisms of action (Figures 6.6 and 6.7). 
Taken together, the killing mechanisms of II-D could potentially be attributed 
to both pore-formation and targeting of intracellular components. Recently, 
non-membrane lytic, cell-penetrating synthetic AMPs (SAMPs) were reported 
to selectively kill M. smegmatis by binding bacterial DNA and consequently 
inhibiting DNA-dependent processes including replication and transcription 
[189]. Hence, the ability of the membrane-active peptide II-D to interact with 





Figure 6.11. Fluorescence intensity profiles of BCG-mCherry along the cell 
length (dashed lines) showing (a) entry of FITC-II-D into the cytoplasm while 
(b) and (c) represent unaffected cells. Fluorescence intensity profiles of BCG 
along the cell width (dashed lines) showing presence of FITC-II-D in the 
bacterial membrane segments (d) and (e). Images were acquired following 2 h 




In summary, synthetic helical AMPs modified with unnatural amino acids 
demonstrated improved anti-mycobacterial activities and stability to trypsin 
degradation as compared to the all L-amino acid peptide, II. The incorporation 
of D-amino acids proved to be the most effective modification, with the 
diastereomer II-D exhibiting a fourfold increase in SI as compared to II, likely 
due to the enhanced stability to M. tuberculosis proteases. In addition to its in 
vitro inhibitory activity against both drug-susceptible and MDR M. 
tuberculosis, II-D was equally, if not more effective, at clearing intracellular 
mycobacteria than both rifampicin and moxifloxacin at MIC equivalent 
concentrations. Mechanistic studies revealed that the site of action of II-D may 
not be limited to the mycobacterial membrane, but could potentially involve 
intracellular targets following internalisation of the peptide. Overall, these 
findings reiterate the importance of unnatural amino acid substitutions towards 
enhancing protease stability while highlighting their applicability in designing 
AMPs with superior mycobacterial selectivity.  
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CHAPTER 7: Disruption of drug-resistant biofilms using de novo 




Besides their direct antimicrobial activity, AMPs demonstrate diverse 
immunomodulatory properties including their ability to reduce the production 
of pro-inflammatory mediators in response to bacterial endotoxins [190]. 
Moreover, these multifunctional molecules also effectively inhibit biofilm 
formation and disrupt mature biofilms [191]. Biofilms are structured 
aggregates of microbial cells enclosed within an extracellular polymeric 
substance (EPS) matrix, which adhere to biological or non-biological surfaces 
[192]. Associated with over 65% of all infections, biofilms are involved in 
various device-related infections and chronic infections, including cystic 
fibrosis pneumonia, endocarditis, necrotising fasciitis and musculoskeletal 
infections [191]. These sessile bacterial communities are inherently resistant 
to antimicrobials due to poor drug penetration through the EPS matrix, and the 
existence of subpopulations of stationary phase and persister cells with drug 
tolerant phenotypes [193]. Despite the immense challenges of eradicating 
biofilm-related infections, the antimicrobials being developed are rarely 
evaluated for their anti-biofilm activities. 
 
Over the past few decades, various efforts directed toward understanding the 
structural determinants of AMPs affecting activity, have revealed that the 
clustering of hydrophobic and cationic amino acids into spatially distinct 
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regions is fundamental to the formation of amphipathic structures [21]. 
Building upon these findings, investigations aimed at optimising the 
amphipathic α-helix as a means of enhancing antimicrobial potency uncovered 
that peptides with idealised facial amphiphilicities, comprising of 
uninterrupted hydrophobic and cationic segments, possessed superior 
membrane-targeting activities and in turn enhanced selectivity [172, 194]. One 
such study found that amongst a series of peptides presenting perfectly 
amphipathic helices, the peptide demonstrating optimal antibacterial 
selectivity, LBU2, also had the highest mean hydrophobic moment – a 
measure of amphiphilicity of an α-helix [195]. The otherwise continuous 
hydrophobic face of the LL-23 fragment of human cathelicidin is interrupted 
by a single hydrophilic Ser residue at position 9, creating two amphipathic 
domains [80]. Substitution of Ser9 with either of the hydrophobic residues Val 
or alanine (Ala) creating the uninterrupted hydrophobic surface found in 
primate cathelicidins not only resulted in higher antimicrobial activity due to 
enhanced membrane penetration and depolarisation, but also increased the 
suppression of LPS-induced pro-inflammatory mediators [80]. These findings 
highlight the importance of optimising the facial amphiphilicity of synthetic 
peptides in order to generate more selective lead compounds to be brought 
forward for clinical testing.   
 
A commonality amongst majority of these studies is the adoption of a 
template-based approach, utilising naturally-occurring or synthetic AMPs as a 
starting point, generating helical wheel projections based on their amino acid 
sequences, and subsequently introducing point mutations to achieve idealised 
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facial amphiphilicity. However, these strategies remain largely empirical, 
often entailing multiple steps and requiring several substitutions for structural 
optimisation [106]. Additionally, optimised sequences derived from natural 
AMPs, with high sequence homology to HDPs, could inadvertently 
compromise innate immunity should antimicrobial resistance develop [104]. 
As such, implementing a rational approach in the design of short synthetic 
peptides presenting idealised facial amphiphilicity, and with distinct sequences 
from natural AMPs, could allay these concerns.  
 
In Chapter 4, the repeating sequence (XXYY)n, devised on the basis of 
mimicking the hydrophobic periodicity of natural α-helical AMPs, was 
successfully applied in the development of short synthetic amphipathic α-
helical peptides. However, in order to maintain a balance between 
hydrophobic and charged residues, the number of repeat units is restricted to 
positive integers (n = 1, 2, 3, and so forth) and, moreover, this sequence 
approach cannot be utilised to generate peptides with idealised facial 
amphiphilicity for n > 2. Therefore, in this study, α-helical amphiphiles with 
perfectly segregated hydrophobic and cationic faces were designed using the 
recurring sequence comprising four amino acids (X1Y1Y2X2)n – where X1 and 
X2 are hydrophobic amino acids, Y1 and Y2 are cationic amino acids, and n is 
the number repeat units. This proposed sequence preserves the α-helical 
periodicity, recognised as a key driver of helical formation [196], while 
allowing for amphipathic peptides of intermediate lengths (n = 1.5, 2.5, 3.5, 
and so forth). Importantly, this sequence enables the de novo design of 
peptides with perfectly amphipathic structures for n ≤ 3. 
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Various amino acid substitutions were performed to understand the effect of 
sequence pattern and length on the biological activity of peptides with 
idealised facial amphiphilicities. The synthetic amphiphiles were initially 
characterised for their α-helical propensity in a membrane-mimicking 
environment, before evaluation of their therapeutic efficacy against a range of 
both drug-susceptible and drug-resistant bacteria. Live-cell imaging studies 
provided insights into the membrane-lytic antimicrobial mechanisms, while 
their versatility in inhibiting biofilm formation and disrupting pre-formed 
drug-resistant biofilms was also assessed. Finally, the anti-endotoxin activity 
of the designed peptides was studied to determine their potential applicability 




7.2. Results and Discussion 
7.2.1. Peptide design and characterisation  
In this study, short cationic helical peptides with idealised facial 
amphiphilicity were designed based on the recurring sequence (X1Y1Y2X2)n, 
where the hydrophobic residues X1 = X2 = Leu or Ile or Trp, and the cationic 
residues Y1 = Y2 = Lys. The influence of size of the cationic and hydrophobic 
faces on the biological and haemolytic activities was assessed by comparing 8-
mer, 10-mer and 12-mer peptides with varying number of repeat units (n = 2 
or 2.5 or 3) (Figure 7.1). Besides the inclusion of residues which were helix 
formers rather than breakers, another key consideration was the selection of 
amino acids that could enhance peptide selectivity for microbial over 
mammalian cells. Hence, Lys was selected over Arg as the polar residue due 
to its high helical propensity [92], and lower cytotoxicity [93]. The 
hydrophobic residue Leu was also included due to its high helical propensity 
[92], while Trp was chosen because of its strong interaction with the lipid 
bilayer interface [197]. Finally, the selection of Ile was supported by evidence 
that Lys to Ile substitutions produced peptides with identical bactericidal 
activity, but markedly reduced toxicity [198]. The synthetic peptides were 
amidated at the C-terminus to improve antimicrobial activity by increasing net 




Figure 7.1. Helical wheel projection of α-helical peptides with idealised facial 
amphiphilicity, possessing the backbone sequence (X1Y1Y2X2)n, where X1 and 
X2 are hydrophobic amino acids, Y1 and Y2 are cationic amino acids, and n is 
the number repeat units. 
 
The sequences of the de novo peptides, their denotations and molecular 
weights are provided in Table 7.1. The molecular weights of the synthetic 
peptides were verified using SELDI-TOF MS, and agreement between the 
theoretical and measured molecular weights confirmed that the peptides had 
been synthesised to the desired specifications.  
Table 7.1. Design of α-helical peptides with idealised facial amphiphilicity 
and their molecular weights. 
a Mw determined by SELDI-TOF MS. 
 
The secondary structures of the synthetic peptides were evaluated in the 
presence of a 25 mM SDS micelle solution to simulate a microbial membrane 
environment. Under these conditions, the synthetic peptides readily adopted 
α-helical conformations, as supported by the characteristic double minima at 
~208 and 222 nm (Figure 7.2). In general, increasing the number of repeat 











L8 2  
LKKL 
 
LKKLLKKL-NH2 982.36 982 +4 
L10 2.5 LKKLLKKLLK-NH2 1223.69 1224 +5 
L12 3 LKKLLKKLLKKL-NH2 1465.02 1465 +6 
I8 2  
IKKI 
 
IKKIIKKI-NH2 982.36 982 +4 
I10 2.5 IKKIIKKIIK-NH2 1223.69 1224 +5 
I12 3 IKKIIKKIIKKI-NH2 1465.02 1466 +6 
W8 2  
WKKW 
 
WKKWWKKW-NH2 1274.57 1276 +4 
W10 2.5 WKKWWKKWWK-NH2 1588.95 1589 +5 
W12 3 WKKWWKKWWKKW-
NH2 
1903.33 1904 +6 
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units enhanced the helical propensity of synthetic peptides comprising of Leu 
and Ile residues, evident from the lower mean residue ellipticity values at 222 
nm (θ222). While the shorter Trp-containing peptides W8 and W10 displayed 
strong helical signatures, the longer W12 exhibited a broader minima between 
208 and 222 nm (Figure 7.2c), possibly due to self-aggregation of the more 
hydrophobic peptide [199].  
 
Figure 7.2. CD spectra representing α-helical propensity of peptides with the 
backbone sequence (a) (LKKL)n, (b) (IKKI)n and (c) (WKKW)n in 25 mM 
SDS micelle solution, where n = 2, 2.5 and 3. Data are expressed as the mean 
of three runs per peptide. 
 
7.2.2. Antimicrobial activity  
The antimicrobial activity of the synthetic peptides was studied against a panel 
of clinically relevant Gram-positive and Gram-negative bacteria and the 
results are summarised in Table 7.2. The designed peptides effectively 
inhibited bacterial growth over a range of concentrations, with L12 and W12 
emerging as the most potent antimicrobials. Both of these peptides recorded 
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the lowest GM of the MICs of 13.1 µM, followed by W10 with a value of 22.1 
µM. The three least effective peptides, L8, I8 and I10 also exhibited the lowest 
α-helical conformation (Figure 7.2), suggesting that folding of peptides into 
amphipathic structures was essential for antimicrobial activity. This 
observation is supported by evidence that helix formation is a major driver of 
peptide insertion into the lipid bilayer [200]. In general, an increase in size of 
the continuous cationic and hydrophobic faces in the amphipathic helix 
corresponded with reduced MIC values. Upon closer examination, the choice 
of non-polar amino acid was a key determinant of the minimum number of 
residues required in each uninterrupted segment for peptide activity. Amongst 
the hydrophobic amino acids studied, the incorporation of Ile proved least 
effective, as a minimum of six residues in each of the continuous cationic and 
hydrophobic faces was necessary for activity. Even then, I12 recorded a 16- 
and 32-fold higher MIC against the Gram-positive S. aureus as compared to 
L12 and W12 respectively. For Leu-containing peptides, cationic and 
hydrophobic segments consisting of at least five amino acids were required to 
inhibit bacterial growth, in line with findings from previous reports [194, 201]. 
However, only four residues per segment were sufficient to render peptides, 
comprising of bulky Trp residues, active. The superior potency of Trp-
containing amphiphiles could be attributed to the strong affinity of Trp for 
membrane interfaces, which facilitates peptide penetration and disruption of 
the lipid bilayer [197, 202]. Therefore, the inclusion of bulky Trp residues 





Table 7.2. MICs and SIs of peptides with idealised facial amphiphilicity 
against Gram-positive and Gram-negative bacteria.  
a The GM of the MICs for the 4 bacterial strains. 
b SI is determined as follows: (HC50/GM). The highest tested concentration of 2000 
µM was used for SI calculations when less than 50% haemolysis was observed at this 
concentration.  
 
7.2.3. Haemolytic activity and cell selectivity 
The synthetic peptides were evaluated for their haemolytic activity using 4% 
(v/v) blood from two healthy donors and as shown in Figure 7.3, all peptides 
induced minimal haemolysis at their respective MICs. The Ile-containing 
peptides (I8, I10 and I12), and those consisting of two repeat units (L8, I8 and 
W8) displayed the lowest haemolysis of <1.5% even at 2000 µM. Notably, the 
most active peptide L12 only induced 16% haemolysis at 2000 µM, a 
concentration 150-fold greater than its GM MIC value. Trp incorporation 
(W8, W10 and W12) produced peptides with stronger haemolytic activity with 
W10 and W12 inducing haemolysis of 28% and 78% at 2000 µM, 
respectively. This corresponded to a far lower HC50 value, defined as the 
lowest peptide concentration producing 50% haemolysis of RBCs, of 483 µM 
for W12 as compared to all other peptides (Table 7.2).  
 
To enhance clinical utility of the amphipathic helical peptides, they should 
preferentially interact with microbial over mammalian cell membranes in 
AMP 
 




b E. coli K. pneumoniae P. aeruginosa S. aureus 
L8 500 > 500 > 500 > 500 - >2000 - 
L10 31.3 > 500 62.5 > 500 - >2000 - 
L12 7.81 31.3 7.81 15.6 13.1 >2000 152 
I8 > 500 > 500 >500 > 500 - >2000 - 
I10 500 > 500 >500 > 500 - >2000 - 
I12 15.6 > 500 15.6 250 - >2000 - 
W8 31.3 250 >250 62.5 - >2000 - 
W10 15.6 62.5 15.6 15.6 22.1 >2000 91 
W12 15.6 15.6 15.6 7.81 13.1 483 37 
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order to maximise antimicrobial efficacy while minimising toxicity. The SI, 
defined as the ratio of HC50 to GM MIC values, is one measure devised to aid 
in the selection of the best therapeutic candidates, with higher SI values 
deemed more desirable. Of the nine peptides designed, L12 displayed the 
highest SI of 152, followed by W10 and W12. Although both L12 and W12 
emerged equally active against the panel of bacteria with similar GM values of 
13.1 µM, the relatively low haemolytic activity displayed by L12 translated 
into a fourfold superior SI compared to W12 (Table 7.2). Among the Trp-
containing peptides, W10 possessed the optimal composition with the highest 
SI of 97, despite recording a higher GM value of 22 µM as compared to W12. 
While increasing the number of lipophilic Trp residues increased both 
antimicrobial and haemolytic activities, the reduction in the HC50 value for 
W12 occurred to a far greater extent than the corresponding decrease in MICs. 
Thus, limiting the continuous hydrophobic face to ≤ 5 Trp residues may be 
crucial in designing more selective peptides, as the expansion of this 
uninterrupted segment beyond that proved detrimental to the SI. 
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Figure 7.3. Haemolytic activity of synthetic α-helical peptides possessing (a) 
2 repeat units, (b) 2.5 repeat units and (c) 3 repeat units tested against blood 
from two healthy donors. Peptides induced minimal haemolysis at 
concentrations corresponding to the respective MICs. Data are expressed as 
mean ± S.D. for two independent experiments. 
 
7.2.4. Antimicrobial mechanisms  
The bactericidal mechanisms of the synthetic peptides were evaluated by 
performing in vitro killing efficiency studies against a panel of Gram-positive 
and Gram-negative bacteria. L12 demonstrated killing efficiencies of > 99.9% 
at 2x MICs of all four species (Figure 7.4). The bactericidal activity was more 
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significant at 4x MIC with L12 achieving > 4 log reduction for P. aeruginosa, 
> 5 log reduction for E. coli and K. pneumoniae, and > 6 log reduction for S. 
aureus.  
 
Figure 7.4. Killing efficiency of antimicrobial peptide L12 against (a) E. coli, 
(b) S. aureus, (c) P. aeruginosa and (d) K. pneumoniae following treatment 
for 18 h at concentrations corresponding to 0, 0.5x, 1x, 2x and 4x MIC. Data 
are expressed as mean ± S.D. for two independent experiments. 
 
AMPs adopting amphipathic helical structures are recognised to interact with 
bacterial membranes in order to exert their antimicrobial effect by creating 
pores, or inducing widespread collapse of membrane structural integrity [22]. 
In this study, live-cell imaging of bacterial cells was performed using the 
CellASIC™ ONIX Microfluidic Platform to elucidate the antimicrobial 
mechanisms of the most selective peptide L12. The DNA intercalating dye PI 
was utilised to detect peptide-mediated membrane damaged to E. coli and S. 
aureus following treatment with L12 at concentrations up to 8x MIC. As 
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shown in Figure 7.5a, E. coli cells doubled continuously without taking up the 
fluorescent dye in the absence of L12. Under similar conditions, S. aureus 
cells also excluded PI and replicated uninterruptedly (Figure 7.5d). However, 
exposure of E. coli to L12 at 4x MIC rapidly induced fluorescent staining of 
bacterial cells within 15 min (Figure 7.5b). The effect was more pronounced at 
8x MIC with PI uptake into bacterial cells occurring within 5 min of peptide 
treatment (Figure 7.5c). Similarly, S. aureus exhibited fluorescence within 15 
min of peptide introduction at both 4x and 8x MIC (Figures 7.5e and f). 
Moreover, the replication of L12-treated E. coli and S. aureus cells was 
promptly halted after 25 min exposure to 8x MIC, suggesting that 
permeabilisation of bacterial membranes likely culminated in cell death. Live-
cell imaging studies also provide a useful means of assessing the relative 
kinetics of the membrane-permeabilising activity of AMPs when comparing 
Gram-positive versus Gram-negative bacteria. Treatment of S. aureus with 
L12 at 8x MIC resulted in rapid fluorescent staining of > 90% and ~100% of 
cells within 15 and 35 min, respectively (Figure 7.5f). For E. coli however, 
membrane permeabilisation was far more gradual with ~65% of cells 
displaying fluorescence within 15 min and > 90% staining only achieved at 45 
min (Figure 7.5c). The more rapid fluorescence observed for S. aureus is 
consistent with the fact that Gram-positive bacteria lack an outer membrane, 
hence binding of PI to intracellular DNA is readily achieved upon compromise 
of cytoplasmic membrane integrity. The presence of an outer membrane in 
Gram-negative bacteria necessitates that both outer and inner membranes are 
sequentially permeabilised before PI can gain access to DNA, thus slowing 









Figure 7.5. Time-lapse fluorescence microscopy images of E. coli (a, b, c) and 
S. aureus (d, e, f) following treatment with (a and d) media alone, (b and e) 
L12 at 4x MIC and (c and f) L12 at 8x MIC in the presence of the membrane 
impermeable dye, PI. The uptake of PI into bacterial cells within minutes of 
exposure supports the rapid membrane-lytic antimicrobial mechanisms of the 
synthetic peptides. No uptake of PI was observed in negative controls while a 
concentration dependent increase in the proportion of fluorescent bacteria was 






7.2.5. Inhibition of MDR bacteria and biofilms  
The antimicrobial activity of the three most selective peptides was further 
evaluated against drug-resistant bacteria including MRSA, and MDR clinical 
isolates of both P. aeruginosa and M. tuberculosis. As shown in Table 7.3, the 
synthetic peptides remained equally effective against drug-resistant pathogens, 
with MICs ranging from 7.81 to 125 µM. While both 12-mers demonstrated 
relatively similar activity against MDR P. aeruginosa and M. tuberculosis, 
W12 recorded an 8-fold lower MIC than L12 against MRSA. The observed 
retention of broad-spectrum inhibitory activity against drug-resistant bacteria 
largely stems from the non-specific membrane-lytic mode of action displayed 
by most AMPs [24].  
Table 7.3. MICs of synthetic peptides against clinical isolates of MRSA 252, 





MRSA 252 PA-W1 PA-W14 PA-W25 CSU87 
L12 62.5 15.6 15.6 15.6 62.5 
W10 15.6 31.3 125 125 62.5 
W12 7.81 15.6 31.3 15.6 62.5 
 
Besides their efficacy against planktonic bacteria, AMPs could provide useful 
alternatives to address challenging biofilm-related infections [191]. Thus, the 
most selective peptide L12 was evaluated for its ability to inhibit biofilm 
formation at sub and supra-MIC levels. As shown in Figure 7.6a, L12 
prevented the development of both drug-susceptible and drug-resistant 
biofilms to similar extents. Though ineffective at sub-MIC levels, L12 
significantly reduced the biomass of PAO1 and PA-W25 biofilms by ~90% at 
both 1x and 2x MIC (p ≤ 0.0001). These findings were corroborated by 
bioluminescent imaging of P. aeruginosa which revealed that L12 effectively 
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inhibited biofilm formation at 1x, 2x and 4x MIC (Figure 7.6b), with > 99% 
reduction in luminescence signal (Figure 7.6c). Unlike the inhibition of P. 
aeruginosa biofilms, the reduction in biomass of S. aureus biofilms occurred 
in a dose-dependent manner (Figure 7.6a). L12 inhibited MSSA and MRSA 
biofilms by ~37% and 39% at 0.25x MIC, respectively, and ~53% and 45% at 
0.5x MIC, respectively. The anti-biofilm properties of AMPs are partly 
attributed to direct killing of planktonic bacteria, hence, the prevention of 
biofilm formation at sub-MIC suggests that alternative mechanisms could 
potentially be involved. It has been shown that coating AMPs onto surfaces 
reduces bacterial adherence in turn inhibiting biofilm formation and this may 
contribute here [121].   
 
The treatment of mature biofilms also poses a significant clinical problem; 
hence L12 was further evaluated for its potential to disrupt pre-formed 
biofilms of drug-resistant pathogens. As shown in Figure 7.6d, L12 displayed 
significant concentration-dependent reduction in cell viabilities of pre-
established biofilms of both MRSA and MDR PA-W25 at 8x and 16x MIC 
within 2 h of treatment (p ≤ 0.0001). Bioluminescent imaging studies of pre-
formed P. aeruginosa biofilms confirmed that L12 effectively eradicates 
mature biofilms at supra-MIC levels after 2 h (Figure 7.6e), accompanied by 
significant reductions in luminescence at 16x MIC (p ≤ 0.05), and 32x and 64x 
MIC (p ≤ 0.01) (Figure 7.6f). All in all, these findings underscore the potential 
utility of the de novo AMPs presented here in tackling the mounting problem 
of MDR biofilms and infections. 
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Figure 7.6. (a) Inhibition of drug-susceptible and drug-resistant P. aeruginosa 
and S. aureus biofilms formation following overnight exposure to L12. (b) 
IVIS imaging and (c) radiance quantification of biofilm growth inhibition of 
bioluminescent P. aeruginosa treated with L12 overnight. (d) Cell viabilities 
of pre-formed PA-W25 and MRSA 252 biofilms after treatment with L12 for 
2 h. (e) IVIS imaging and (f) radiance quantification of pre-formed biofilm 
disruption of bioluminescent P. aeruginosa exposed to L12 for 2 h. Rows in 
(b) and (e) represent individual replicates. L12 inhibits biofilm formation at 1x 
and 2x MIC, and effectively disrupts pre-established biofilms at supra-MIC 







7.2.6. Anti-endotoxin activity  
Host innate immune responses during sepsis, elicited by exposure to the 
Gram-negative bacterial cell wall component, LPS, could lead to septic shock 
and eventually death if uncontrolled. The neutralisation of endotoxins by 
amphipathic peptides could provide an effective means of blocking the 
overproduction of inflammatory mediators induced by LPS. Thus, the LPS-
binding abilities of the de novo peptides were evaluated from 3.9 to 31.3 µM 
using the LAL chromogenic assay, as cell viabilities were > 70% for all 
peptides, except L12 which recorded ~30% cell viability at the highest 
concentration (Figure 7.7c). As shown in Figure 7.7a, the most hydrophobic 
12-mer, W12, bound LPS most effectively with ≥ 90% binding even at low 
peptide concentrations of 7.81 µM. In comparison, I12 and L12 only 
neutralised ~29% and 47% of LPS, respectively at similar concentrations. 
Increasing the number of repeat units by 0.5 contributed to stronger LPS-
binding for W12 to W10 at all concentrations tested. Taken together, these 
findings suggest that both peptide length and hydrophobicity are important 
determinants of the LPS-neutralising properties of amphipathic peptides. 
 
The overproduction of the pro-inflammatory mediator NO has been implicated 
in the pathogenesis of septic shock, inducing harmful effects including tissue 
damage and myocardial depression [203]. Hence, the ability of the peptides to 
restrict LPS-induced macrophage activation was assessed by quantifying 
nitrite production from LPS-stimulated RAW 264.7 cells treated with 
peptides. The most potent inhibitors L12 and W12 limited NO production to 
levels similar to controls even at the lowest peptide concentration of 3.9 µM (p 
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≤ 0.0001) (Figure 7.7b). W10 and I12, however, demonstrated a dose-
dependent reduction in NO release from macrophages. While NO production 
was enhanced > 6-fold in the absence of peptides, treatment with 7.81 µM of 
W10 and I12 suppressed NO production to concentrations ~2.7 and 2.5-fold, 
respectively, higher than that of controls. In general, there was close 
agreement between the LPS-binding and neutralising activities of the peptides, 
except for I12 which demonstrated similar LPS-blocking activity as W10 
despite exhibiting the lowest LPS-binding affinity. This finding suggests that 
in addition to the direct binding of LPS by I12, other mechanisms may be 
involved in the suppression of pro-inflammatory responses induced by LPS 
[204, 205]. Overall, the short amphiphilic peptides presented in this study 
could potentially be developed as anti-inflammatory agents in the treatment of 




Figure 7.7. The ability of de novo designed peptides to (a) bind LPS within 30 
min exposure and (b) restrict LPS-stimulated NO production following 24 h 
treatment with peptides at various concentrations. The synthetic peptides L12 
and W12 strongly bound LPS and effectively inhibited NO production at sub-
MIC concentrations of 3.9 µM. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, # p ≤ 
0.0001). (c) The effect of synthetic peptides on viability of RAW 264.7 mouse 
macrophage cells following 24 h treatment with peptides at various 




In summary, the design principles proposed in this study, with peptides 
comprising of the backbone sequence (X1Y1Y2X2)n, were successful in 
producing broad-spectrum α-helical AMPs. Optimisation of peptide selectivity 
by varying the number of repeat units and choice of hydrophobic amino acid, 
found that the sequences (LKKL)3 and (WKKW)2.5 possessed the highest SIs 
of 152 and 91 respectively. The bactericidal activity of L12 was likely due to 
membrane-lysis, inducing rapid disruption of Gram-positive and Gram-
negative bacterial membranes within minutes. L12 also effectively inhibited 
the formation, and promoted the disruption, of drug-resistant biofilms. Finally, 
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both L12 and W12 demonstrated potent suppression of LPS-induced pro-
inflammatory mediators even at low peptide concentrations of 3.9 µM. All in 
all, the design strategies presented in this study could provide a useful tool for 
developing therapeutic peptides with broad-ranging clinical applications in the 
treatment and prevention of drug-resistant biofilms and endotoxemia. 
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CHAPTER 8: Conclusions and future perspectives 
 
The overall aim of this thesis was to apply a de novo approach in the design of 
short synthetic AMPs to develop novel compounds for anti-infective 
applications. We tested the hypothesis that rationally designed synthetic 
AMPs, comprising of repeat sequences corresponding to the hydrophobic 
periodicity of natural α-helical peptides, could be safely and effectively 
applied in TB mono- and combination therapy, and in the treatment and 
prevention of drug-resistant biofilms and endotoxemia. In Chapter 4, we 
provided important evidence that short synthetic amphipathic α-helical 
peptides, of only eight to ten residues, could effectively inhibit both drug-
susceptible and drug-resistant M. tuberculosis. While the presence of free thiol 
groups in Cys residues did not serve to enhance the anti-mycobacterial activity 
of the parent peptide (LLKK)2, enhancement in hydrophobicity by 
incorporating Met residues was shown to be an effective strategy to improve 
activity. The most selective peptide, M(LLKK)2M, was found to be minimally 
toxic at its MIC, and rapidly disrupted the mycobacterial membrane within 10 
min of treatment. Notably, mycobacteria did not develop resistance after 
multiple exposures to sub-lethal doses of this peptide. In addition, AMPs 
displayed synergism in combination with rifampicin against both M. 
smegmatis and M. bovis BCG and additivity against M. tuberculosis. 
Moreover, such combination therapy was effective in delaying the emergence 
of rifampicin resistance, highlighting the potential utility of AMPs as 
adjuvants in combinatorial treatment regimens for TB. 
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In Chapter 5, the effect of key physicochemical parameters including 
hydrophobicity and helicity on anti-mycobacterial activity and synergism of 
our synthetic AMPs was investigated for the first time. The three most 
hydrophobic peptides (WW, MM and II) were the most active, and exhibited 
synergism with rifampicin. However, increasing hydrophobicity beyond a 
certain threshold was found to be detrimental to cell selectivity, with peptides 
possessing intermediate hydrophobicity displaying the highest SI. Flow 
cytometric analysis revealed that enhancements in hydrophobicity and helicity 
increased the rate and extent of peptide-mediated membrane permeabilisation. 
This finding corroborated the postulation that synergism between the peptides 
and rifampicin was likely mediated via peptide-induced pore formation. The 
rapid, concentration-dependent membrane depolarisation, leakage of 
intracellular ATP and calcein release from PE/PG LUVs supported the 
membrane-lytic mechanism of action of the peptides. Together, these findings 
suggest that hydrophobicity and helicity significantly impact anti-
mycobacterial activity and optimisation of both parameters is necessary to 
develop synthetic analogues with superior selectivity indices and enhanced 
synergistic potential with conventional antibiotics. 
 
In Chapter 6, unnatural amino acid-modified α-helical peptides were 
systematically evaluated in an attempt towards enhancing anti-mycobacterial 
activities and stability. Substitutions were well tolerated without an 
appreciable effect on toxicity profiles and secondary conformations, and the 
modified peptides withstood proteolytic digestion by trypsin. The most 
selective peptide II-D, the all D-amino acid analogue, exhibited a fourfold 
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increase in selectivity index in comparison to the unmodified L-amino acid 
peptide. This peptide also effectively reduced the intracellular bacterial burden 
of both drug-susceptible and MDR clinical isolates of M. tuberculosis after 4-
days of treatment. Live-cell imaging studies with BCG provided evidence of 
the membrane-permeabilising mechanisms of II-D. Flow cytometric analysis 
of II-D treated H37Rv and CSU87 further corroborated the membrane-
targeted mode of action of this peptide. Overall, unnatural amino acid 
modifications not only serve to decrease the susceptibility of peptides to 
proteases, but also enhance mycobacterial selectivity. 
 
In Chapter 7, a new sequence-based approach is presented in the de novo 
design of α-helical peptides with idealised facial amphiphilicity. Synthetic 
amphiphiles composed of the backbone sequence (X1Y1Y2X2)n, where X1 and 
X2 are hydrophobic residues (Leu or Ile or Trp), Y1 and Y2 are cationic 
residues (Lys), and n is the number repeat units (2 or 2.5 or 3), demonstrated 
potent broad-spectrum antimicrobial activities against clinical isolates of drug-
susceptible and MDR bacteria. The most selective peptide, L12, promoted 
rapid permeabilisation of bacterial membranes. Importantly, L12 not only 
suppressed biofilm growth, but effectively disrupted mature biofilms after 
only 2 h of treatment. The peptides bound LPS, with L12 and W12 
suppressing the production of LPS-induced pro-inflammatory mediators to 
levels of unstimulated controls at low micromolar concentrations. Thus, the 
proposed rational design strategy can be implemented to develop potent, 
selective and multifunctional α-helical peptides to eradicate drug-resistant 
biofilm-associated and endotoxemia.      
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In addition to providing insights into the rational design of short α-helical 
AMPs for broad-ranging clinical applications, the present study has helped 
identify possible new avenues for future research. While findings from the in 
vitro efficacy studies are promising, the clinical potential of the optimised lead 
compounds needs to be established in vivo using animal models of TB 
infection. Combinatorial drug regimens form the bedrock of successful TB 
chemotherapy, and hence new anti-tubercular agents are unlikely to obtain 
approval for use as monotherapy [206]. Thus, it is necessary for new or re-
purposed drugs to be evaluated either as adjuncts to first-line anti-tubercular 
drugs or as part of a new combination regimen. As such, synergistic two, three 
or four drug combinations comprising of peptides plus rifampicin, isoniazid, 
ethambutol and pyrazinamde should first be evaluated for their intracellular 
bactericidal activity using macrophage cell lines. This can be done by 
enumeration of CFU after treatment with various drug combinations over four 
and seven days. For MDR-TB, synergistic interactions can be evaluated 
between peptides and second-line drugs including moxifloxacin, amikacin, 
kanamycin and streptomycin. Following this, promising drug combinations 
should be brought forward for further evaluation in vivo. Therapeutic efficacy 
of drug combinations can be determined by enumeration of CFU in the lungs 
and spleen, and histopathological evaluation of the degree of lung tissue 
damage [207].  
 
Since the in vivo activity of AMPs is affected by the presence of salts, proteins 
and enzymes in serum, the route of administration could have a profound 
impact on the bioavailability and in turn, efficacy of peptides at the site of 
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infection [109]. While first-line anti-tubercular drugs are typically 
administered orally, therapeutic doses of AMPs have been delivered either 
subcutaneously, intranasally or intratracheally [32, 207-209]. Furthermore, 
variation in the dosing frequency and treatment duration between studies 
raises pertinent questions regarding the ideal therapeutic regimen for AMPs in 
TB chemotherapy. The pharmacokinetics of synthetic AMPs can be studied by 
measuring peptide concentrations in plasma, urine, liver, kidney and lung 
homogenates following administration via the different routes. Samples can be 
obtained at every 10 min intervals up to 90 min and quantification of peptides 
can be carried out using a HPLC system couple to a MS (LC-MS) [210]. This 
would provide information on the drug concentration immediately after 
administration, the maximum drug concentration achieved, the half-life, 
volume of distribution and clearance rate. The peptides should be evaluated at 
two different doses in order to determine which achieves a more favourable 
therapeutic range (period of time the drug concentration remains over the 
MIC). With a better understanding of how long a peptide remains in the 
therapeutic range, the dosing interval can then be adjusted accordingly. Such a 
systematic comparison of the effect of different administration routes and drug 
regimens on the dose requirements and pharmacokinetics of synthetic AMPs 
for effective clearance of TB infection in vivo is necessary. This would 
provide invaluable guidance for the preclinical testing of drug candidates and 
ensure that promising compounds are fairly evaluated under similar treatment 
conditions, according to robust and established protocols.   
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The spread of AMR has compelled the exploration of alternative anti-infective 
strategies, and modulation of host immunity using immunotherapies is one 
approach which holds promise [176]. This paradigm shift towards host-
directed, rather than pathogen-directed therapies, is beneficial from the 
standpoint of avoiding selection pressure for microbial resistance development 
[176]. The use of immunomodulating AMPs, or their inducers, as therapeutic 
agents in the control of pulmonary TB has been proposed as a promising 
strategy [211]. As discussed in Chapter 5, the peptides presented in this study 
do not activate macrophages, implying that the observed intracellular activity 
was likely due to direct antimicrobial killing rather than immunomodulatory 
effects. Recently, N-formylation of synthetic peptides was found to 
significantly improve their immunomodulatory effects, which in turn 
enhanced H37Rv clearance in vivo, both alone and in combination with 
rifampicin and isoniazid [212]. Hence, this strategy could be exploited to 
impart the most selective α-helical peptides presented here with 
immunomodulatory properties. An investigation into the effect of N-
formylation on the immunomodulatory activity of synthetic AMPs, followed 
by both intracellular and in vivo efficacy studies can be performed to 
determine the feasibility of this strategy in augmenting mycobacterial killing. 
N-formylated peptides including M(LLKK)2M and I(LLKK)2I can be 
evaluated in combination with rifampicin and isoniazid in animal models and 
their effectiveness determined by quantifying CFU in the lungs and spleen. 
Pulmonary histopathological changes following treatment with drug 
combinations should be compared to both monotherapy and untreated controls 
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in order to assess their effect on the size and distribution of TB lesions and the 
extent of granuloma formation.  
 
In conclusion, the findings of this thesis have supported the hypothesis that 
rationally designed synthetic AMPs, adopting α-helical conformations, are 
safe and effective in TB mono- and combination therapy, and in the treatment 
and prevention of drug-resistant biofilms and endotoxemia. While there is 
immense therapeutic potential for synthetic AMPs in anti-infective 
applications, several issues including production costs, toxicity and stability 
need to be overcome. However, with advances in peptide synthesis and drug 
delivery, it may be sooner rather than later that the first HDP, or synthetic 
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